



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/42, 31/275, 31/415, 31/40, 31/535, C07C 251/86, A61K 31/505, 31/47, 31/495, 31/44, 31/165, C07D 231/38, 239/88, 241/42, 487/04, C07C 255/23, 255/41</p>	A2	<p>(11) International Publication Number: WO 95/19169</p> <p>(43) International Publication Date: 20 July 1995 (20.07.95)</p>
<p>(21) International Application Number: PCT/US95/00363</p> <p>(22) International Filing Date: 6 January 1995 (06.01.95)</p> <p>(30) Priority Data: 08/179,570 7 January 1994 (07.01.94) US</p> <p>(71) Applicants: SUGEN, INC. [US/US]; 515 Galveston Drive, Redwood City, CA 94063-4720 (US). BIOSIGNAL LTD. [HU/HU]; Varosmajor u. 9, H-1122 Budapest (HU). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; 46 Jabotinsky Street, P.O. Box 4279, 91042 Jerusalem (IL). MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstrasse 2, D-80539 München (DE). REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, Oakland, CA 94612-3550 (US).</p>		<p>(72) Inventors: HIRTH, Klaus, Peter; 633 Grand View Avenue, San Francisco, CA 94114 (US). SCHWARTZ, Donna, Pruess; 812 Foothill Drive, San Mateo, CA 94402 (US). MANN, Elaina; 23 Redondo Court, Alameda, CA 94501 (US). SHAWVER, Laura, Kay; 216 Cotter Street, San Francisco, CA 94112 (US). KERI, Gyorgy; Modori u. 4, H-1021 Budapest (HU). SZEKELY, Istvan; Krajcar u. 6, H-2120 Dunakeszi (HU). BAJOR, Tamas; Almos u. 75, H-1221 Budapest (HU). HAIMICHAEL, Janis; Regenyess u. 5, H-1221 Budapest (HU). ORFI, Laszlo; Bathyanz u. 92, H-1161 Budapest (HU). LEVITZKI, Alex; 36 Palmach Street, Jerusalem (IL). GAZIT, Aviv; 14 Nof Harim, Jerusalem (IL). ULLRICH, Axel; Adalbertstrasse 108, D-8000 München 40 (DE). LAMMERS, Reiner; Karlsbergstrasse 3, D-81475 München (DE). KABBINAVAR, Fairouz, F.; 5809 Melissa Lane, Woodland Hills, CA 91367 (US). SLAMON, Dennis, J.; 23122 Calvert, Woodland Hills, CA 91367 (US). TANG, Cho, Peng; 827 Camino Ricardo, Moraga, CA 94556 (US).</p> <p>(74) Agents: HEBER, Sheldon, O. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p> <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR</p> <p>(57) Abstract</p> <p>The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity of other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see Figure 1A), and its ability to inhibit growth of tumor cells <i>in vivo</i> is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTION**TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS
CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR**Field of Invention

The present invention relates to methods and compositions for treating cell proliferative disorders characterized by inappropriate platelet derived growth factor
5 receptor (PDGF-R) activity.

Related Application

The present application is a continuation-in-part of Hirth et al., entitled "TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS" U.S.
10 serial number 08/179,570, filed January 7, 1994, the entire contents of which including the drawings are hereby incorporated by reference herein.

Background of the Invention

Platelet derived growth factor receptor (PDGF-R) is
15 a transmembrane receptor tyrosine kinase. Ligand binding to the receptor results in dimerization of two receptors generally leading to intermolecular phosphorylation of each receptor, commonly referred to as autophosphorylation or transphosphorylation, and activation of the receptor
20 complex. PDGF, which is a ligand for PDGF-R, is a dimeric protein having two polypeptide chains joined by disulfide bonds. Each polypeptide is either an A chain polypeptide or a B chain polypeptide. Thus, PDGF can have either two
A chains, two B chains, or an A and a B chain.

25 The PDGF-R consists of two isozymes α and β . Both α and β -containing receptors have been associated with mitogen activity, while only the β -containing receptor has been associated with chemotaxis and actin reorganization (Heldin, C-H, *EMBO Journal* 11:4251-4259, 1992).

According to Plate et al., *Laboratory Investigation* 4:529-534, 1992:

PDGF is a potent growth factor for mesenchymal and neuroectodermal cells. Endothelial cells
5 have been considered nonresponsive to PDGF, but a recent study has shown that PDGF may have a role in angiogenesis during placenta development. In addition, it has been demonstrated, that PDGFR-b is expressed in endothelial cells
10 in inflammatory tissue and glial tumors. This suggests, that PDGF may play a role in vascular functions in pathological conditions.
[Citations omitted.]

Heldin, *supra*, describes the relationship of PDGF and
15 its receptor, and discusses the role of PDGF in cancer, noting that some cancers do not produce PDGF and have central necroses. Heldin states:

The adverse effects of PDGF in certain diseases, as discussed above, make PDGF antagonists highly desirable. We and others have
20 recently taken several approaches to develop such antagonists. Antibodies against PDGF have proven to be useful for inhibiting both autocrine stimulation in SSV-transformed cells and the atherosclerotic process that occurs after
25 de-endothelialization of the carotid arteries of rats. Moreover, a soluble form of the PDGF receptor has been shown to bind and inactivate PDGF, and could thus be potentially useful for
30 inhibiting PDGF action *in vivo*.

Another approach would be to design or find agents that compete in an antagonistic manner with PDGF for receptor binding. In order to
identify peptides that interfere with PDGF
35 binding, we systematically screened peptides derived from the B-chain sequence. One peptide was found that inhibited PDGF binding and

autophosphorylation of α - as well as β -
receptors. However, the peptide also showed
some cell toxicity and further development will
be necessary before peptide antagonists become
5 useful for in vivo studies. Low molecular
weight compounds that interfere with receptor
binding have been described, e.g., suramin.
However, suramin is not specific enough to be
clinically useful as a PDGF antagonist. We
10 recently found that another low molecular weight
compound, neomycin, at high concentrations
inhibited the binding of PDGF-BB to the α -
receptor, but did not inhibit binding to the β -
receptor. This compound thus represents an
15 antagonist that distinguishes between the two
receptor types; however, its low potency makes
it unsuitable for use in vivo. Hopefully, the
experiences with suramin and neomycin will aid
the future design of more potent and specific
20 PDGF receptor antagonists. The design of such
antagonists would be much facilitated by the
elucidation of the three-dimensional structure
of the PDGF-receptor complex.

PDGF antagonistic activity could also be
25 achieved by inhibition of PDGF receptor dimeri-
zation. We hypothesized that monomeric PDGF
might fail to induce receptor dimerization and
might thus have antagonistic activity. Since
reduction of PDGF results in loss of receptor
30 binding, we attempted to identify the interchain
disulfide bonds in order to mutate these resi-
dues and thereby prevent dimerization of the
ligand. This turned out to be quite difficult
due to the high density of cysteine residues in
35 PDGF. The approach that finally succeeded
involved partial reduction of the PDGF molecule
using a concentration of dithiothreitol that

reduced only the interchain disulfide bonds, and left the intrachain bonds unaffected. By this procedure the second and fourth cysteine residues from the N-terminus were found to form the two interchain bonds in PDGF. Analysis of a PDGF B-chain mutant in which these two cysteine residues had been mutated to serine residues revealed that it retained receptor binding activity. Is it a receptor antagonist? The answer is no, in fact, the monomeric PDGF induced both receptor dimerization and autophosphorylation. This result may indicate that PDGF-induced receptor dimerization is not only a matter of forming a bridge between two receptor molecules: the dimerization may also involve a ligand-induced conformational change of the extracellular domains of the receptors which promotes receptor-receptor interactions. One possible way of achieving an antagonistic effect, which we are currently exploring, is to combine a wild-type PDGF chain with a mutated chain that does not bind to PDGF receptors but can actively prevent dimerization of receptors. [Citations omitted.]

Spada A. P., et al., entitled "Bis Mono- and Bicyclic Aryl and Heteroaryl Compounds Which Inhibit EGF and/or PDGF Receptor Tyrosine Kinase," PCT/US92/03736, mentions the use of certain bis mono and bicyclic aryl compounds. According to Spada:

In accordance with the present invention, there is provided a method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration to a patient of an EGF and/or PDGF receptor inhibiting effective amount of a bis mono- and/or bicyclic aryl and/or heteroaryl compound exhibiting

protein tyrosine kinase inhibition activity wherein each aryl and/or heteroaryl group is a ring system containing 0-4 hetero atoms, said compound being optionally substituted or polysubstituted.

Summary of the Invention

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see Figure 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Unwanted cell proliferation can result from inappropriate PDGF-R activity occurring in different types of cells including cancer cells, cells surrounding a cancer cell (stromal cells), endothelial and smooth muscle cells. For example, an increase in PDGF-R activity of endothelial cells surrounding cancer cells may lead to an increased vascularization of the tumor, thereby facilitating growth of the cancer cells. Thus, inappropriate PDGF-R activity can contribute to a cell proliferative disorder in different ways such as through increasing the production of growth factors, causing aberrant growth of a cell, and increasing formation and spreading of blood vessels in solid tumors thereby supporting tumor growth.

Other members of the PDGF-R super family are also involved in supporting tumor growth. Member of the PDGF-R super family have a kinase domain containing at least 45% sequence similarity with the kinase domain of α - or β - PDGF-R. Vascular endothelial growth factor (VEGF) 5 activates at least tyrosine kinase receptors; Flk-1 or its human homologue KDR, and Flt-1. Both of these receptors are expressed on endothelial cell and appear to be important in angiogenesis. Plate et al., *Nature* 359:845-848, 10 1992; Shweiki, et al., *Nature* 359:843-845, 1992; Millauer et al., *cell* 72:835-846, 1993; Plate et al., *Cancer Res.*, 53:5822-5827, 1993; Waltenberger et al., *Journal of Biological Chemistry* 43:26988-26995, 1994. Vascularization is essential for solid tumor growth and is thought to be 15 regulated by tumor cell factors which have chemotactic and/or mitogenic effects of endothelial cells. PDGF-R, KDR and Flt-1, are all involved in blood vessel formation and spreading feeding solid tumors. By inhibiting both PDGF-R and one or more related tyrosine kinase activities 20 both aberrant cell growth and the feeding of such growth can be inhibited.

Many examples of compounds (see Figs. 1 a-k) belonging to the featured groups (see Figs. 2 a-j) are described. Those skilled in the art can obtain other 25 compounds, to inhibit PDGF-R and preferably Flt and/or KDR, having equivalent or greater activity at these receptor tyrosine kinases using the present disclosure as a guide. For example, the assays described herein can be used to readily screen other compounds belonging to the 30 featured groups (see, Figs. 2 a-j) for equivalent activity. Using standard assays, the site of action of any one of the compounds described below may be determined and other compounds active at the same site determined.

The methods and compositions are designed to inhibit 35 unwanted cell proliferation by altering the activity of the PDGF-R, and preferably also altering activity of Flt and/or KDR. Without being bound to any theory, inhibition

of unwanted cell proliferation may be brought about by altering the activity of the PDGF-R (e.g., by inhibiting tyrosine phosphorylation of PDGF-R, by inhibiting substrate or adaptor protein binding to the receptor, or by
5 inhibiting other downstream signaling events), thereby inhibiting the activity of the PDGF-R. However, unless otherwise stated, the use of the claimed methods and compositions are not limited to this particular theory.

Thus, a first aspect of the present invention
10 features a method for treating a patient inflicted with a cell proliferative disorder characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition comprising a compound illustrated in
15 Figure 2 a-j, or the active product formed when any such compound is placed under physiological conditions (i.e., the active structural entity of a pro-drug described above). Administration of a particular compound is achieved by providing a particular compound to the patient
20 or providing a prodrug of the compound to a patient which forms the particular compound in vivo.

"Cell proliferative disorders" refer to disorders wherein unwanted cell proliferation of one or more subset of cells in a multicellular organism occurs resulting in
25 harm (e.g., discomfort or decreased life expectancy) to the multicellular organism. Cell proliferative disorders can occur in different types of animals and in humans. Cell proliferative disorders include cancers, blood vessel proliferative disorders, and fibrotic disorders.

30 "Inappropriate PDGF-R activity" refers to either 1) PDGF-R expression in cells which normally do not express PDGF-R; 2) PDGF expression by cells which normally do not express PDGF; 3) increased PDGF-R expression leading to unwanted cell proliferation; 4) increased PDGF expression
35 leading to unwanted cell proliferation; or 5) mutations leading to constitutive activation of PDGF-R. The existence of inappropriate or abnormal PDGF and PDGF-R levels

or activities is determined by procedures well known in the art.

The compositions can be used to treat a cell proliferative disorder by administering a therapeutically effective amount of the composition to a patient (*i.e.* a human or an animal having a cell proliferative disorder). The compositions may also be used in *in vitro* studies of the mechanism of action of the PDGF-R or PDGF itself.

A "therapeutically effective amount", in reference to the treatment of a cancer refers to an amount sufficient to bring about one or more of the following results: reduce the size of the cancer, inhibit the metastasis of the cancer, inhibit the growth of the cancer, stop the growth of the cancer, relieve discomfort due to the cancer, or prolong the life of a patient inflicted with the cancer.

A "therapeutically effective amount", in reference to the treatment of a cell proliferative disorder other than a cancer refers to an amount sufficient to bring about one or more of the following results: inhibit the growth of cells causing the disorder, relieve discomfort due to the disorder, or prolong the life of a patient suffering from the disorder.

"Significant" inhibition of a receptor tyrosine kinase activity refers to an IC_{50} of less than or equal to $75 \mu M$ using one or more of the assays described in the Examples *infra*. Preferably, the compound can inhibit PDGF-R activity with an IC_{50} of less than or equal to $50 \mu M$, more preferably less than or equal to $10 \mu M$, more preferably less than or equal to $1 \mu M$. Lower IC_{50} are preferred because the IC_{50} provides an indication as to the *in vivo* effectiveness of the compound. Other factors known in art, such as compound half-life, biodistribution, and toxicity should also be considered for therapeutic uses. Such factors may enable a compound with a lower IC_{50} to have greater *in vivo* efficacy than a compound having a higher IC_{50} .

Selective inhibition of the PDGF-R super family is achieved by significantly inhibiting PDGF-R activity, while having an insignificant effect (i.e. an IC_{50} for tyrosine phosphorylation greater than 100 μM on EGF-R.

5 Preferably, at least one other member of the PDGF-R super family, is significantly inhibited.

Preferably, the compound is either A10, A11, A12, A13, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, C10, C11, C13, D11, D12, D13, D14, D15, D16, D17, D18,
10 D20, E10, E11, E12, E13, E14, E15, E16, F10, F11, F12, G10, G11, G12, G13, G14, G15, G16, G17, G18, G19, G20, G21, G22, G23, G24, G25, G27, G28, G29, G30, H12, I10, J11, P10, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25 or the active drug of such
15 compounds, or pharmaceutically acceptable salts thereof. The compound is preferably used in a pharmaceutical composition formed by mixing one of the above compounds and a physiological acceptable carrier.

A physiological acceptable carrier is a formulation
20 to which the compound can be added to dissolve or otherwise facilitate administration of the compound. Examples of physiological acceptable carriers include water, saline, physiologically buffered saline, cyclodextrins and PBTE:D5W. Hydrophobic compounds such as A10 are preferably administered using a carrier such as PBTE:D5W. An
25 important factor in choosing an appropriate physiological acceptable carrier is choosing a carrier in which the compound remains active or the combination of the carrier and the compound produces an active compound. The
30 compound may also be administered in a continuous fashion using a slow release formulation or a pump to maintain a constant or varying drug level in a patient.

Another aspect of the present invention features a method of treating a patient suffering from a cell
35 proliferative disorder characterized by inappropriate PDGF-R activity using A10, A12, or B11. The method

involves administering to a patient a therapeutically effective amount of A10, A12, or B11.

Another aspect of the present describes a method of treating a patient suffering from a cancer characterized
5 by inappropriate PDGF-R activity using combination therapy. Combination therapy is carried out using one or more agent described herein along with standard anti-cancer agents. The method is carried out by administering to a cancer patient a therapeutically effective amount of
10 a composition comprising an agent able to significantly inhibit PDGF-R activity and a cytotoxic agent. Preferably, the cytotoxic agent is VP-16 or cisplatin. More preferably, the cytotoxic agent is cisplatin and the cancer is lung cancer.

15 Another aspect of the present invention features a method for treating a patient having a cell proliferation disorder characterized by inappropriate PDGF-R activity using mutated PDGF-R, or nucleic acid encoding a mutated PDGF-R. "Mutated" PDGF-R refers to PDGF-R wherein one or
20 more amino acid is missing or altered. As illustrated below a nucleic acid encoding a mutated (*i.e.*, a truncated) PDGF-R lacking a kinase domain can inhibit tumor growth *in vivo*. Mutated PDGF-R can be administered as a protein, or recombinant nucleic acid encoding the
25 protein and expressing the protein inside a cell.

In other aspects, the invention features novel compositions including one of the featured compounds herein described and PBTE:D5W carrier where the featured compound is soluble in PBTE:D5W; and the novel compounds
30 B10, B12, C10, C11, E10, E11, E12, E13, E14, E15, E16, F10, F11, F12, G21, G22, H11, H12, H13, and H14.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Figures

Figures 1 a-k illustrate the chemical structures of the preferred compounds.

Figures 2 a-j illustrate the generic chemical structure of groups 1-10 respectively.

Figure 3. NIH3T3 cells overexpressing the human PDGF-b (A) or the human EGF (B) receptor were treated with A10 as indicated. The percentage of cells in the S phase of the cell cycle was determined by flow cytometry.

Figure 4. In two separate experiments, C6 cells (1×10^5 cells in $4 \mu\text{L}$) were implanted into the cerebrum of BALB/c, nu/nu mice. A10 was administered IP in $100 \mu\text{L}$ PBTE:D5W at the indicated doses every day starting one day post-implantation. V = vehicle control. $n = 8$ to 12 (Expt #1), or 5 (Expt #2) animals per group. * $P < 0.00001$; ** $P < 0.002$; *** $P < 0.02$ compared to vehicle control.

Figure 5. In two separate experiments, C6 cells (5×10^4 cells in $20 \mu\text{L}$ [Expt #1] or $5 \mu\text{L}$ [Expt #2]) were implanted into the cerebrum of athymic rats. A10 was administered IP in $500 \mu\text{L}$ PBTE at the indicated doses every day starting one day post-implantation. V = vehicle control. $n = 7$ to 8 animals per group. * $P = 0.0002$; ** $P = 0.0003$ compared to vehicle control.

Detailed Description of the Invention

The present invention features methods and compositions for treating cell proliferative disorders characterized by inappropriate PDGF-R activity. The present application demonstrates the ability of compounds able to significantly inhibit activity of Flt-1 and/or PDGF-R, and provides examples of such compounds useful for treating a proliferative disease, such as cancer. The compounds described herein can be used in treatment of other proliferative diseases associated with inappropriate expression of PDGF-R, for example, blood vessel proliferative disorders and fibrotic disorders characterized by inap-

appropriate PDGF-R activity. Using the present disclosure as a guide, those in the art can readily determine which of the compounds described herein are useful to treat a particular proliferative disease.

5 A single target site, the presence of inappropriate PDGF-R activity, for a large number of disorders out of the many proposed targets in the art along with compounds able to inhibit PDGF-R activity and preferably Flt and/or KDR activity are described by the present application.
10 Preferably, PDGF-R activity along with KDR and/or Flt activities are inhibited by a single compound such as A10. Combinations of compounds or types of treatments can also be used to target different PDGF-R related tyrosine kinases. Examples of such combinations include using a
15 PDGF-R activity inhibitory compounds along with a KDR inhibitory compound, and using and PDGF-R nucleic acid to inhibit production of PDGF-R along with a KDR inhibitory compound.

 Compounds (also referred to herein as "drugs") useful
20 in this invention belong to at least eight different groups. The preferred compounds of these groups, and in other as yet undefined groups, that have generally exhibited significant inhibition of PDGF receptor activity are shown in Figures 1 a-k. While generic formulae are
25 presented, those in the art will recognize that those compounds useful in the invention can be determined by screening procedures described herein and known in the art.

 The ability of A10, truncated versions of a PDGF-R
30 and other compounds to inhibit tumor growth in animals illustrates the effectiveness and efficacy of these compounds. Such animal studies support the effectiveness of the compounds by demonstrating that the compounds can be effective in animals despite various problems which are
35 inherently associated with using compounds in animals to treat a particular ailment. The inherent problems include the animal being comprised of a heterogeneous cell

population, various pharmacological considerations such as bioavailability of the compound, the half life of the compound, and clearance of the compound. These inherent problems often prevent a compound from exerting a physiological effect.

Examples are provided below illustrating the ability of various compounds to inhibit PDGF-R phosphorylation. Examples are also provided illustrating the ability of the compound termed A10 (see Fig. 1a) to inhibit cancers in vivo. Rather, using the present disclosure as a guide one skilled in the art can use the featured methods and compositions to obtain additional inhibitory compounds and to target other cell proliferative disorders characterized by an inappropriate PDGF-R activity.

I. PDGF-R Super Family

A. PDGF-R Activity

Ligand binding to the PDGF-R induces the formation of receptor dimers and allosteric changes that activate the intracellular kinase domains, and results in the trans-phosphorylation and/or autophosphorylation of the receptor on tyrosine residues. Receptor phosphorylation stimulates a physical association of the activated receptor with target molecules. Some of the target molecules are in turn phosphorylated, which transmits the signal to the cytoplasm. Other target molecules are not phosphorylated, but assist in signal transmission by acting as docking or adapter molecules for secondary signal transducer proteins. The secondary signal transducer molecules generated by activated receptors results in a signal cascade that regulates cell functions such as cell division. (See, Fry M.J. et al., *Protein Science* 2:1785-1797, 1993).

Thus, an increase in PDGF-R activity is characterized by an increase in one or more of the activities which can occur upon PDGF-R ligand binding: (1) phosphorylation or autophosphorylation of PDGF-R, (2) phosphorylation of a PDGF-R substrate (e.g., PL 3-kinase, RasGAP, PLCg, see Fry

supra), (3) activation of an adapter molecule, and (4) increased cell division. These activities can be measured using techniques described below and known in the art. For example autophosphorylation of PDGF-R can be measured
5 as described in the examples below using an anti-phosphotyrosine antibody, and increased cell division can be performed as described below by measuring ³H-thymidine incorporation into DNA. Preferably, the increase in PDGF-R activity is associated with an increased amount of
10 phosphorylated PDGF-R and DNA synthesis.

B. PDGF-R Related Kinases

PDGF-R related kinases Flt-1 and KDR can be activated by VEGF. VEGF is a monodimeric glycoprotein with structural homology to PDGF. Four different splice variants of
15 VEGF have been isolated. Rosenthal, et al., *Growth Factors*, 4:53-59, 1990; Conn, et al., *Proc. Natl. Acad. Sci. (USA)*, 87:1323-1327, 1990; Houck, et al., *Mol. endocrinol.*, 5:1806-1814, 1991; two are secreted forms and two remain cell-associated. VEGF has been shown to be
20 upregulated by hypoxia and acts specifically on endothelial cells. Plate et al., *Nature*, 359:845-848, 1992; Shweike, et al., *Nature* 359:843-845, 1992.

KDR activity is characterized by an increase in one or more of the activities which can occur upon VEGF ligand
25 binding: (1) phosphorylation or autophosphorylation of KDR, (2) phosphorylation of a KDR substrate, (3) activation of an adapter molecule, and (4) increased cell division.


Flt-1 activity is characterized by an increase in one
30 or more of the activities which can occur upon VEGF ligand binding: (1) phosphorylation or autophosphorylation of Flt-1, (2) phosphorylation of a Flt-1 substrate, (3) activation of an adapter molecule, and (4) increased cell division.

II. FEATURED COMPOUNDS

Compounds of groups 1 to 11 are shown in Figs. 2 a-k.

A. Group 1 compounds

Group 1 compounds have the following basic structure:



5 where R_1 , R_2 , R'_2 , R''_2 , and R'''_2 are independently selected from the group consisting of hydrogen, halogen, trihalomethyl, and NO_2 ; preferably R_1 and R_2 are independently CF_3 , NO_2 or hydrogen, and R'_2 , R''_2 , and R'''_2 are hydrogen; and

10 R_3 is selected from the group consisting of hydrogen, carboxy, alkoxy, or carbalkoxy; preferably hydrogen, carboxy, or methyl.

Examples of group 1 compounds are listed in Table I and shown in Fig 1a.


15 Table I

Compound	R_1	R_2	R_3
A10	CF_3	H	H
A11	H	CF_3	H
A12	CF_3	H	Carboxy
20 A13	CF_3	H	CH_3

These compounds are believed to act as prodrugs in that the ring is cleaved *in vivo* to yield active metabolites.

B. Group 2 compounds

Group 2 compounds have the following basic structure:



where R_4 and R_5 are independently halogen, hydrogen, trihalomethyl, or NO_2 ; preferably R_4 is CF_3 and R_5 is H; R_6 is either aryl, alkyl, alkenyl, or alkynyl;


R_6 is alkyl or one of the substituents of the compounds listed in Table II. Examples of group 2 compounds are listed in Table II and shown in Fig 1b.

Table II

Compound	R_4	R_5	R_6
B10	NO_2	H	CH_3
B17	CF_3	H	CH_3
B12	CF_3	H	4-fluorophenyl
B13	CF_3	H	cyclohexyl
B14	CF_3	H	2,2,3,3-tetramethylcyclopropyl
B15	CF_3	H	pentafluorophenyl
B16	CF_3	H	3-phenoxy-phenyl
B17	CF_3	H	benzyl
B18	CF_3	H	2-methylpropyl
B19	CF_3	H	diphenylmethyl

C. Group 3 Compounds

Group 3 compounds have the following structure:



where R_7 , R'_7 , and R_8 are independently halogen, OH, hydrogen, alkoxy, SH, NH_2 , or $C(CH_3)_3$, preferably R'_7 , R_7 , and R_8 is independently selected from H, OH, and $C(CH_3)_3$; more preferably, R_7 and R_8 are OH; R_9 is aryl or hydrogen, preferably hydrogen or phenyl. Examples of group 3 compounds are listed in Table III and shown in Fig 1c.


Table III

Compound	R'_7	R_7	R_8	R_9
C10	H	OH	OH	phenyl
C11	H	OH	OH	H
C13	$C(CH_3)_3$	OH	$C(CH_3)_3$	H

D. Group 4 Compounds

Group 4 compounds have the following chemical structure:

18



where R_{10} is either $=S$, $=O$, SH , OH , or NH_2 ; and

R_{11} is SH , OH , NH_2 , $=C(CN)_2$ or aryl, preferably NH_2 , $=C(CN)_2$, or dihydroxyl-phenyl; or R_{10} and R_{11} taken together are aryl, preferably 3-amino-4-cyano-5-pyrazole or 1-phenyl-3-amino-4-cyano-5-pyrazole; and R_{12} is hydrogen, aryl, alkyl, alkenyl, or alkynyl, preferably hydrogen, $-(CH_2)_2CN_2$ or $-(CH_2)_2N(CH_3)_2$.

Examples of group 4 compounds are listed in Table IV and shown in Fig 1d.


10 Table IV

Compound	R_{10}	R_{11}	R_{12}
D11	$=S$	NH_2	H
D12	NH_2	$=C(CN)_2$	H
D13	$=O$	NH_2	H
D14	3-amino-4-cyano-5-pyrazoyl		H
D15	3-amino-4-cyano-5-pyrazoyl		$-(CH_2)_2N(CH_3)_2$
D16	$=O$	3,4-dihydroxyl-phenyl	$-(CH_2)_2N(CH_3)_2$
D17	$=O$	3,4-dihydroxyl-phenyl	$-(CH_2)_2CN_2$
D18	3-amino-4-cyano-5-pyrazoyl		$-(CH_2)_2N(CH_3)_2$
D20	1-phenyl-3-amino-4-cyano-5-pyrazoyl		H

SUBSTITUTE SHEET (RULE 26)

E. Group 5 Compounds

Group 5 compounds have the following chemical structure:



where R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , and R_{18} are independently hydrogen, halogen, alkoxy, OH, amino, alkylamino, or SH; preferably hydrogen or OH.

Examples of group 5 compounds are listed in Table V and shown in Figure 1e.


Table V

Compound	R_{13}	R_{14}	R_{15}	R_{16}	R_{17}	R_{18}
E10	OH	OH	H	H	H	$N(CH_3)_2$
E11	OH	OH	H	H	OH	H
E12	H	H	OH	H	OH	H
E13	OH	OH	H	OCH_3	H	H
E14	OH	OH	H	OC_2H_5	H	H
E15	OH	OH	H	H	NO_2	H
E16	OH	H	H	H	NO_2	H

F. Group 6 Compounds

Group 6 compounds have the following chemical structure:

20



where R_{19} is aryl, alkyl, alkenyl or alkynyl preferably 2-(3,4,-dihydroxyphenyl) ethenyl; R_{20} is an alkyl preferably ethylenedihydroxy; or R_{19} and R_{20} are together aryl preferably a morpholine ring having a =CH-
 5 (mono or dihydroxy-phenyl) substituent.


Examples of group 6 compounds are set forth in Table VI and shown in Figure 1f.

Table VI

Compound	R_{19}	R_{20}
F10	$(CH_2)_2OH$	$CH=CH-3,3\text{-dihydroxyphenyl}$
F11	$2-C=CH-(3,4\text{-dihydroxyphenyl})$	morpholino
F12	$2-C=CH-(3\text{-hydroxyphenyl})$	morpholino

G. Group 7 Compounds

Group 7 compounds have the following chemical
 15 structure:



where b is an optional pi bond,

Y and Z are independently carbon or nitrogen;

R_{21} and R_{22} , are independently hydrogen, halogen, OH, SH, NH_2 , NO_2 , alkyl, alkenyl, alkynyl, alkoxy, benzoyl,

SUBSTITUTE SHEET (RULE 26)

COOH, or carbalkoxy, preferably OH, NO₂, CH₃, methoxy, benzoyl, or COOH; or R₂₁ and R₂₂ together form an aromatic ring to give an aryl, preferably phenyl;

R₂₃ is hydrogen, halogen, =O, OH, SH, NH₂, alkoxy, COOH, aryl, preferably or a substituted or unsubstituted anilino, a substituted or unsubstituted phenyl, hydrogen, COOH, =O, alkoxy, or methoxy, provided that if R₂₃ is =O b is present as a bond;

R₂₄ is H, or aryl, preferably a substituted or unsubstituted anilino, phenyl, or 2-thienyl; and

R₂₅ is hydrogen, halogen, =S, or =O, wherein if R₂₅ is =O or =S, b is present as a bond; provided that if b is no bond, the adjacent nitrogen optionally has a substituent selected from the consisting of hydrogen, alkyl, alkyleneamino, alkyleneaminoalkyl, and alkylenecyano.

Examples of group 7 compounds are set forth in Table VII and shown in Figure 1g.


Table VII

Compound	b	Y	Z	R ₂₁	R ₂₂	R ₂₃	R ₂₄	R ₂₅
G10	bond	N	C	H	H	H	phenyl	H
G11	bond	C	C	OCH ₃	OCH ₃	OCH ₃	phenyl	Cl
G12	bond	C	C	OCH ₃	OCH ₃	H	phenyl	Cl
G13	bond	N	C	CH ₃	CH ₃	H	phenyl	H
G14	bond	N	C	OCH ₃	OCH ₃	H	phenyl	H
G15	bond	N	C	H	H	H	2-thienyl	H
G16	bond	N	N	H	H	H	phenyl	H
G17	bond	N	C	OH	OCH ₃	H	phenyl	H
G18	no bond	N	C	CH ₃	CH ₃	=O	phenyl	H
G19	bond	N	C	H	CH ₃	H	phenyl	H
G20	bond	N	C	OH	OH	H	phenyl	H
G21	bond	N	C	H	benzoyl	H	phenyl	H
G22	bond	N	C	phenyl		H	phenyl	H
G23	bond	N	C	H	NO ₂	H	phenyl	H

5	G24	bond	N	C	CH ₃	CH ₃	3,4-dyhyd-roxy-phenyl	phenyl	H
	G25	bond	N	C	CH ₃	CH ₃	COOH	phenyl	H
	G27	bond	N	C	CH ₃	CH ₃	H	NO ₂	H
	G28	bond	N	C	CH ₃	CH ₃	H	3-bromo-phenyl amino	H
	G29	bond	N	C	CH ₃	CH ₃	3-iodo-phenyl amino	H	N
	G30	bond	N	C	CH ₃	CH ₃	4-iodo-phenyl amino	H	H

H. Group 8 Compounds

Group 8 compounds have the following chemical structure:



10 where R₂₆ and R₂₈ is independently alkyl, aryl, alkenyl, or alkynyl; and


R₂₇ is aryl. Examples of group 8 compounds are set forth in Table VIII and shown in Figure 1h.

Table VIII.

Compound	R ₂₆	R ₂₇	R ₂₈
H10	CH ₃	benzyl	3,4-dihydroxyphenyl
H11	CH ₃	benzyl	2-hydroxyphenyl
H12	CH ₃	benzyl	3-hydroxyphenyl
H13	CH ₃	benzyl	4-hydroxyphenyl
H14	CH ₃	benzyl	3,4,5-trihydroxyphenyl

I. Group 9 Compounds

Group 9 compounds have the following chemical structure:



where R₃₀ is either alkyl, alkenyl, or alkynyl, preferably CH₃;

R₃₁ is aryl, preferably phenyl; and


R₃₂ is either O or S.

An example of a group 8 compound is I10, shown in Figure 1i.

J. Group 10 Compounds

Group 9 compounds have the following chemical structure:

24



where R_{33} is alkyl or aryl;

R_{34} , R_{35} , and R_{36} are independently halogen, OH, hydrogen, alkoxy, SH, NH_2 , or $C(CH_3)_3$, preferably R_{34} , R_{35} , and R_{36} is independently selected from H, OH, and $C(CH_3)_3$.

5 Examples of group 9 compounds are J10 and J11, shown in Figure 1j.

K. Group 11 Compounds

Examples of Group 11 compounds are shown in Figure 1k. Group 10 compounds are identified by a "P."

10 L. Chemical Nomenclature

Definitions of some of the chemical groups mentioned in the application are described below.

An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and
 15 cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons, more preferably from 3 to 9 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted groups is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO_2 or $N(CH_3)_2$, amino, SH,
 20 or aryl.

An "alkenyl" group refers to an unsaturated hydrocarbon group containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12
 25 carbons, more preferably from 3 to 9 carbons. The alkenyl group may be substituted or unsubstituted. When substi-

tuted the substituted groups is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino, SH, or aryl.

An "alkynyl" group refers to an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons, more preferably from 3 to 9 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted groups is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino, SH, or aryl.

An "alkoxy" group refers to an "-O-alkyl" group, where "alkyl" is defined as described above.

An "aryl" group refers to an aromatic group which has at least one ring having conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituents of aryl groups are hydroxyl, cyano, alkoxy, alkyl, alkenyl, alkynyl, amino, and aryl groups.

Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are carbon atoms. The carbon atoms are optionally substituted. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and optionally substituted naphthyl groups.

Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted.

A "carbalkoxy" group refers to a COOX group, wherein "X" is an lower alkyl group.

The term "lower" referred to herein in connection with organic radicals or compounds respectively defines such with up to and including 7, preferably up to and including 4, and advantageously one or two carbon atoms. Such groups may be straight chain or branched.

SUBSTITUTE SHEET (RULE 26)

II. Cell Proliferative Disorders

The described compositions and methods are designed to inhibit cell proliferative diseases by inhibiting PDGF-R activity. As discussed above, proliferative disorders
5 result in unwanted cell proliferation of one or more subset of cells in a multicellular organism resulting in harm to the organism. Inappropriate PDGF activity can stimulate of cell proliferative disorders. Two ways in which inappropriate PDGF or PDGF-R activity can stimulate
10 unwanted cell proliferation of a particular type of cell are by directly stimulating growth of the particular cell, or by increasing vascularization of a particular area, such as tumor tissue, thereby facilitating growth of the tissue.

15 The use of the present invention is facilitated by first identifying whether the cell proliferation disorder is PDGF-R driven. Once such disorders are identified, patients suffering from such a disorder can be identified by analysis of their symptoms by procedures well known to
20 medical doctors. Such patients can then be treated as described herein.

Determination of whether the cell proliferation disorder is PDGF-R driven can be carried out by first determining the level of PDGF-R activity occurring in the
25 cell or in a particular body location. For example, in the case of cancer cells the level of one or more PDGF-R activities is compared for non-PDGF-R driven cancers (e.g. A431 cells as described below) and PDGF-R driven cancers (e.g., T98G glioblastoma cells as described below). If
30 the cancer cells have a higher level of PDGF-R activity than non-PDGF-R driven cancers, preferably equal to or greater than PDGF-R driven cancers, then they are candidates for treatment using the described PDGF-R inhibitors.

In the case of cell proliferative disorders arising
35 due to unwanted proliferation of non-cancer cells, the level of PDGF-R activity is compared to that level occurring in the general population (e.g., the average level

occurring in the general population of people or animals excluding those people or animals suffering from a cell proliferative disorder). If the unwanted cell proliferation disorder is characterized by a higher PDGF-R level
5 then occurring in the general population then the disorder is a candidate for treatment using the described PDGF-R inhibitors.

Cell proliferative disorders include cancers, blood vessel proliferation disorders, and fibrotic disorders.
10 These disorders are not necessarily independent. For example, fibrotic disorders may be related to, or overlap with, blood vessel disorders. For example, atherosclerosis (which is characterized herein as a blood vessel disorder) results in the abnormal formation of fibrous
15 tissue.

A cancer cell refers to various types of malignant neoplasms, most of which can invade surrounding tissues, and may metastasize to different sites, as defined by Stedman's Medical Dictionary 25th edition (Hensyl ed.
20 1990). Examples of cancers which may be treated by the present invention include those intra-axial brain cancers, ovarian cancers, colon cancers, prostate cancers, lung cancers, Kaposi's sarcoma and skin cancers, which have inappropriate PDGF-R activity. These types of cancers can
25 be further characterized. For example, intra-axial brain cancers include glioblastoma multiforme, anaplastic astrocytoma, astrocytoma, ependymoma, oligodendroglioma, medulloblastoma, meningioma, sarcoma, hemangioblastoma, and pineal parenchymal.

30 The formation and spreading of blood vessels, or vasculogenesis and angiogenesis respectively, play important roles in a variety of physiological processes such as embryonic development, wound healing and organ regeneration. They also play a role in cancer develop-
35 ment. Blood vessel proliferation disorders refer to angiogenic and vasculogenic disorders generally resulting in abnormal proliferation of blood vessels. Examples of

such disorders include restenosis, retinopathies, and atherosclerosis.

The advanced lesions of atherosclerosis result from an excessive inflammatory-proliferative response to an
5 insult to the endothelium and smooth muscle of the artery wall. (Ross R., *Nature* 362:801-809 (1993).) Part of the response appears to be mediated by PDGF-BB secretion, and activation of PDGF-R in endothelial and smooth muscle cells. Both cell migration and cell proliferation play a
10 role in the formation of atherosclerotic lesions.

Fibrotic disorders refer to the abnormal formation of extracellular matrix. Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders.

15 Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can cause diseases such as cirrhosis of the liver. An increased extracellular matrix resulting in a hepatic scar can also
20 be caused by viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis. Inappropriate PDGF-R activity can stimulate lipocyte proliferation.

Mesangial cell proliferative disorders refer to
25 disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant
30 rejection, and glomerulopathies. PDGF has been implicated in the maintenance of mesangial cell proliferation. (Floege, J. et al., *Kidney International* 43S:47-54 (1993).)

As noted above, other such proliferative diseases can
35 be identified by standard techniques, and by determination of the efficacy of action of the compounds described herein.

A. Ovarian cancer

One aspect of the invention relates to the treatment of ovarian cancer. Epithelial ovarian cancer accounts for nearly 90% of all ovarian tumors and continues to be a highly lethal malignancy. Approximately 19,000 new cases of ovarian cancer are diagnosed in the United States annually, and 12,000 of these women will die from the cancer (Rodriguez et al., in DeVita, Hellman, Rosenberg (eds) *Biologic Therapy of Cancer*, JB Lippincott, 1991).

10 Treatment for advanced ovarian cancer generally includes cytoreductive surgery followed by combination chemotherapy with alkylating agents such as cisplatin and cyclophosphamide. However, long term survival of advanced ovarian cancer patients is extremely poor, in the range of 15 10% - 20%, principally because of the high incidence of metastatic tumors throughout the peritoneal cavity, and, in some cases, the lymph-nodes. Moreover, chemotherapy with cisplatin carries a potential for renal toxicity and progressive neuropathy.

20 The invention reveals a pathological relationship between PDGF receptor expression and epithelial ovarian cancer, and provides compositions and methods for inhibiting inappropriate PDGF-R activity in epithelial ovarian cancer cells to inhibit proliferation of the disease. 25 Methods of treating ovarian cancers comprise administering a composition which inhibits inappropriate PDGF-R activity in ovarian carcinoma cells, in supporting stromal cells (i.e., the framework upon which a tumor or metastatic lesion grows, including but not limited to connective 30 tissue and vascular endothelial cells), and/or in associated vascular endothelial cells.

Ovarian cancers susceptible to treatment with the compounds described herein include epithelial ovarian carcinoma, ovarian tumor metastases, and other cells of 35 the ovary which express PDGF receptors. As described below, compositions which inhibit PDGF-R activity also inhibit proliferation of ovarian cancer cells in vitro and

inhibit the growth of ovarian tumors *in vivo*. More specifically, the use of one composition of the invention, A10, results in nearly complete inhibition of ovarian tumor growth in mice xenotransplanted with human ovarian cancer cells, without significant cytotoxicity or mortality, thus providing a dramatic therapeutic effect.

Accordingly, as an example of the method of the invention, A10 is administered to a patient diagnosed with ovarian cancer via any route of administration and in any suitable pharmaceutical carrier which results in bringing A10 in contact with PDGF receptor-positive ovarian cancer cells and/or cells of the surrounding stroma. In view of the localized spread of ovarian cancer throughout the peritoneal cavity, a preferred method of administration, particularly in advanced cases, is by intravenous or intraperitoneal injection of a non-toxic pharmaceutical formulation of A10.

The preparation and use of therapeutically effective compositions for treating ovarian cancers are described in detail in the sections which follow and by way of examples, *infra*. In addition to the compositions specifically disclosed herein, the invention provides for the identification of other compositions which, because of their inhibitory effect on PDGF-R activity may be useful for inhibiting the proliferation of ovarian neoplasms. Candidate compositions may be identified by their ability to inhibit PDGF receptor autophosphorylation using any suitable assay, such as *in vitro* autophosphorylation inhibition ELISA and tyrosine kinase inhibition assays. Candidate compositions may be evaluated for therapeutic efficacy by testing their capacity to inhibit ovarian cancer cell growth and, ideally, by testing inhibition of xenografted tumors *in vivo*. The procedures described in the examples, *infra*, or similar procedures, may be employed for conducting such tests.

B. Glioma

Another aspect of the invention relates to the treatment of primary intra-axial brain tumors of the glioma family, including, but not limited to, astrocytomas and glioblastomas. Glioblastoma multiforme is the most common and most malignant tumor of astrocytic origin in human adults and accounts for more than half of all primary brain tumors (See, for example, *Cecil Textbook of Medicine*, Wyngaarden, Smith, Bennett (eds) WB Saunders, 1992, p. 2220).

Gliomas have the common property of direct invasive involvement of brain tissue, are fundamentally malignant, and are inevitably fatal. Glioblastoma patients have a median survival time of less than one year even when treated aggressively with a combination of surgery, chemotherapy, and radiotherapy. Unfortunately, successful surgical intervention is extremely rare in view of the difficulty or impossibility of defining the microscopic borders of a glioma within normal brain tissue. Similarly, chemotherapy with alkylating agents has met with very little success, and no more than 10% of glioma patients respond significantly. Radiation therapy has demonstrated some value in controlling the growth of gliomas, but often results in substantial neurologic impairment. Therapy with interferon- β , in combination with radiotherapy and chemotherapy, has met with some success (DeVita, Hellman, Rosenberg (eds) *Biologic Therapy of Cancer*, JB Lippincott, 1991).

The invention reveals a pathological relationship between PDGF receptor expression and glioma, and provides compositions and methods for inhibiting PDGF activity in glioma cells to inhibit proliferation of the disease. Methods of treating gliomas comprise administering a composition which inhibits PDGF-R activity expressed in glioma cells and/or in proximate vascular endothelial cells. In particular, most of the compositions specifically disclosed herein are highly active at inhibiting PDGF

receptor autophosphorylation in human glioma cells in vitro. Several of these compositions inhibit the growth of cultured glioma cells, and one of these, A10, also inhibits the growth of various glioma explant cultures.

5 Moreover, A10 strongly suppresses the growth of xenografted gliomas in mice; in some animals, tumor growth was inhibited by greater than 95% relative to untreated controls.

Accordingly, as an example of the method of the invention, A10 is administered to a glioma patient via any route of administration and in any suitable pharmaceutical carrier which will result in bringing A10 in contact with PDGF receptor-positive glioma cells, as well as proximate vascular endothelial cells, which typically proliferate in high grade gliomas. Intravenous and intra-arterial routes may be preferred routes of administration. In addition, recently-developed micro-catheter technology may be particularly effective at delivering the compositions of the invention directly to the site of the glioma, thereby achieving immediate localized contact with the cancer and proximate endothelial cells and possibly minimizing potential toxicity associated with more distal intra-arterial delivery.

The preparation and use of therapeutically effective compositions for the treatment of gliomas are described in detail in the sections which follow and by way of examples, *infra*. In addition to the compositions specifically disclosed herein, the invention provides for the identification of other compositions which, because of their inhibitory effect on PDGF receptor activity, may be useful for inhibiting the proliferation of various intra-axial tumors. Candidate compositions may be identified by their ability to inhibit PDGF receptor activity using any suitable assay, such as in vitro autophosphorylation inhibition ELISA and tyrosine kinase inhibition assays. Candidate compositions may be evaluated for therapeutic efficacy by testing inhibition of glioma cell growth and,

ideally, by testing inhibition of xenografted tumors *in vivo*.

III. A10

The present invention describes various compositions
5 which can be used to inhibit PDGF-R activity and thereby
inhibit cell proliferation disorders. The use of A10 to
inhibit tumor growth in animals demonstrates the ability
of these compositions to function *in vivo* despite various
pharmacological considerations which are expected to
10 prevent the composition from exerting its effect. Such *in vivo*
inhibition is illustrated in the examples described
below.

A10 is also known as leflunomide, HWA 486, and 5-
methylisoxazole-4 carboxylic acid-(4-trifluoromethyl)-
15 anilide. Various publications have discussed different
possibly uses of A10. According to the abstracts of
Kömmerer F-J, et al., U.S. Pat. No. 4,284,786 (1981) and
Kömmerer F-J, et al., U.S. Pat. No. 4,351,841 (1982), A10
"has antirheumatic, antiphlogistic, antipyretic and
20 analgesic action, and can be used for the treatment of
multiple sclerosis." According to Talmadge J.E., and
Twardzik D.R. *Agents and Actions* 35S:135-141 (1991), "the
hypothesis was suggested that the mechanisms of
Leflunomide activity may be the inhibition of a cytokine
25 specific kinase." Robertson S. M. and Lang L.S., European
Patent Application 0 413 329 A2 (published 1991) which is
concerned with 5-methylisoxazole-4-carboxylic acids that
encompass leflunomide, asserts:

The present invention is directed to methods for
30 treating ocular diseases with immune etiology
through the use of 5-methyl-isoxazole-4-
carboxylic acid anilides and hydroxyethylidene-
cyano acetic acid anilide derivatives. In
addition the compounds are useful for treating
35 ocular manifestation associated with systemic
diseases with immune etiology. The compounds

exhibit immunosuppressive, antiinflammatory, and mild antiallergic activity and are useful for the treatment of eye diseases such as uveitis (including rheumatoid nodules), retinitis, 5 allergy (vernal keratoconjunctivitis and allergic or giant papillary conjunctivitis) and dry eye (Sjogren's syndrome). Additionally the compounds are useful for prolonging graft survival of corneal or other ocular tissue and 10 are useful as surgical adjuncts in patients which are atopic or immune impaired.

The abstract of Barlett R.R. et al., entitled "Isoxazole-4-Carboxamides and Hydroxyalkylidene-Cyanoacetamides, Drugs Containing These Compounds and Use 15 of Such Drugs" PCT/EP90/01800, asserts:

Isoxazole-4-carboxamide derivatives and hydroxy-alkylidene-cyanoacetamide derivatives are suitable for the treatment of cancer diseases. These compounds can be prepared by prior art 20 methods. Some of them are new and are suitable, in addition, for the treatment of rheumatic diseases.

Bartlett R.R. et al., *Agents and Actions* 32:10-21 (1991), asserts that "[l]eflunomide has been shown to be 25 very effective in preventing and curing several autoimmune animal diseases." Barlett also asserts that:

... , we could show that tyrosine phosphorylation of the RR-SRC peptide substrate and the autophosphorylation of the epidermal growth 30 factor (EGF) receptor were, dose dependently, inhibited by leflunomide.

Matter et al., *FEBS* 334:161-164 (Nov. 1993) (not admitted to be prior art) describes the use of the active metabolite of leflunomide to inhibit EGF-dependent cell 35 growth, including A431 cells. Matter also asserts:

Platelet-derived growth factor-dependent tyrosine phosphorylation was also inhibited by

A77 1726 in intact cells at concentrations similar to EGF-dependent phosphorylation described in Fig. 3 (data not shown).

Studies on one composition of the invention, A10, described more fully and by way of example *infra*, establish its potency against brain, lung, prostate, ovarian, skin, and colon cancer cells characterized by inappropriate PDGF-R activity rather than EGF activity. As illustrated in the examples described below A10 inhibits PDGF-R activity while having little if any effect on EGF-receptor or HER2 phosphorylation. In addition, while A10 inhibited growth of tumors characterized by inappropriate PDGF-R activity, A10 did not significantly inhibit the growth of xenotransplanted cells expressing EGF receptor (A431 epidermoid cells). This data is surprising in view of the results described by Bartlett *et al.*, *supra*, *Agents and Actions* in which leflunomide was shown to inhibit EGF induced EGF receptor autophosphorylation and cell proliferation, and Matter *et al.*, *supra*, in which the active metabolite of leflunomide inhibited growth of A431 cells.

The present disclosure demonstrates the ability of A10 to inhibit inappropriate PDGF-R activity and unwanted cell proliferation *in vivo*, such as occurs in cancers characterized by inappropriate PDGF-R activity. As illustrated by the examples described below, A10 can be used to selectively inhibit inappropriate PDGF-R activity.

A compound is judged to effect phosphorylation if its ability to inhibit phosphorylation of a receptor (e.g., the IC_{50} as described below) is less than its cytotoxic effect (e.g., the LD_{50} as described below). Inhibition of phosphorylation of different receptor such as PDGF-R, EGF-R or HER-2 receptor is dependent on conditions such as drug concentration. By "selectively inhibit" it is meant that a compound can be used at a particular concentration to inhibit phosphorylation of the PDGF-R and have little if any effect on the phosphorylation of the EGF-R and/or HER-2 receptor at the same concentration.

Preferably, the compound, like A10 can inhibit PDGF-R while having little if any effect on EGF-R and/or HER-2 phosphorylation. By "little if any effect" on EGF-R, or HER-2, activity is meant the receptor activity is effected
5 no more than 35%, more preferably, no more than 20%, most preferably no more than 10%, at a particular receptor.

Tyrosine kinases are important in many biological processes including cell growth, differentiation, aggregation, chemotaxis, cytokine release, and muscle contraction.
10 tion. Many of these events are mediated through different tyrosine kinase receptors. In addition, different tyrosine kinase receptors may be important for a particular biological function in different cell types. By developing selective inhibitors of PDGF-R the possible toxic
15 effect of the compound is decreased.

The compounds described herein vary in their ability to selectively inhibit PDGF-R. For example D14, G12, G13 and G14 inhibit PDGF-R phosphorylation but do not effect EGF or Her-2 phosphorylation, while C10 effects EGF-R,
20 PDGF-R, and Her-2 phosphorylation.

IV. Mutated PDGF-R

Cell proliferative disorders characterized by inappropriate PDGF-R activity can also be inhibited using a mutated PDGF-R. Ueno H., et al., Science 252:844-252
25 (1991), describe nucleic acid encoding truncated PDGF-R to inhibit PDGF-R phosphorylation in vitro. According to Ueno:

When truncated receptors were expressed in excess compared to wild-type receptors, stimulation by PDGF of receptor autophosphorylation,
30 association of phosphatidylinositol-3 kinase with the receptor, and calcium mobilization were blocked.

Ueno did not demonstrate that inhibition of PDGF-R activity by a mutated protein could inhibit unwanted cell proliferation.
35

Such *in vivo* inhibition of unwanted cell proliferation is illustrated in the examples described below using nucleic acid encoding the PDGF-R having a stop codon just upstream from the first tyrosine kinase domain. The nucleic acid is used to introduce the truncated protein into a cell. For example, the nucleic acid encoding a truncated PDGF-R is placed into a retroviral vector using standard recombinant DNA techniques. The vector then infects a cell where its nucleic acid is ultimately translated into protein producing a truncated PDGF-R. Other means of introducing the mutated protein into a cell include preparing the mutated protein *in vitro* and introducing the protein into the cell with a vector, such as a liposome.

Mutant PDGF-R should be constructed to interfere with intermolecular phosphorylation that occurs between dimerized receptor. This can be accomplished by various means such as 1) truncation of the PDGF-R, preferably to eliminate one tyrosine kinase domain, and most preferably to eliminate both tyrosine kinase domains; 2) mutations which inhibit the catalytic ability of the PDGF-R catalytic domain, such as mutation of lysine 602 to arginine which prevents the binding of ATP. Of these methods, mutation of tyrosine residues is preferred and truncation of the receptor is most preferred.

The use of nucleic acid encoding truncated PDGF-R to inhibit tumor growth in animals demonstrates the ability of such truncated receptors to function *in vivo* despite various pharmacological considerations which would be expected to prevent the composition from exerting its effect. Thus, the present disclosure demonstrates that the use of nucleic acid encoding truncated PDGF receptor is not limited to inhibition of PDGF-R in cell culture. Rather nucleic acid encoding PDGF-R can be used to inhibit inappropriate PDGF-R activity in animal cells thereby inhibiting the growth of tumors in animal cells, and having application in other PDGF-R related disorders.

V. Administration of Featured Compounds

The compounds of this invention can be administered to a patient alone, or in a pharmaceutical composition comprising the active compound and a carrier or excipient.

- 5 The compounds can be prepared as pharmaceutically acceptable salts (i.e., non-toxic salts which do not prevent the compound from exerting its effect).

Pharmaceutically acceptable salts can be acid addition salts such as those containing hydrochloride, 10 sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzene-sulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. (See e.g., supra. PCT/US92/03736). Such salts can derived using acids such as hydrochloric acid, 15 sulfuric acid, phosphoric acid and sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzene-sulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.

- 20 Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the compound is first dissolved in a suitable solvent such as an aqueous or aqueous-alcohol solution, containing the appropriate acid. The salt is then isolated by evaporat- 25 ing the solution. In a another example, the salt is prepared by reacting the free base and acid in an organic solvent.

- Carriers or excipient can be used to facilitate administration of the compound, for example, to increase 30 the solubility of the compound. Examples of carriers and excipient include calcium carbonate, calcium phosphate, various sugars or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or 35 pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal,

subcutaneous, and intramuscular, orally, topically, or transmucosally.

Several of the featured compounds, such as A10 and B11, are hydrophobic and thus not very soluble in water.

5 Effective doses of A10 can be obtained by using A10 in combination with PBTE:D5W. PBTE consists of a solution of 3% w/v benzyl alcohol, 8% w/v polysorbate 80, and 65% w/v polyethylene glycol (MW = 300 daltons) in absolute ethanol. PBTE:D5W consists of PBTE diluted 1:1 in a

10 solution of 5% dextrose in water. The solubility of A10 in PBTE is about 60 mg/ml, and the solubility of A10 in PBTE:D5W is about 5 mg/ml. The solubility of the other compounds described herein can be obtained using standard techniques. In addition, the active drug itself (e.g.,

15 B11) may be administered in an oral formulation.

Another way of overcoming the hydrophobicity problem includes the use of frequent small daily doses rather than a few large daily doses. For example, the composition can be administered at short time intervals, preferably the

20 composition can be administered using a pump to control the time interval or achieve continuously administration. Suitable pumps are commercially available (e.g., the ALZET® pump sold by Alza corporation, and the BARD ambulatory PCA pump sold by Bard MedSystems).

25 Alternatively, prodrugs having increased solubility can be used. Prodrugs can break down into the active drug under physiological conditions. For example, Patterson et al., *J. Med. Chem.* 35:507-510 (1992), describes A12 (3-carboxy-5-methyl-N-[4(trifluoromethyl)phenyl]-4-isoxazolecarboxamide) which, like A10, can act as a prodrug for

30 B11.

The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used, and the size and physiological

35 condition of the patient. For the treatment of cancers the expected daily dose of A10 is between 1 to 2000 mg/day, preferably 1 to 250 mg/day, and most preferably 10

to 150 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness.

A factor which can influence the drug dose is body weight. Drugs should be administered at doses ranging from 0.02 to 25 mg/kg/day, preferably 0.02 to 15 mg/kg/day, most preferably 0.2 to 15 mg/kg/day. Alternatively, drugs can be administered at 0.5 to 1200 mg/m²/day, preferably 0.5 to 150 mg/m²/day, most preferably 5 to 100 mg/m²/day. The average plasma level should be 50 to 5000 mg/ml, preferably 50 to 1000 mg/ml, and most preferably 100 to 500 mg/ml. Plasma levels may be reduced if pharmacological effective concentrations of the drug are achieved at the site of interest.

15 VI. Administration of Mutated PDGF-R

The PDGF-R mutants can be administered as nucleic acid expressing the protein, using standard techniques some of which are discussed below. Delivery vehicles include liposomes and other pharmaceutical compositions. Nucleic acid encoding a mutated PDGF-R can also be introduced into a cell using standard techniques such as a retroviral and ion paired molecules. In those cases where the technique is carried out *ex vivo* the cell is then put into a patient. Administration of protein is facilitated using a carrier or excipient as described above.

The specific delivery route of any selected agent depends on the use of the agent (such considerations are also applicable for the administration of the featured compounds). Generally, a specific delivery program for each agent focuses on agent uptake with regard to intracellular localization, followed by demonstration of efficacy. Alternatively, delivery to these same cells in an organ or tissue of an animal can be pursued. Uptake studies include uptake assays to evaluate, e.g., cellular nucleic acid or protein uptake, regardless of the delivery

vehicle or strategy. Such assays also determine the intracellular localization of the agent following uptake, ultimately establishing the requirements for maintenance of steady-state concentrations within the cellular compartment containing the target sequence (nucleus and/or cytoplasm). Efficacy and cytotoxicity can then be tested. Toxicity not only includes cell viability but also cell function. Generally, the dosages of the mutated protein and nucleic acid is as described above for the featured compounds.

Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell. An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles falling into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. Pumps can also be used for this purpose.

From this category of delivery systems, liposomes are preferred. Liposomes increase intracellular stability, increase uptake efficiency and improve biological activity. Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids making up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Antibodies can be attached to liposomes to target particular cells.

Topical administration of PDGF-R mutants and the featured compounds is advantageous since it allows localized concentration at the site of administration with minimal systemic adsorption. This simplifies the delivery strategy of the agent to the disease site and reduces the

extent of toxicological characterization. Furthermore, the amount of material applied is far less than that required for other administration routes. Effective delivery requires nucleic acid to enter the cell membrane or the cytoplasm of cells characterized by inappropriate PDGF-R activity and express the protein.

Agents may also be systemically administered. Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperitoneal, intranasal, intrathecal and ophthalmic. Each of these administration routes expose the drug to an accessible diseased tissue. Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size.

VII. Examples

Examples are provided below to illustrate different aspects and embodiments of the present invention. These examples are not intended in any way to limit the disclosed invention. Rather, they illustrate methodology by which drugs having the disclosed formula can be readily identified by routine procedure to ensure that they have the desired activity. That is, compounds within the formula claimed herein can be screened to determine those with the most appropriate activity prior to administration to an animal or human. Other compounds can also be screened to determine suitability for use in methods of this invention.

A description of some of the procedures used in the following examples is described in the appendices below. The use of A10 in the different procedures is mentioned, however, compounds other than A10 were tested by these procedures by replacing A10 with the tested compound.

Appendix 11. Cell Lines

Cell lines were purchased from the ATCC unless otherwise specified. U1240 and U1242 cells were obtained
5 from Dr. Joseph Schlessinger (New York University) and SF763 and SF767 cells were obtained from Dr. Michael Berens (Barrow Neurological Institute).

SF767T, SF763T, U118T, and SKOV3T are sublines of SF767, SF763, U118 and SKOV3 cells, respectively. They
10 were derived by implanting the parental cells SC into BALB/c, nu/nu mice. Tumors which displayed desirable growth characteristics were resected and finely minced in a sterile petri dish. Two to five mL of appropriate medium was added to the slurry and the tumor pieces were
15 further mechanically teased apart. The resulting suspension was placed into tissue culture flasks and fed with the appropriate culture medium supplemented with 100 unit/mL penicillin G sodium and 100 µg/mL streptomycin sulfate (Gibco, Grand Island, NY). Medium was changed
20 every two to three days. After three to five passages, the antibiotic supplements were removed and the cells maintained in antibiotic-free medium.

NIH3T3 mouse fibroblasts overexpressing the EGF receptor, Flk-1, IGF-1 receptor or PDGF-b receptor were
25 engineered using retroviral vectors. MCF7/HER2 cells were derived by overexpressing the HER2 gene using retroviral constructs in an MCF7 background.

2. Cell Culture

All cell culture media, glutamine, and fetal bovine
30 serum were purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All cells were grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37°C. All cell lines were routinely subcultured twice a week and were negative for mycoplasma as determined by the
35 Mycotect method (Gibco).

C6 cells were maintained in Ham's F10 supplemented with 5% fetal bovine serum (FBS) and 2 mM glutamine (GLN). T98G cells were cultured in MEM with 10% FBS, 2 mM GLN, 1 mM sodium pyruvate (NaPyr) and non-essential amino acids (NEAA). SKOV3T cells were cultured in DMEM, 10% FBS and 2 mM GLN.

NIH3T3 mouse fibroblasts engineered to overexpress Flk-1 or the EGF receptor were maintained in DMEM containing 10% calf serum (CS) and 2 mM GLN. NIH3T3 cells engineered to overexpress the IGF-1 or insulin receptor were maintained in DMEM containing 10% FBS and 2 mM GLN. HL60 cells were maintained in RPMI 1640 with 10% FBS and 2 mM GLN. T47D and BT474 cells were maintained in RPMI 1640 with 10% FBS, GMS-G and 2 mM GLN.

DU 145 cells were grown in DMEM F12 with 10% FBS and 2 mM GLN. A172, A431, U118MG and RAG cells were grown in DMEM with 10% FBS and 2 mM GLN. L1210 cells were grown in DMEM with 10% horse serum and 2 mM GLN. C1300 cells were grown in DMEM with 10% heat inactivated FBS, 2 mM GLN and 50 mM β -mercaptoethanol. T98G, U138MG, U87MG, U373MG, U1240, U1242, Calu-3, Calu-6, SF767, SF767T, SF763, SF763T, SK-N-MC and SK-N-SH cells were grown in MEM with 10% FBS, NEAA, 1 mM NaPyr and 2 mM GLN. MDA MB 361 and MDA MB 468 cells were grown in L15 with 10% FBS and 2 mM GLN. PC-3 cells were grown in HAM'S F12 with 7% FBS and 2 mM GLN. A549 cells were grown in HAM'S F12 with 10% FBS and 2 mM GLN. ZR75-30 cells were grown in RPMI 1640 with 10% FBS, 2 mM GLN and 1 mM NaPyr. MCF7, MCF7/HER2, A375, BT549, 9L, C81-61, ZR 75-1 and K562 cells were grown in RPMI 1640 with 10% FBS and 2 mM GLN. Ovcara3 cells were grown in RPMI 1640 with 20% FBS, 2 mM GLN and 10 mg/mL insulin. D1B and T27A cells were grown in RPMI 1640 with 10% heat-inactivated FBS, 2 mM GLN and 50 mM β -mercaptoethanol; 7TD1 cells were grown in the same medium supplemented with 50 units/mL of recombinant murine IL-6. Colo 320DM, WEHI-164.13, and HBL100 cells were grown in RPMI 1640 with 10% heat-inactivated FBS and 2 mM GLN.

SUBSTITUTE SHEET (RULE 26)

SKBR3 cells were grown in McCoy's 5A with 15% FBS and 2 mM GLN. PA-1 cells were grown in MEM with 10% heat-inactivated FBS, 2 mM GLN and NEAA. Neuro 2A cells were grown in MEM with 10% heat inactivated FBS, 2 mM GLN, 5 NEAA, NaPyr and 50 mM β -mercaptoethanol.

Appendix 2

1. Receptor Phosphorylation

The inhibition of receptor tyrosine kinase activity by A10 was studied by western blot and ELISA procedures.

10 For western blotting, cells were plated in 2 mL growth medium into 6-well dishes (500,000 cells per well) and allowed to attach overnight. The medium was replaced with 2 mL MCDB 105 (UCSF Cell Culture Facility) supplemented with 1% FBS. The plates were then incubated overnight at

15 37°C, ambient CO₂. To test the effects of compounds on ligand-mediated receptor autophosphorylation, cells were exposed to A10 or DMSO for 1 hr at 37°C before the stimulation of receptor tyrosine kinase activity with ligand. After a 7 min incubation at room temperature with ligand,

20 the plates were put on ice and washed three times with 1 mL ice-cold PBS plus 1 mM orthovanadate. Lysis was achieved by pipetting cells in 0.5 mL of buffer containing 50 mM Tris, pH 7.4, 10% glycerol, 1% NP-40, 2 mM EDTA, 1 mM sodium vanadate (Na₃VO₄), 10 mM pyrophosphate, 1 mM

25 PMSF, 10 mg/mL aprotinin, 10 mg/mL leupeptin. A 300 μ L aliquot of each lysate was immediately added to 100 μ L 4x Laemmli sample buffer (0.2 mM Tris pH 6.9, 20% glycerol, 7% SDS, 5 mM EDTA, 5% β -mercaptoethanol) containing phosphatase inhibitors, 2 mM Na₃VO₄ and 10 mM pyro-

30 phosphate. Samples were boiled for 5 min, frozen in dry ice-ethanol, and stored at -80°C. Proteins were resolved by SDS-PAGE (Bio-Rad Miniprotean II) and transferred to nitrocellulose membrane (Schleicher & Schuell) at 120 volts for 1 hr at room temperature in buffer containing 25

35 mM Tris pH 8.3, 20% methanol, 0.2 M glycine, 0.1% SDS. The integrity of the protein-to-membrane transfer was

SUBSTITUTE SHEET (RULE 26)

determined by staining with 1% Ponceau S in 5% acetic acid for 5 min. After destaining in several distilled water rinses, the membrane was soaked overnight in blocking buffer containing 5% milk in Tris-buffered saline, 0.05% Tween 20. Phosphotyrosine was detected by incubating the membrane (1 hr at room temperature) with an anti-phosphotyrosine antiserum diluted in blocking buffer at 1:3000. For C6 cells, PDGF-b receptor content in the lysates was confirmed in duplicate sample lanes by western blotting using an antibody specific for PDGF-b receptor (UBI). The antibodies were visualized using ECL reagent from Amersham and by exposure to Fuji RX film.

For ELISA assays, cells were grown to 80-90% confluency in growth medium and seeded in 96-well tissue culture plates in 0.5% serum at 25,000 to 30,000 cells per well. After overnight incubation in 0.5% serum-containing medium, cells were changed to serum-free medium and treated with test compound for 2 hr in a 5% CO₂, 37°C incubator. Cells were then stimulated with ligand for 5-10 min followed by lysis with HNTG (20 mM Hepes, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM Na₃VO₄, 0.2% Triton X-100, and 2 mM NaPyr). Cell lysates (0.5 mg/well in PBS) were transferred to ELISA plates previously coated with receptor-specific antibody and which had been blocked with 5% milk in TBST (50 mM Tris-HCl pH 7.2, 150 mM NaCl and 0.1% Triton X-100,) at room temperature for 30 min. Lysates were incubated with shaking for 1 hr at room temperature. The plates were washed with TBST four times and then incubated with polyclonal anti-phosphotyrosine antibody at room temperature for 30 min. Excess anti-phosphotyrosine antibody was removed by rinsing the plate with TBST four times. Goat anti-rabbit IgG antibody was added to the ELISA plate for 30 min at room temperature followed by rinsing with TBST four more times. ABTS (100 mM citric acid, 250 mM Na₂HPO₄ and 0.5 mg/mL 2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) plus H₂O₂ (1.2 mL 30% H₂O₂ to 10 mL ABTS) was added to the ELISA plates to

start color development. Absorbance at 410 nm with a reference wavelength of 630 nm was recorded about 15 to 30 min after ABTS addition. Cell lines used in ELISA assays included U1242 (PDGF-b receptor), HL-60 cells (GMCSF receptor/JAK-2), or NIH3T3 cells overexpressing the EGF receptor, Flk-1, IGF-1 receptor or the insulin receptor. IC₅₀ values were estimated by comparing drug inhibition of tyrosine phosphorylation in the absence or presence of appropriate ligand.

10 2. DNA Synthesis

The effects of A10 on PDGF-dependent DNA synthesis was determined by measuring the ³H-thymidine incorporation into DNA of cells. The conditions for the assay were essentially those described by Pollack, et al. J. Neurosurg., 73:106-112, 1990, with some modifications. T98G cells in log phase growth were transferred to 96-well dishes at 20,000 cells in 200 µL of serum-containing growth medium. After an overnight attachment period, the monolayers were washed twice with 200 µL MCDB 105 medium and the cells were cultured in 200 µL serum-free MCDB 105 medium for 24 hr. Medium in wells was replaced with fresh medium alone (MCDB 105 plus 5 µg/mL insulin), medium containing PDGF-BB alone, or medium containing PDGF-BB in combination with various concentrations of A10. The plates were incubated at 37°C at ambient CO₂ for approximately 18 hr. ³H-thymidine (Amersham, 5 Ci/mmol) was added to each well to yield a final concentration of 5 µCi/mL and the plates were returned to 37°C incubator. After 4 hr the medium was removed, the plates were put onto ice, and washed twice with 200 µL ice-cold PBS per well. Radioactivity incorporated into DNA was separated from unincorporated ³H-thymidine by precipitation with 100 µL ice-cold TCA for 10 min on ice. After two washes with ice-cold TCA, the precipitate was solubilized (1% SDS in 100 mL 10 mM Tris base) and transferred to liquid scintillation counting vials. Six mL of cocktail (Ready Safe,

Beckman) was added and radioactivity quantified in a Beckman liquid scintillation counter model LS6000SC.

3. Cell Cycle Analysis

NIH3T3 mouse fibroblasts overexpressing the human PDGF-b receptor were seeded in DMEM supplemented with 10% CS and 2 mM GLN. Cells were grown to about 80% confluence and then treated overnight in serum-free medium (DMEM, 2 mM GLN, 2 mM NEAA, 2 mM NaPyr, and 2 mM HEPES). The cells were incubated for 20 hr in the presence of PDGF-BB at 100 ng/mL and with various concentrations of A10 (0.1, 1, 10, 25, or 100 mM). Cells were then collected, stained and analyzed by flow cytometry for DNA content.

4. Growth Assays

A10 was tested for inhibition of anchorage-dependent tumor cell growth using the colorimetric assay described by Skehan, et al., *J. Natl. Cancer Inst.*, 82:1107-1112, 1990. The assay measures protein content of acid-fixed cells using the counterion binding dye sulforhodamine B (SRB, Sigma). A10 was solubilized in DMSO (Sigma, cell culture grade) and diluted into appropriate growth medium at two-fold the desired final assay concentration. In assays using C6 cells, A10 (100 μ L) was added to 96-well plates containing attached cellular monolayers (2000 cells/well in 100 μ L). For other cell lines, the cells (2000 cells/well in 100 μ L) were introduced into wells immediately after dispensing the drug solutions. After 4 days (37°C, 5% CO₂) the monolayers were washed 3 times with PBS and fixed with 200 μ L ice-cold 10% TCA (Fisher Scientific), and kept at 4°C for 60 min. The TCA was removed and the fixed monolayers were washed 5 times with tap water and allowed to dry completely at room temperature on absorbent paper. The cellular protein was stained for 10 min with 100 μ L 0.4% SRB dissolved in 1% acetic acid. After 5 washes with tap water, the dye was solubilized in 10 mM Tris base (100 μ L per well) and absorbance

read at 570 nm on a Dynatech plate reader model MR5000. Growth inhibition data are expressed as a percentage of absorbance detected in control wells which were treated with 0.4% DMSO alone. DMSO controls were not different
5 from cells grown in regular growth medium. IC₅₀ values were determined using a four parameter curve fit function.

For the anchorage-independent tumor cell growth assay, cells (3000 to 5000 per dish) suspended in 0.4% agarose in assay medium (DMEM containing 10% FCS) with and
10 without A10 were plated into 35 mm dishes coated with a solidified agarose base layer (0.8% agarose). After a 2 to 3 week incubation at 37°C, colonies larger than 50 µm were quantified using an Omnicon 3800 Tumor Colony counter.

15 Appendix 3

1. Growth Assays for Tumor Cell Lines

For most tumor cell lines, inhibition of cell growth by A10 was assessed using an SRB assay as described in Appendix 2. For K562, D1B, L1210, 7TD1, T27A, and Colo320
20 DM cells, an MTT assay was used to assess cell growth. (Hansen et al., *J. Immunol. Methods*, 119:203-210, 1989.) Briefly, 50 mL of growth medium containing various concentrations of A10 and 50 mL of cell suspension (2,000 cells) were added to each well of a 96-well plate. The cells
25 were incubated at 37°C for 4 days in a humidified 7% CO₂ atmosphere. At the end point, 15 mL of MTT (5 mg/mL in PBS, Sigma) was added to each well. The plates were incubated at 37°C for 4 hr followed by addition of 100 mL of solubilization solution (20% w/v of SDS in 50% N, N-
30 dimethylformamide, pH 4.7) to each well. The plates were incubated overnight in a sealed container with a humidified atmosphere. The absorbance was determined at 570 nm wavelength with a reference wavelength of 630 nm using an ELISA plate reader.

2. Growth Assay for Primary Tumors

The effect of A10 on primary tumor growth was examined by Oncotech, Inc. (Irvine, CA). Viable tumors were placed into medium by the pathologist at the referring institution immediately after surgery, and shipped to Oncotech by overnight delivery. As soon as a tumor was received, a portion was fixed in formalin for sectioning and the remainder trimmed of necrotic, connective and adipose tissues. All tumor manipulations were performed aseptically. The remaining tumor was placed into a Petri dish containing 5 mL of medium (RPMI 1640 supplemented with 10% FBS, 100 IU/mL penicillin, 100 mg/mL streptomycin and L-glutamine) and disaggregated mechanically with scissors into pieces 2 mm or smaller. The resultant slurries were mixed with medium containing 0.003% DNase (2650 Kunitz units/mL) and 0.14% type I collagenase (enzymes from Sigma Chemical Co., St. Louis Mo.), placed into 50 mL flasks with stirring, and incubated for 90 min at 37°C in a humidified 5% CO₂ atmosphere. A portion of the cell suspension was used for cytospin slide preparation and was examined after hematoxylin and eosin staining of the tissue sections by a medical pathologist to confirm the diagnosis, and to determine the tumor cell count and viability.

After enzymatic dispersion into a near single-cell suspension, tumor cells were filtered through nylon mesh, washed in medium, suspended in soft agarose (0.12%) and plated at approximately 20,000 cells per well onto an agarose underlayer (0.4%) in 24-well plates. Cells were incubated under standard culture conditions for five days in the presence or absence of A10. Cells were pulsed with ³H-thymidine (Amersham, 5 mCi per well) for the last 48 hr of the culture period. After the appropriate labeling period, tissue culture plates were heated at 60°C to melt the agarose, the cells harvested with a micro-harvester onto glass fiber filters and the radioactivity determined. Percent inhibition (PCI) was determined using the formula:

PCI = 1 - (CPM treatment group Π CPM control group). Determinations of control group proliferation were performed in quadruplicate, while treatment group proliferation was determined in triplicate.

5 Appendix 4

1. Animals

Female athymic mice (BALB/c, nu/nu), BALB/c mice, Wistar rats and Fisher 344 rats were obtained from Simonsen Laboratories (Gilroy, CA). Female A/J mice were
10 obtained from Jackson Laboratory (Bar Harbor, ME). DA rats were obtained from B&K Universal, Inc. (Fremont, CA). Athymic R/Nu rats, DBA/2N mice, and BALB/c mice were obtained from Harlan Sprague Dawley (Indianapolis, IN). Female C57BL/6 mice were obtained from Taconic
15 (Germantown, NY). All animals were maintained under clean-room conditions in Micro-isolator cages with Alpha-dri bedding. They received sterile rodent chow and water *ad libitum*.

2. Subcutaneous Xenograft Model

20 Cell lines were grown in appropriate medium (see Appendix 1). Cells were harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets were resuspended in sterile PBS or media (without FBS) to a particular concentration and the cells
25 were implanted into the hindflank of mice. Tumor growth was measured over 3 to 6 weeks using venier calipers. Tumor volumes were calculated as a product of length x width x height unless otherwise indicated. P values were calculated using the Students' t-test. A10 in 50 - 100 μ L
30 excipient (DMSO, PBTE, PBTE6C:D5W, or PBTE:D5W) was delivered by IP injection at different concentrations.

3. Intracerebral Xenograft Model

For the mouse IC model, rat C6 glioma cells were harvested and suspended in sterile PBS at a concentration

of 2.5×10^7 cells/mL and placed on ice. Cells were implanted into BALB/c, nu/nu mice in the following manner: the frontoparietal scalps of mice were shaved with animal clippers if necessary before swabbing with 70% ethanol.

5 Animals were anesthetized with isofluorane and the needle was inserted through the skull into the left hemisphere of the brain. Cells were dispensed from Hamilton Gas-tight Syringes using 30 gauge 1/2 inch needles fitted with sleeves that allowed only a 3 mm penetration. A repeater

10 dispenser was used for accurate delivery of 4 μ L of cell suspension. Animals were monitored daily for well-being and were sacrificed when they had a weight loss of about 40% and/or showed neurological symptoms.

For the rat IC model, rats (Wistar, Sprague Dawley,

15 Fisher 344, or athymic R/Nu; approximately 200 g) were anesthetized by an IP injection of 100 mg/kg Ketaset (ketamine hydrochloride; Aveco, Fort Dodge, Iowa) and 5 mg/kg Rompun (xylazine, 2% solution; Bayer, Germany). After onset of anesthesia, the scalp was shaved and the

20 animal was oriented in a stereotaxic apparatus (Stoelting, Wood Dale, IL). The skin at the incision site was cleaned 3 times with alternating swabs of 70% ethanol and 10% Povidone-Iodine. A median 1.0 - 1.5 cm incision was made in the scalp using a sterile surgical blade. The skin was

25 detached slightly and pulled to the sides to expose the sutures on the skull surface. A dental drill (Stoelting, Wood Dale, IL) was used to make a small (1-2 mm diameter) burrhole in the skull approximately 1 mm anterior and 2 mm lateral to the bregma. The cell suspension was drawn into

30 a 50 μ L Hamilton syringe fitted with a 23 or 25 ga standard bevel needle. The syringe was oriented in the burrhole at the level of the arachnoidea and lowered until the tip of the needle was 3 mm deep into the brain structure, where the cell suspension was slowly injected.

35 After cells were injected, the needle was left in the burrhole for 1-2 minutes to allow for complete delivery of the cells. The skull was cleaned and the skin was closed

with 2 to 3 sutures. Animals were observed for recovery from surgery and anesthesia. Throughout the experiment, animals were observed at least twice each day for development of symptoms associated with progression of intracerebral tumor. Animals displaying advanced symptoms (leaning, loss of balance, dehydration, loss of appetite, loss of coordination, cessation of grooming activities, and/or significant weight loss) were humanely sacrificed and the organs and tissues of interest were resected.

10 4. Intraperitoneal Model

Cell lines were grown in the appropriate media as described in Appendix 1. Cells were harvested and washed in sterile PBS or medium without FBS, resuspended to a suitable concentration, and injected into the IP cavity of mice of the appropriate strain. Prior to implantation of 7TD1 cells, C57BL/6 mice were primed by IP injection of 0.5 mL Pristane. SKOV3T cells were implanted into athymic mice without Pristane priming. Mice were observed daily for the occurrence of ascites formation. Individual animals were sacrificed when they presented with a weight gain of 40%, or when the IP tumor burden began to cause undue stress and pain to the animal.

5. Immunohistochemistry

Acetone-fixed, 5 μ m frozen tissue sections from untreated xenograft tumors derived from human, rat, or murine tumor cells were analyzed by immunohistochemistry using highly specific receptor antibodies. Briefly, non-specific binding sites were blocked with 10% normal goat serum prior to the application of the primary antibody. Appropriate antibody concentrations were used to achieve the desired sensitivity and specificity (rabbit anti-human PDGF-b receptor, 1:400 and rabbit anti-mouse Flk-1, 5.5 μ g/mL). Tissue sections known to contain the protein of interest served as positive controls. Appropriate negative controls of normal rabbit IgG and mouse anti-chicken IgG

of the same protein concentration and isotype as the primary antibodies were used. The detection method was a three-step indirect procedure and consisted of the primary antibody bound to a biotin-labeled secondary antibody
5 (goat anti-rabbit IgG 1:500) followed by streptavidin conjugated horseradish peroxidase.

The chromagen/substrate used was 0.05% diaminobenzidine/0.03% H₂O₂. Tissue sections were counterstained with hematoxylin, dehydrated through ascending grades of
10 ethanol, cleared in Xylene Substitute, and coverslipped with Permount for microscopic evaluation. A + to +++ grading system was used to identify the overall intensity of the expression with + = low, ++ = moderate, and +++ = high intensity. Specific staining reaction was seen as
15 either (T) tumor cell or (V) vascular endothelial cell or both.

Appendix 5

1. In Vitro Immunology Assays

At the indicated times, animals were sacrificed, and
20 the spleens were aseptically removed and placed into sterile medium. Spleens were processed into single cell suspensions by grinding between sterile frosted glass microscope slides. After a single wash to remove tissue debris, the spleen cells were resuspended in a hypotonic
25 ammonium chloride buffer to lyse erythrocytes. Lymphocytes were washed and resuspended to the appropriate concentrations in complete medium, consisting of RPMI plus 10% heat-inactivated FBS, 2 mM glutamine, 50 μ M β -mercaptoethanol, and penicillin-streptomycin. The
30 responses of the lymphocytes were examined in the following assays according to accepted procedures (*Current Protocols in Immunology*. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (eds.) John Wiley and Sons, Inc., 1992).

1.a. Mitogen Responses

The T-cell mitogen, ConA, and the T-cell independent B-cell mitogen, LPS, were added to 96-well round-bottom wells at the indicated concentrations. Lymphocytes from normal, vehicle-dosed, and drug-dosed animals were added at a final concentration of 2.5×10^5 /well. Cultures were usually set up in triplicate or quadruplicate. The plates were incubated at 37°C in a humidified atmosphere containing 5% CO₂ for the indicated times. Supernatants (approximately 100 µL) were carefully removed from the wells and stored at -80°C for lymphokine and immunoglobulin analyses. To measure proliferation of the lymphocytes, 1 µCi of ³H-thymidine was added to each well, and the plates were incubated for 6 hr. The cultures were harvested onto glass fiber filters, and the incorporated radioactivity was quantitated by liquid scintillation counting (Betaplate, Wallac).

1.b. Mixed Lymphocyte Responses

Lymphocytes from normal, vehicle-dosed, and drug-dosed animals were plated at 2.5×10^5 /well in round-bottom 96-well plates. Stimulator cells were then added at the same cell concentration. The stimulator cells consisted of syngeneic or allogeneic lymphocytes which had been treated with 50 µg/mL of mitomycin C for 30 min prior to the assay. The plates were incubated for 3 to 4 days, at which time supernatants were harvested and the cultures were pulsed as described for the mitogen assays.

1.c. Lymphokine Assays

Supernatants from mitogen and MLR cultures were assayed for IL-2 and IL-6 content by the ability to support the growth of factor-dependent cell lines. HT-2 cells (10^4 /well, IL-2-dependent) and 7TD1 cells (2×10^3 /well, IL-6-dependent) were plated in 96-well flat-bottom plates, in 50 µL/well. Supernatants were added in 50 µL/well, and the plates were incubated overnight (HT-2) or

four days (7TD1). Cellular proliferation was determined in the MTT colorimetric assay (Appendix 3.1).

1.d. Immunoglobulin ELISA

Flat bottom 96-well EIA plates were coated with goat anti-mouse Ig antibodies (Southern Biotechnology) overnight at 4°C. The plates were blocked by the addition of PBS + 1% BSA. After washing with PBS, supernatants from murine mitogen and MLR cultures were added and incubated at room temperature for 1 hr. The plates were washed with PBS, then HRP-labeled goat anti-mouse Ig antibodies were added and incubated at room temperature for 1 hr. The plates were washed and developed by the addition of substrate (ABTS).

Appendix 6

1. HPLC Assay

At specific times after treatment of mice or rats with A10, blood was collected in heparinized tubes by terminal cardiac puncture. Plasma was prepared and frozen in liquid nitrogen. Tissues and organs were resected and immediately frozen in liquid nitrogen. After the addition of an internal standard, plasma samples were acidified with HCl and extracted with acetonitrile. The acetonitrile fraction was evaporated to dryness in a vacuum centrifuge with heating and redissolved in methanol. Tissue and organ samples were homogenized according to the weight ratio of 1:5 (w:v) in 50 mM Tris-HCl, pH 7.4, at 20,000 rev/min, using a tissue homogenizer (Brinkmann Polytron Model PT3000). After the addition of an internal standard, the homogenate was acidified with HCl and then extracted with acetonitrile. The acetonitrile fraction was then extracted with an equal volume of diethyl ether. The ether fraction was evaporated to dryness in a vacuum centrifuge with heating and redissolved in methanol.

Samples for HPLC analysis were injected onto a Hewlett Packard Hypersil 5- μ m C18 cartridge column (100 x

4.6 mm). The mobile phase was methanol:35 mM KH_2PO_4 (pH 4.5) 55:45 containing 4 mM triethylamine. The flow rate was 1.2 mL/min. The compounds were monitored by UV absorption at 254 nm using a Hewlett-Packard diode-array detector (HP Model 1090). Plasma and tissue concentrations were determined from standard curves using peak area for quantitation. Plasma and tissue standard curves were prepared from plasma and tissue homogenates obtained from drug-free rats, and spiked with known amounts of A10 and B11. The results were corrected for recovery of the internal standard. The internal standard used was 5-methyl-pyrazole-4-carboxylic acid-(4-trifluoromethyl)-anilide.

Appendix 7

1. Effects of A10 on Body Weight

Athymic mice (BALB/c, nu/nu, female, 4 - 5 weeks old) received IP administration of A10 (20 mg/kg/day) every day in 100 μL PBTE:D5W (1:1, v:v) for 101 days. Vehicle control animals received IP administration of 100 μL PBTE:D5W (1:1, v:v) every day for 101 days, and untreated control animals received no treatments. There were eight animals in each group. Weights were measured on day 0 (one day prior to drug administration) and two times/week until experiment termination. The percent weight change was calculated as mean weight at each determination as compared to the mean weight on day 0.

2. Determination of LD_{50}

Groups of five to ten athymic mice (BALB/c, nu/nu, female), or BALB/c mice (male and female) were treated with A10 IP in 50 μL PBTE, 100 μL PBTE, or 50 μL DMSO. In one experiment, groups of five BALB/c female, mice received IP administration of Decadron® (dexamethasone sodium phosphate for injection, 1.5 mg/kg) once per day for seven days prior to administration of a single IP dose of A10. In an additional experiment, groups of five

BALB/c female mice received IP injection of Dilantin® (phenytoin sodium for injection, 20 mg/kg) once per day for seven days prior to administration of a single dose of A10. All animals were observed for 7 to 14 days after the last dose was administered. The LD₅₀ was calculated from a plot of % mortality versus dose (log M) using a four parameter logistic equation with goat anti-mouse Ig antibodies (Southern Biotechnology) overnight at 4°C. The plates were blocked by the addition of PBS + 1% BSA. After washing with PBS, supernatants from murine mitogen and MLR cultures were added and incubated at room temperature for 1 hr. The plates were washed with PBS, then HRP-labelled goat anti-mouse Ig antibodies were added and incubated at room temperature for 1 hr. The plates were washed and developed by the addition of substrate (ABTS).

Example 1: Inhibition of PDGF-R Autophosphorylation by A10

This example illustrates the ability of A10 to inhibit PDGF-R autophosphorylation of rat C6 glioma cells. Rat C6 glioma cells (5×10^5) were plated in MCDB105 medium containing 5% FCS in a 6-well plate and incubated for 24 hours at 37°C. The cells were then placed in media with 1% FCS for another 24 hours. The cells were treated with A10 at 50, 100, or 200 mM for one hour at 37°C. The cells were then treated with 20 ng/ml of PDGF-BB for 10 minutes at 37°C. The cells were lysed in 50 mM Tris-HCl (pH 7.4) containing 2 mM EDTA, 10% glycerol, 1% NP-40, 1 mM Na⁺ orthovanadate, 10 mM pyrophosphate, 1 mM PMSF, 10 mg/ml aprotinin and 10 mg/ml leupeptin.

Proteins were then separated by SDS-polyacrylamide gel electrophoresis (PAGE). Proteins containing phosphorylated tyrosine were identified by western blotting with an anti-phosphotyrosine antibody. The level of phosphorylated tyrosine was determined by quantitating the amount of bound anti-phosphotyrosine. Quantitation was carried out by peak area integration using a Molecular

Dynamics Computing Densitometer (Model 300S), and Image Quant v3.0 software (Molecule Dynamics). Data were expressed as relative peak intensity (phosphorylation of a receptor divided by the total amount of phosphorylated tyrosine).

PDGF-BB stimulated autophosphorylation of the PDGF-R, while A10 inhibited such stimulation. Increasing concentrations of A10 resulted in reduced PDGF stimulated receptor phosphorylation. A10 at a concentration of 200 mM reduced PDGF-R phosphorylation below that occurring in the absence of PDGF-BB stimulation.

Example 2: Selective Inhibition of PDGF-R Autophosphorylation by A10

A10 inhibits autophosphorylation of the PDGF-R in human T98G glioblastoma cells, while having little if any effect on autophosphorylation of the EGF receptor. T98G cells were plated in MCDB105 medium containing 2% FBS and incubated for 24 hours at 37°C. The media was aspirated and then replaced with MCDB105 and the cells were treated for one hour with 200, 500 or 1,000 mM A10. Cells were treated with different concentrations of A10 (0, 200, 500 and 1000 mM) and in the presence or absence of ligand. The cells were then treated with ligand for 10 minutes (20 ng/ml PDGF-BB or 50 ng/ml EGF). The cells were lysed and the level of phosphorylated receptor was quantitated as described in Example 1. A10 inhibited autophosphorylation of PDGF-R by PDGF, but had little if any effect on the ability of EGF to stimulate autophosphorylation of EGF-R.

Example 3: Inhibition of PDGF-R Phosphorylation by Various Compounds

This example illustrates the ability of various compounds to inhibit PDGF-stimulated receptor phosphorylation. U1242 MG cells were plated in 96-well plates at a concentration of 5×10^4 cells/well in cultured media containing 0.5% FBS. The cells were incubated for 24

hours. The cells were then treated with a particular compound for 2 hours followed by the addition of 100 ng/ml PDGF-BB and incubation for 10 minutes.

Cells were lysed in 0.2 M Hepes, 0.15 M NaCl, 10% V/V
5 glycerol, 0.04% Triton X-100, 5 mM EDTA, 5 mM Na⁺ vanadate
and 2 mM Na⁺ pyrophosphate. Cell lysates were then added
to an ELISA plate coated with an anti-PDGF receptor
antibody (Genzyme). ELISA plates were coated at 0.5 mg of
antibody/well in 150 ml of PBS for 18 hours at 4°C prior
10 to the addition of the lysate.

The lysate was incubated in the coated plates for 1
hour and then washed four times in TBST (35 mM Tris-HCl pH
7.0, 0.15 M NaCl, 0.1% Triton X-100). Anti-
phosphotyrosine antibody (100 ml in PBS) was added and the
15 mixture was incubated for 30 minutes at room temperature.
The wells were then washed four times in TBST, a secondary
antibody conjugated to POD (TAGO) was added to each well,
and the treated wells were incubated for 30 minutes at
room temperature. The wells were then washed four times
20 in TBST, ABTS/H₂O₂ solution was added to each well and the
wells were incubated for two minutes. Absorbance was then
measured at 410 nm.

The cytotoxicity of each drug was also determined.
The cells were plated as described above. Following
25 incubation with drug, cell survival was measured by an MTT
assay as described by Mossman *J. Immunol. Methods* 65:55-63
(1983), or by measuring the amount of LDH released
(Korzeniewski and Callewaert, *J. Immunol. Methods* 64:313
(1983); Decker and Lohmann-Matthes, *J. Immunol. Methods*
30 115:61 (1988).

The results are shown in Table IX. IC₅₀ values (i.e.,
the dose required to achieve 50% inhibition) were deter-
mined using the ELISA screening assay. LD₅₀ values (i.e.,
the dosage which results in 50% toxicity) were determined
35 using an MTT or LDH assay.

IC₅₀ values for inhibiting PDGF-stimulated receptor
phosphorylation in U1242 cells ranged from 0.4 to > 500

mM. As seen in Table IX most of the compounds tested inhibited PDGF-stimulated receptor phosphorylation. In all cases inhibition of receptor phosphorylation was not due to non-specific effects on cell viability as shown by the higher LD₅₀. Thus, these drugs are good candidates for compounds which can be used to treat cell proliferative diseases by inhibiting PDGF-R activity. G13 and G14 had the lowest IC₅₀ but had a LD₅₀ less than A10. Generally, the preferred compounds are those having the highest therapeutic index (LD₅₀/IC₅₀), which is a measure of the safety index.

Table IX

Compound	ELISA	CYTOXICITY	
	P-TYR U1242 IC50 (mM)	LDH U1242 LD50 (mM)	MTT U1242 LD50 (mM)
A10	65	>500	700
B10	180		
B12	160	>500	>1351
B13	180		
B14	180		
B15	120		200
B16	35		50
B17	125	>1000	>500
B18	160		
B19	100		
C10	25		>500
C11	70	>500	>500
D11	8	>441	90
D12	60	>386	>390
D13	30	>500	>500
D14	20	>100	>500
D15	20	400	80
D16	50	>168	>167
D17	>100		
E10	45		
E11	90		
E12	180		

SUBSTITUTE SHEET (RULE 26)

	E13	>100		
	E14	100		
	E15	5		>100
	E16	125		
5	F10	45		
	F11	100		
	F12	70		
	G10	10	>485	>490
	G11	15	90	145
10	G12	10	>333	>333
	G13	0.4	>100	100
	G14	0.8	>100	>500
	G15	100		
	G16	35		>100
15	G17	100		
	G18	10	>100	
	G19	90		
	G20	>100		
	G21	6	>100	
20	G22	1	>100	
	H12	30		
	I10	90	>317	>320

Example 4: A10 Inhibits PDGF-stimulated DNA Synthesis and Cell Cycle Progression

25 This example illustrates the ability of A10 to inhibit PDGF-BB stimulated DNA synthesis and cell cycle progression. The effect of A10 on DNA synthesis in T98G cells in the absence or presence of PDGF-BB was determined by measuring ³H-thymidine incorporation into DNA. The
30 percentage of cells in the S phase of the cell cycle was determined by flow cytometry.

Cells were cultured as described in the appendices above. The assay conditions were essentially those described by Pollack et al., *J. Neurosurg.* 73:106-112
35 (1990) with some modifications. Cells (rat C6 or human T98G) in log phase growth were transferred to 96-well dishes at 2×10^4 cells in 200 ml MCDB 105 medium

containing 2% FBS. After an overnight attachment period the media was changed to serum free assay media (MCDB 105 with 5 mg/ml insulin) and the cells were incubated for 18-24 hours.

5 DNA synthesis studies were initiated by adding 50 ng/ml of PDGF-BB alone or in combination with various concentrations of A10. The effect on basal ³H-thymidine incorporation was determined in the absence of PDGF. The plates were incubated at 37°C for approximately 18 hours.
10 ³H-thymidine (Amersham, 5 Ci/mmol) was added to each well to yield a final concentration of 5 mCi/ml, the plates were returned to the 37°C incubator, after 4 hours the medium was removed and the plates were put on ice. Each well was then washed twice with 200 ml ice-cold PBS.
15 Radioactivity incorporated into DNA was separated from unincorporated ³H-thymidine by precipitation with 100 ml ice-cold TCA for 10 minutes. After two washes with ice-cold TCA, the precipitate was solubilized (1% SDS in 100 ml 20 mM Tris-base) and transferred to liquid scintillation counting vials. Six ml of cocktail (Ready Safe, Beckman) was added and radioactivity quantified in a
20 Beckman liquid scintillation counter model LS6000 SC.

A10 decreased PDGF-stimulated DNA synthesis in both types of cells, however a greater effect was seen in human
25 T98G glioblastoma cells than rat C6 glioma cells. To confirm these results, the effect of A10 on PDGF-stimulated entry into the S phase of the cell cycle was examined. NIH3T3 cells engineered to overexpress the human PDGF-b receptor were growth-arrested (serum-starved) followed by
30 treatment with PDGF ligand in the presence or absence of A10. The cells were analyzed for DNA content by flow cytometry. The results of this analysis are summarized in Figure 3. Treatment with PDGF resulted in a marked increase in cells residing in S phase (62%) relative to
35 cells not treated with PDGF (11%). However, cells treated with A10 showed a dose-dependent decrease in the number of cells progressing to the S phase of the cell cycle in

response to PDGF, indicating that PDGF-stimulated mitosis was blocked by A10.

These results contrast with the results of a similar experiment in which A10 at a concentration of 100 mM was not able to inhibit EGF-stimulated mitosis in NIH3T3 cells overexpressing the human EGF receptor (Figure 3). These results confirm the selectivity of A10 for PDGF-mediated signaling.

Example 5: Inhibiting the Activity of Different Receptor Kinases

The ability of different compound to inhibit different receptor tyrosine kinases was tested. The testing results are shown in Table X.

TABLE X

Compound	PDGFR IC50 (μ M)	EGFR IC50 (μ M)	HER2 IC50 (μ M)	FLK-1 IC50 (μ M)
G14	0.8 (W)	NT	NT	>30 (W)
G25	0.9	>50	>50	>50
J10	1 (W)	>100	>100	NT
P13	1.1	>50	>50	>50
G13	1.5	NT	>50	>10 (W)
P10	3 (W)	31	>100	NT
J11	3	>100	>50	>25
F10	8 (W)	NT	NT	>50
G24	5	>100	>50	9.3
D11	8 (W)	NT	NT	>50
G10	10 (W)	NT	NT	>50
G12	10 (W)	NT	NT	>50
G18	10 (W)	550 (W)	NT	NT
E14	10 (W)	NT	NT	>50
G22	14	>100	>50	4.4
D20	14	>50	>50	>50

65

	C13	16	16	29	3.3
	D15	19 (W)	NT	NT	>50
	G11	20 (W)	NT	NT	NT
	G29	23	<0.8	34	10
5	C10	25 (W)	NT	NT	NT
	G23	25 (W)	>100	>100	325.2
	H10	25 (W)	NT	NT	>50
	H12	25 (W)	NT	NT	NT
	P12	25 (W)	NT	<50	>50
10	P14	26	>50	10	>200
	D13	30 (W)	NT	NT	>50
	P25	30 (W)	>100	>100	>500
	G30	32	>100	34	10
	D18	34	>50	>50	>50
15	P15	46	>100	>50	>50
	D14	47	>100	>50	>50
	G27	48	>100	>50	>50

Example 6: In vitro Efficacy

The efficacy of A10 as a direct growth inhibitor was determined on tumor cell lines, and primary tumors isolated from patients. The effects of A10 on tumor cell lines were determined by exposing cells to a range of drug concentrations and quantitating cell density after 4 days using the procedures described in Appendix 3. Table XI provides the results of testing different cell lines.

Table XI

Effects of A10 on Growth of Various Tumor Types

Tumor Type	Cell Line	IC ₅₀ (μM)
glioma	SF763T	0.8
	SF767T	3
	U1242	19
	A172	32
	T98G	62
	U87MG	78
	SF767	87
	SF763	110
	U373MG	115
	U118MG	150
	U1240	250
	U138MG	>400
ovarian	SKOV3T	40
	PA-1	40
	SKOV3	>100
	Ovcar3	>100
breast	BT474	>100
	MCF7/HER2	116
	MDA MB 468	150
	T47D	195
	MDA MB 361	200
	MCF7	288
	ZR75-30	300
	ZR 75-1	355
	HBL100	>400
	BT549	>400
	SKBR3	>400
lung	Calu-6	70
	A549	118
	Calu-3	>400

SUBSTITUTE SHEET (RULE 26)

prostate	PC3	46
	DU145	>100
melanoma	A375	25
	C81-61	40
colon	Colo 320DM	34
epidermoid	A431	34
leukemia	K562	26

The IC_{50} values for A10 ranged from 0.8 μM up to >400 μM .

The effects of A10 on *in vitro* growth of primary tumor cells isolated from six patients with glioblastoma multiformae (GBM) and six patients with ovarian carcinoma were tested. Specimens were obtained from newly diagnosed and previously untreated patients and evaluated as described in Example 13, Appendix 3.

A positive correlation between inhibition of tumor growth by A10 and PDGF-R expression was observed for both tumor types. As the concentration of A10 increased (from 0 to 400 mM) tumor cell growth decreased for both types of tumors. The growth inhibition was dose-dependent for both tumor types and varied among the tumor cells. The IC_{50} values ranged from 39 μM to 198 μM for the GBM tumors and from 20 mM to 140 mM for the ovarian tumors.

Example 7: In Vivo Efficacy Studies Using A10 and B11

This example summarizes several experiments illustrating the ability of A10 to inhibit the growth of different tumors *in vivo*. The first series of experiments looks at effects of different formulation and treatment regimens. The second series of experiments looks at the effects of A10 on a variety of different tumors.

Different Formulations and Treatment Regimens

C6 and SKOV-3(T) cells were grown in culture, as described in "cell growth" above, and implanted into the hind flank of a female Balb/c nu/nu mouse at 3×10^6 cells

(for C6 experiments), or 1×10^7 cells (for SKOV-3 experiments) in 100 ml of PBS on Day 0. U87MG, U118MG or U373MG human glioblastoma cells (obtained from the ATCC), or A4312 were also implanted into athymic mice. Mice
5 implanted with tumors, and non-implanted mice were administered A10 or B11 via intraperitoneal injection in a volume of 50 ml of DMSO, 100 ml PBTE:D5W, or 100 ml PBTE beginning on Day 1 or as otherwise indicated. Tumors were measured using venier calipers and tumor volume was calculated as a product of tumor length, width, and height.
10

In one set of experiments mice were implanted with A431, rat C6 glioma cells, SKOV-3(T) ovarian tumor cells and treated with 15 mg/kg/day of A10 (DMSO). Tumor growth progressed logarithmically in untreated, and DMSO controls. In contrast, tumor growth progressed only slightly
15 (*i.e.*, greater than 90% inhibition in tumor growth after 20 days compared with control) in A10 treated animals implanted with rat C6 glioma cells or SKOV-3(T) ovarian tumor cells. A10 had little (*i.e.* no more than 25%)
20 effect on A431 tumor growth. Tumor growth of mice implanted with rat C6 glioma cells was inhibited with 15 mg/kg/day of B11 (DMSO) to the same extent as implanted mice treated with 15 mg/kg/day of A10 (DMSO).

In another set of experiments mice implanted with C6
25 glioma cells were treated with A10. Table XII summarizes the ability of A10 to inhibit rat C6 glioma cells in athymic mice using different treatment regimens. The percent inhibition refers to size of the tumor from A10 treated animals, divided by the size of the tumor from
30 vehicle control treated animals. The different treatment regimens resulted in inhibition of 51% to greater than 95%.

Table XII

A10 Dosing Regimen Studies		
Dose	Regimen	% Inhibition
20 mg/kg (PBTE:D5W)	daily	>95%
20 mg/kg (DMSO)	2 days	77%
20 mg/kg (DMSO)	4 days	60%
30 mg/kg (DMSO)	2 days	91%
30 mg/kg (DMSO)	3 days	87%
40 mg/kg (PBTE)	2 days	>95%
60 mg/kg (PBTE)	weekly	51%
100 mg/kg (PBTE)	weekly	63%

In another set of experiments the affects different A10 dosing regimens were examined on C6 glioma cells. A10 was administered IP at different doses using different regimens beginning one day post-implantation. The total dose of A10 administered to the animals was compared to percent inhibition. These studied showed that higher doses of A10 administered less frequently have anti-tumor efficacy equivalent to that seen with lower doses administered daily provided that the total dose administered is equal. For example, 95% inhibition of tumor growth could be achieved by the administration of A10 to mice at 20 mg/kg every day, 40 mg/kg every two days, or 80 mg/kg every four days. C6 cells (3×10^6 cells) were implanted SC into the hindflanks of BALB/c, nu/nu mice.

In another set of experiments the affect of different doses of A10 on glioblastoma were determined. Table XIII presents data illustrating the ability of A10 to inhibit glioblastoma cells in vivo.

Table XIII

Cell Line	Dose (mg/kg)	% Inhibition
U87	5	52
	10	58
	15	66
	20	92
U118	15	57
U 373	15	54
SF763T	20	89
SF767T	20	70

The percent inhibition refers to tumor size in treated animals versus tumor size in untreated animals.

Table XIV compares the efficacy of different A10 formulations *in vivo* (mice implanted with C6 cells). PBTE, PBTE:D5W and DMSO formulations showed equivalent *in vivo* inhibition of tumor growth.

Table XIV

Efficacy vs. Formulation		
Dose	Formulation	% Inhibition
15 mg/kg/day	DMSO	90%
20 mg/kg/day	DMSO	95%
15 mg/kg/day	PBTE	92%
20 mg/kg/day	PBTE	>95%
40 mg/kg/2 days	PBTE	>95%
20 mg/kg	PBTE:D5W	>95%

The effects of A10 on animal mortality, using DMSO, PBTE, or PBTE:D5W formulations is presented in Table XV (mice implanted with C6 cells). PBTE:D5W formulations significantly reduced the mortality rate compared to DMSO formulations, and PBTE formulations.

Table XV

Effects of A10 on Mortality			
Dose	Treatments	Mortality	n
20 mg/kg/day (DMSO)	21	54%	26
20 mg/kg/day (PBTE:D5W)	27-100	0%	80
25 mg/kg/day (PBTE:D5W)	67	0%	8
20 mg/kg/day (PBTE)	20-48	8%	12
30 mg/kg/day (PBTE)	48	50%	4
40 mg/kg/day (PBTE)	48	75%	4

Inhibition of Different Tumor Types by A10

This section describes experiments comparing the ability of A10 to inhibit the growth of different types of tumors. In one set of experiments the ability of A10 to inhibit ovarian, melanoma, prostate, lung, and mammary tumor cell lines established as SC xenografts was examined using the procedures described in the appendices. In a second set of experiments the effects of A10 on the growth of murine leukemia cell lines in a synthetic model were tested as using the procedures described in the appendices above.

Table XVI summarizes the results of the studies using SC xenografts. At doses ranging from 12 to 20 mg/kg/day, A10 effectively inhibited the growth of glioma, SKOV3T (human ovarian), PA-1 (human ovarian), A375 (human melanoma), PC-3 (human prostate), Calu-6 (human lung), and D1B and L1210 (murine leukemias). However, A10 failed to significantly inhibit the growth of A549 (human lung), MCF7 (human mammary) and A431 (human epidermoid) xenografts.

Table XVI

Effect of A10 on Tumor Growth

Tumor type	Cell line	Strain	Dose mg/kg/day	% Inhibition (day)**	P < ***
glioma	C6*	nu/nu	20	>95 (21)	0.00001
	C6*	nu/nu†	20	84 (18)	0.00001
	9L*	nu/nu	20	83 (20)	0.00001
	U87MG	nu/nu	15	75 (28)	0.0092
	U118T	nu/nu	15	57 (47)	0.0027
	U373MG	nu/nu	15	54 (37)	0.0477
	SF763T	nu/nu	20	85 (22)	0.00001
5 ovarian	SF767T	nu/nu	20	70 (22)	0.00001
	SKOV3T	nu/nu	15	94 (21)	0.0014
	PA-1	nu/nu	20	53 (36)	0.04
melanoma	A375	nu/nu	20	53 (31)	0.03
	A375	SCID [‡]	15	35 (31)	0.002
prostate	PC-3	nu/nu	20	71 (45)	0.01
	PC-3	SCID [§]	12	47 (36)	0.001
lung	Calu-6	nu/nu	20	64 (28)	0.0001
	A549	SCID [¶]	15	19 (48)	NS
leukemia	D1B*	DBA/2	20	95 (22)	0.00001
	L1210*	DBA/2	20	75 (18)	0.04
10 epidermoid	A431	nu/nu	15	40 (15)	NS
mammary	MCF7	SCID	15	8 (27)	NS

Table XVI. Tumor cells were implanted SC into the indicated strains of mice. Daily treatment with vehicle or A10 was initiated on day one post-implant, with the following exceptions: † = day 4, ‡ = day 9, § = day 15, ¶ = day 29, || = day 8. *D1B and L1210 are murine tumor cell lines, C6 and 9L are rat tumor cell lines; all others are human tumor cell lines. ** Data are presented as percent inhibition of tumor growth on the day indicated as compared to vehicle control; n= 8 to 10 mice/group except D1B and L1210 where n=4 mice/group. *** P values were calculated by Student's t-test; NS = not significant.

In the second set of experiments, A10 was found to significantly increase the survival of animals bearing SKOV3T IP Xenografts and mice bearing 7DT1 iosgrafts. In one experiment, SKOV3T cells (2×10^6 cells) were implanted into the IP cavity of BALB/c, nu/nu mice. A10 was admin-

istered IP in 50 μ L DMSO at 15 mg/kg/day for 21 days beginning one day post-implantation and mice were monitored for survival (8 animals per treatment and control group). All animals in the control group died after 27 days, while one of A10 treated animals died by 28 days and 40% of A10 treated animals were alive after 32 days.

In another experiment, 7TD1 (B-cell hybridoma) cells were implanted IP in syngeneic immunocompetent C57BL/6 mice and the animals were treated for 30 days with 15 mg/kg/day of A10 (8 animals per treatment and control group). A10 was administered IP in 50 μ L DMSO at 15 mg/kg/day for 30 days beginning one day post-implantation. Dosing ceased on day 30, and surviving mice were observed for an additional 50 days. All animals in the control group died by day 9, while 3 of 8 animals in the A10-treated group survived past day 80.

Example 8: Targeting Cancer Characterized by Inappropriate PDGF-R Activity

This example illustrates the ability of A10 to inhibit cancers characterized by inappropriate PDGF-R activity while having little or no effect on tumors not characterized by PDGF-R activity. PDGF-R expression was measured qualitatively using a western blot. SRB assays assessed cell growth by determining total cellular protein using sulforhodamine-B (Skehan, T et al., *J. Natl. Cancer Inst.* 82:1107-1112 (1990)). Soft agar assays (SAA) were carried out by seeding cells at colony density in a semi-solid agar medium onto a base layer of agar after two to three weeks the size and number of colonies were quantitated with an automated Omincon 3800TM tumor colony counter. SRB and SAA values are expressed as IC₅₀ values in mM. In vivo inhibition was determined in xenografted athymic mice. The results are shown in Table XVII.

Table XVII

RECEPTOR EXPRESSION vs. GROWTH INHIBITION				
Cell Line	PDGF-R Expression	SRB	SAA	In Vivo
C6	++	0.3	0.4	95%
SF767	-	100	ND	18%
SF767T	++	3	0.5-2	70%
SF763	-	>100	ND	35%
SF763T	++	ND	ND	89%
SKOV-3	-	>100	6.3	ND
SKOV-3T	++	50	0.3	95%

As seen in Table XVII growth inhibition is strongest on cells expressing high levels of PDGF-R, establishing a clear link between receptor activity and cancer cell proliferation.

Example 9: Post Implant In Vivo Inhibition Using A10

This example describes the effects of A10 when administered to mice a number of days after cancer implantation. In one experiment, SCID mice containing PC-3 prostate cell line were treated with A10 starting 15 days after tumor transplant. The weekly treatment comprised 12 mg/kg/day of A10 (PBTE:D5W) for five days and two days of no treatment. The mice were treated for three week. In another experiment, mice containing A375 melanoma were treated in the same way as those implanted with PC-3 except 15 mg/kg/day of A10 was used and treatment began 9 days after tumor implant.

In both cases, tumor growth was inhibited by A10. PC-3 tumor growth was inhibited about 50% after three weeks. A375 melanoma growth was inhibited about 40% after three weeks. Thus, this example further illustrates the utility of A10 to inhibit tumor growth by showing its ability to inhibit tumor which have been growing in a host

prior to treatment (Cf. Example 7 where treatment of tumor began one day after transplant).

Example 10: Effect of A10 on Intracerebral Tumor Growth

The effect of A10 on tumor growth in brain tumor models was examined in a series of experiments.

In two separate experiments A10 was administered to athymic mice following intracerebral (IC) implantation of C6 cells, the average survival time of A10-treated animals was significantly increased compared to controls. The results of this experiment are shown in Figure 4).

In another experiment, in which A10 was administered to athymic mice following IC implantation of U87MG cells, the mean survival of the A10-treated animals was 65 days compared to a mean survival of 60 days in control animals an increase that was not significant ($P = 0.15$).

The efficacy of A10 was also tested in an IC model in athymic rats. As shown in Figure 5, A10 had a slight but significant positive effect on the survival of athymic rats following the IC implantation of C6 tumor cells.

Example 11: Immunology Studies

The effects of A10 on several parameters of normal immune function, including proliferation of lymphocytes, generation of cytotoxic effector cells, lymphokine production, and immunoglobulin secretion, were examined. These studies involved *in vivo* treatment of rats and mice with A10, followed by *in vitro* analyses of immune function. A detailed summary of the methods used in the immunology studies are described in Appendix 5.

Effects of *in vivo* Administration of A10 on Immune Function of Normal Mice

Naive BALB/c mice were treated with 15 mg/kg/day of A10 or vehicle (PBTE:D5W) for 7 and 21 days. The animals were sacrificed and their spleen cells were assayed *in vitro* for responses to ConA (a T-cell mitogen), LPS (a T-

cell independent B-cell mitogen), and alloantigens (C3H/HeJ spleen cells) as described in Appendix 5. The IL-2, IL-6, Ig content and cellular proliferation were measured after 48 hr (mitogens) or 72 hr (alloantigens).

5 The results are summarized in Table XVIII.

Table XVIII

Effects of A10 on Normal Immune Function in Naive Mice

Stimulus	IL-2 production		IL-6 production		Ig production		³ H-thymidine uptake	
	d7	d21	d7	d21	d7	d21	d7	d21
ConA	0	0	++	0	0	0	0	0
10 LPS	0	0	0	0	+	+/-	0	0
Allo	0	0	0	0	0	0	0	0

Table XVIII. Female BALB/c mice were treated with A10 for 7 or 21 days. Spleen cells were removed and stimulated in vitro with mitogens or alloantigens. Cellular proliferation, cytokine production, and Ig production were assayed as described in Appendix 5. Results are presented as a comparison between drug-treated and vehicle-treated (PBTE:D5W) animals. 0 = no change; +/- = slight increase in some animals; + = moderate increase in all animals; ++ = strong increase in all animals.

Two parameters appeared to be affected by A10 treatment: ConA-induced IL-6 production was higher in the A10-treated group than in controls at day 7, but this difference was not apparent at day 21. LPS-induced Ig production was slightly higher in the A10 group than in controls following 7 days of treatment, but this difference was not apparent in 3 of 4 mice treated with drug for 21 days. These data indicate that the effects of A10 on IL-6 production and Ig production by splenocytes were transient even with continued administration of A10.

Effects of in vivo Administration of A10 on Immune Function of Mice During a Primary Immunization

The effect of A10 in animals responding to an active primary immunization was also examined. BALB/c mice were immunized SC with 50 μ g keyhole limpet hemocyanin (KLH) suspended in complete Freund's adjuvant (CFA); control mice were mock-immunized with an emulsion of phosphate-buffered saline (PBS) in CFA. Beginning on day 1, mice were divided into three treatment groups: untreated, vehicle (PBTE:D5W) only, or A10 at 20 mg/kg/day. On day 14, all mice were sacrificed, and their spleen cells were assayed. In addition, immune responses to KLH and tetanus toxoid were measured as described in Appendix 5.

Cytokine production (IL-2 and IL-6) by splenocytes was not significantly affected by vehicle alone or drug as summarized in Table XIX. However, A10 treatment was associated with a slight inhibition of the proliferative responses of spleen cells after restimulation with the immunizing antigen (KLH) *in vitro*, (Table XIX). Similar effects were seen when the spleen cells were stimulated with LPS or allogeneic cells (Table XIX).

Table XIX

Effects of A10 on Normal Immune Function in Mice Responding to a Primary Immunization

Stimulus	IL-2 production	IL-6 production	Ig production	³ H uptake
KLH	0	0	0	-
ConA	0	0	0	0
LPS	0	0	0	-
Allo	0	0	0	-

Table XIX. BALB/c mice were immunized with KLH, then divided into three treatment groups; dosing began on day 1 and continued until day 14 post-immunization. Spleen cells from untreated, vehicle-treated, or A10-treated

mice, as well as non-immune control mice (normal) were cultured with the indicated mitogens or alloantigens. Cellular proliferation, cytokine production, and immunoglobulin production were assayed as described in Appendix 5. Results are presented as a comparison of the responses of drug-treated animals to those of vehicle-treated (PBTE:D5W) controls. 0 = no change; - = slight decrease in all animals.

Effects of in vivo Administration of A10 on Immune
10 Function of Tumor-Bearing Mice

BALB/c mice received SC implants of syngeneic WEHI-164.13 fibrosarcoma cells on day 0. On day 1, the mice were divided into three treatment groups: untreated, daily treatment with vehicle alone (PBTE:D5W), or daily treatment with A10 at 20 mg/kg/day. On day 17, the animals were sacrificed and their spleens were removed. The spleen cells were assayed in vitro for responses to alloantigens and mitogens. Treatment with A10 did not affect the proliferation, cytokine secretion, or Ig secretion of spleen cells stimulated with alloantigen or mitogens as summarized in Table XX.

The spleen cells were also assayed for the generation of WEHI-164.13-specific cytotoxic T-lymphocytes (CTL) in the mixed lymphocyte tumor cell culture (MLTC). Spleen cells from untreated tumor-bearing animals mounted a vigorous CTL response (44% specific lysis at E:T = 50:1). This response was inhibited almost completely in animals receiving the vehicle alone (13% specific lysis). The vehicle has an ethanol content of ~15% and ethanol is known to transiently effect CTL generation and activity. (Walia, et al., *Proc. Soc. Exp. Biol. Med.*, 192:177-200, 1989.)

Treatment with A10 enhanced the CTL response (78% specific lysis) compared to vehicle-treated animals; the CTL response of spleen cells from A10-treated mice was also higher than that from untreated control animals.

SUBSTITUTE SHEET (RULE 26)

Thus, it appears that in this immunocompetent mouse model, A10 dosing overcomes the inhibitory effect of the vehicle in the generation of CTL.

Table XX

- 5 Effects of A10 on Normal Immune Function in Mice
Bearing a Primary Tumor

Stimulus	IL-2 production	IL-6 production	Ig production	CTL activity
Tumor	0	0	0	++
ConA	0	0	0	NT
10 LPS	0	0	0	NT
Allo	0	0	0	NT

Table XX. Tumor-bearing mice were treated with vehicle or A10, or left untreated, for 17 days post-implantation. Mice were sacrificed and spleen cells were cultured with
15 the indicated mitogens, alloantigens, or mitomycin C-treated WEHI-164.13 tumor cells. Cellular proliferation, cytokine production, immunoglobulin production, and CTL activity were assayed as described in Appendix 5. Results are presented as a comparison of the responses of drug-
20 treated animals to those of vehicle-treated (PBTE:D5W) controls. 0 = no change; ++ = strong increase in all animals; NT = not tested.

Effects of in vivo Administration of A10 on Immune Function of Rats

25 Wistar rats received SC implants of C6 cells on day 0. Beginning on day 1, and daily thereafter, the rats received IP doses of vehicle (PBTE:D5W) or A10 at 8.4 mg/kg/day (equivalent to 20 mg/kg/day of A10 in mice). The control group was not treated after tumor implanta-
30 tion. On day 21, the animals were sacrificed and the spleens were removed for in vitro analyses. Splenocytes

were stimulated with ConA, LPS, and alloantigen (DA rat spleen cells) as in the murine studies.

Of the parameters measured, only cellular proliferation in the syngeneic mixed lymphocyte response (MLR) appeared to be affected by A10 treatment as summarized in Table XXI. The syngeneic MLR of the untreated, vehicle-treated, or tumor-bearing animals was much higher than that of the non-tumor bearing animals. This proliferative response was reduced in one of four A10-treated tumor-bearing animals to a level similar to non-tumor bearing controls. The allogeneic response was not reduced.

The spleen cells from Wistar rats were also assayed for the generation of C6-specific CTL in the MLTC and the results summarized in Table XXI. Spleen cells from tumor-bearing, untreated animals mounted a vigorous CTL response (35% specific lysis at E:T=100:1), while cells from non-tumor bearing control rats mounted a weak response (13% specific lysis at E:T=100:1). Similar to the studies in BALB/c mice, it appeared that the vehicle inhibited the generation of CTL in a 7-day culture. In contrast to the murine studies however, A10 did not overcome the inhibitory effect of the vehicle in immunocompetent rats.

Table XXI

Effects of A10 on Normal Immune Function in Rats Bearing a Primary Tumor

Stimulus	IL-2 production	IL-6 production	³ H- thymidine uptake	CTL activity
Tumor	0	0	0	0
ConA	0	0	0	NT
LPS	0	0	0	NT
Syn	0	0	+/-	NT
Allo	0	0	0	NT

Table XXI. Wistar rats received SC implants of C6 cells, followed by daily treatment with vehicle or A10; tumor-bearing, untreated animals and normal, non-tumor-bearing animals were included in the study. On day 21, animals were sacrificed and their spleen cells were stimulated with the indicated mitogens (ConA, LPS), syngeneic (Syn) or alloantigens (Allo), or mitomycin C-treated C6 tumor cells. Cellular proliferation, cytokine production, and CTL activity were assayed as described in Appendix 5. Results are presented as a comparison of the responses of drug-treated animals to those of vehicle-treated (PBTE:D5W) controls. 0 = no change; +/- = decrease in some drug-treated animals to levels detected in normal (non-tumor-bearing, non-drug-treated) animals; NT = not tested.

The results of these immunology studies indicate that A10 does not adversely affect the normal immune responses of immunocompetent or immunodeficient rodents during or following *in vivo* dosing. Furthermore, the efficacy of the drug when tested against murine tumor cell lines in syngeneic immunocompetent hosts indicates that A10 does not impair anti-tumor immunity.

Example 12: Pharmacology of A10

Several pharmacological properties of A10 have been studied in mice and rats including its metabolism and half-life in plasma and brain tissue. A detailed description of the methods utilized in studying the pharmacology of A10 can be found in Appendix 6. In addition, the pharmacokinetic profile of A10 was studied in conjunction with formal toxicity studies of the compound in rats and monkeys.

Metabolism of A10

The isoxazole ring of A10 undergoes an intramolecular rearrangement to 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (B11). The metabolism of A10 to B11

was investigated ex vivo in fresh heparinized plasma from humans or rats. The conversion of A10 to B11 was monitored using reverse-phase HPLC as described in Appendix 6. At 25°C (ambient temperature), A10 underwent complete conversion to B11 by 21 hr in human plasma. A similar experiment was performed using rat plasma with incubation at 37°C; A10 was completely converted to B11 after a 2 hr incubation. The conversion of A10 to B11 does not occur in heat-inactivated plasma (15 min at 60°C) from humans or rats. Additionally, both B11 and A10 together were incubated with fresh human plasma and the concentrations monitored. No A10 was detected after 21 hr; only B11 was present.

The metabolite, B11, appears to be equipotent to A10 in in vitro growth assays as well as equipotent in inhibiting PDGF-stimulated DNA synthesis and PDGF-stimulated cell cycle progression. B11 is also equipotent in the inhibition of the growth of C6 tumors in vivo. These data suggest that B11 is an active metabolite of A10. The use of A10 to treat cell proliferative disorders is preferred because it is more suitable than B11 for formulation as an IV solution.

Pharmacokinetics of A10 and B11 in vivo

The pharmacokinetics of A10 and its metabolite (B11) were investigated in vivo after intraperitoneal (IP) administration of A10 to mice and rats. When athymic (BALB/c, nu/nu, female) mice received A10 (120 mg/m², 40 mg/kg), the drug was converted to B11 at 3 hr post-dose, while the concentration of the parent compound was below the limits of detection in the systemic circulation. B11 was detected in plasma for more than 48 hr and had a $t_{1/2}$ of 16 hr and T_{max} of 3 hr. The area under the concentration time curve (AUC) for B11 was calculated to be 2773 µg.h/mL. The clearance rate (CL) was calculated to be 0.29 mL/hr. assuming 100% bioavailability and mean input time is zero. The volume of distribution (VD) was

SUBSTITUTE SHEET (RULE 26)

calculated to be 6.7 mL. In the brains of these mice, B11 exhibited a $t_{1/2}$ of 14 hr and a T_{max} of 3 hr.

Table XXII

Pharmacokinetics of A10 and B11 in Mice and Rats After IP

5 Administration

		athymic mice			BALB/c mice	Wistar rats	
		40 mg/kg 120 mg/m ² single dose	75 mg/kg 225 mg/m ² single dose	75 mg/kg 225 mg/m ² 1/week x 4	40 mg/kg 120 mg/m ² single dose	80 mg/kg 560 mg/m ² single dose	
10	Plasma						
	t _{1/2} (hr)	B11	16	15.5	16.9	14.9	6
		A10	< 1.5	<1	<1	ND	<2
	T _{max} (hr)	B11	3	3	3	3	6
		A10	< 0.5	ND	ND	ND	< 2
15	C _{max}	B11	111 ± 14	249 ± 26	190 ± 12	208 ± 34	260
		A10	ND	ND	ND	ND	5.0
	AUC (μg.hr/mL)		2773	5660	5012	4444	6417
	CL (mL/hr)		0.29	0.27	0.30	0.18	0.26
	VD (mL)		6.7	6.4	8.2	3.1	5.3
20							
	Brain						
	t _{1/2} (hr)	B11	14	NT	NT	2	6
		A10	< 1.5	NT	NT	<1	20
	T _{max} (hr)	B11	3	NT	NT	1	6
	A10	1.0	NT	NT	1.0	7	

25 Table XXII. Female athymic mice (BALB/c, nu/nu; four per group) were treated IP with A10 as indicated. BALB/c mice (female, four per group) were treated IP with 120 mg/m² (40

mg/kg) A10. Wistar rats (female, one per time point) were treated IP with 560 mg/m² (80 mg/kg) A10. Plasma and brain samples were prepared and analyzed by HPLC as described in Appendix 6. All results were calculated by the method of internal standardization. NT = not tested, ND = not detected.

The pharmacokinetic profile was also determined in athymic mice for the A10 dose calculated to be the LD₁₀. Intraperitoneal administration of A10 at 225 mg/m² (75 mg/kg) resulted in the detection of B11 in plasma for more than 48 hr (the last time point analyzed) with a $t_{1/2}$ of 15.5 hr and T_{max} of 3 hr (Table XXII). The AUC was calculated to be 5660 μ g.hr/mL. The CL was calculated to be 0.27 mL/hr, assuming 100% bioavailability and mean input time is zero. The VD was calculated to be 6.4 mL.

The pharmacokinetic profile of the A10 LD₁₀ (75 mg/kg) was also studied in mice after four IP treatments given once every 7 days. B11 was detected in plasma for 48 hr after the last dose and had a $t_{1/2}$ of 16.9 hr and T_{max} of 3 hr (Table XXII). The AUC for B11 was calculated to be 5012 μ g.hr/mL. The CL was calculated to be 0.3 mL/hr, assuming 100% bioavailability and mean input time is zero. The VD was calculated to be 8.2 mL.

The pharmacokinetic profile of A10 was determined in BALB/c mice. BALB/c mice received a single IP dose of A10 (120 mg/m², 40 mg/kg). A10 had been completely converted to B11 and was undetectable by 1 hr following drug administration. B11 was detected in plasma for more than 48 hr (the last time point analyzed) and had a $t_{1/2}$ of 14.9 hr and T_{max} of 3 hr as summarized in Table XXII. The AUC was calculated to be 4444 μ g.hr/mL. The CL was calculated to be 0.18 mL/hr, assuming 100% bioavailability and mean input time is zero. The VD was calculated to be 3.1 mL. In the brains of these mice, B11 exhibited a $t_{1/2}$ of 2 hr and a T_{max} of 1 hr (Table XXII).

When rats (Wistar, female) received a single IP dose of A10 (560 mg/m², 80 mg/kg) the drug was converted to B11

by 2 hr post dose, the first time point analyzed. However, A10 was detectable up to 8 hr post-dose. As summarized in Table XXI, A10 had a $t_{1/2}$ of < 2 hr and T_{max} of < 2 hr. B11 was detected for greater than 24 hr post-dose and had a $t_{1/2}$ of 6 hr and T_{max} of 6 hr. The AUC was calculated to be 6417 $\mu\text{g}\cdot\text{hr}/\text{mL}$. The CL was calculated to be 0.26 mL/hr, assuming 100% bioavailability and mean input time is zero. The VD was calculated to be 5.3 mL. In the brains of these rats, B11 exhibited a $t_{1/2}$ of 6 hr and a T_{max} of 6 hr while A10 exhibited a $t_{1/2}$ of 20 hr and a T_{max} of 7 hr (Table XXII).

In vivo Plasma Levels

In vivo plasma levels of B11 were determined in athymic mice after either a single dose or repeated daily doses of A10 and the results are summarized in Table XXII. Three hours (at the T_{max}) after a single administration of A10 (20 mg/kg), the B11 concentration was determined to be $51.2 \pm 7.3 \mu\text{g}/\text{mL}$ (range 38.8 - 55.2 $\mu\text{g}/\text{mL}$) while A10 was not detected. The plasma steady-state levels of B11 were also determined in athymic mice after repeated administration (20 mg/kg/day) of A10 at 24 hr intervals (8 administrations). The steady-state maximum plasma level of B11 was $79.7 \pm 11.2 \mu\text{g}/\text{mL}$ (range 65.2 - 94.6 $\mu\text{g}/\text{mL}$), and the steady-state minimum or trough level was $33.6 \pm 7.3 \mu\text{g}/\text{mL}$ (range 23.4 - 45.8 $\mu\text{g}/\text{mL}$). The plasma level of B11 after achieving steady-state (maximum steady-state level) was 64% greater than after a single dose (Table XXII).

Table XXII

Plasma Levels of B11

A10 Dose	B11 Concentration ($\mu\text{g}/\text{mL}$)		
	Single Dose	Multiple Doses	% Increase
20 mg/kg	51.2 ± 7.3	79.7 ± 11.2	64
40 mg/kg	110.9 ± 15.3	161.1 ± 27.8	69

Table XXII. Plasma levels of B11 were determined after single or multiple daily administrations of A10 at 20 or 40 mg/kg/day in athymic mice. All data are the mean of 4 animals.

5 The B11 plasma concentration at T_{\max} was also determined after a single administration of A10 at 40 mg/kg. The B11 concentration was $110.9 \pm 15.3 \mu\text{g/mL}$ (range 93.5-131.3 $\mu\text{g/mL}$) while A10 was not detected. The plasma steady-state levels of B11 were also determined in athymic
10 mice after repeated administration (40 mg/kg) of A10 at 24 hr intervals (6 administrations). The steady-state maximum plasma level of B11 was $161.1 \pm 27.8 \mu\text{g/mL}$ (range 119.9 - 204.1 $\mu\text{g/mL}$), and the steady-state minimum or
15 $\mu\text{g/mL}$). The plasma level of B11 after achieving steady-state was 69% greater than after a single dose (Table XXII). These data demonstrate that B11 accumulates in plasma after multiple daily administrations of A10.

 In addition to plasma levels, concentrations of A10
20 and B11 were determined in brain tissue after administration of A10 to rats and mice. The results are summarized in Table XXIV. The brain levels of B11 and A10 differed between both species and strains. The highest level of B11 in the brain was detected in athymic mice, followed by
25 BALB/c mice, and Wistar rats respectively. At 2 and 4 hr post-dose, there was 11 and 6.5 times, respectively, more B11 in the brains of athymic mice compared to Wistar rats. At 2 hr post-dose, there was 2 times more A10 in the
30 brains of athymic mice as compared to Wistar rats; at 4 hr post-dose approximately equivalent amounts of A10 were detected in the brains of athymic mice and Wistar rats.

Table XXIV

Comparison of B11 and A10 Levels in Brain Tissue

Time Post- dose	B11 and A10 Concentration in Brain Tissue (ng/mg)					
	Athymic mice		BALB/c mice		Wistar rats	
	B11	A10	B11	A10	B11	A10
2 hr	21.9 ± 12.7	19.9 ± 13.5	3.5 ± 2.8*	9.1 ± 13.5*	1.9 ± 1.5	8.9 ± 4.8
4 hr	21.3 ± 19.3	1.8 ± 1.6	10.7 ± 3.7	3.8 ± 2.9	3.3 ± 1.5	2.1 ± 3.2

Table XXIV. B11 and A10 levels in brain tissue were determined as described in Appendix 6. *Determined at 2.5 hr post-dose. n = 4 animals.

These pharmacology studies demonstrate that A10 is metabolized to B11 in both mice and rats. In addition, A10 and B11 can be detected in both plasma and brain tissue. However, there appears to be a difference in both the pharmacokinetics and distribution of A10 and B11 to plasma and brain between the two species examined.

Example 13: Preliminary Toxicology Studies Using A10

Preliminary toxicology studies of A10 included testing the effect of A10 on blood cells, body weight, LD₅₀ determinations. To determine the effect of potential ancillary medications on the LD₅₀ of A10, combination experiments were also performed. A detailed description of the methods used can be found in Appendix 7. The pharmacology and toxicology studies illustrate that A10 can be administered to animals under conditions having little if any adverse effect on the animal, particularly when PBTE:D5W formulations are used. Other suitable formulations can be obtained by one skilled in the art using this application as a guide.

Effect of A10 on Blood Cells

Many cancer therapeutics are cytotoxic in nature and have profound effects on blood cells resulting in cytopenia. The effects of A10 on the number of red blood cells, white blood cells, and the percent of lymphocytes versus polymorphonuclear cells were examined.

A10 at 15 mg/kg/day, did not appear effect blood differentials over a 21 day period for drug delivered in DMSO, PBTE or PBTE:D5W (1:1). Drug delivered in PBTE:D5W at 20 or 25 mg/kg/day did not affect the number of RBCs, WBCs or percent lymphocytes:neutrophils. However, drug delivered in PBTE alone at 30 mg/kg/day showed a slight decrease in WBCs after 2-3 weeks of treatment. Animals given 40 mg/kg/day showed both anemia and leukopenia after several weeks of treatment when given A10 in PBTE alone. No effects on blood cell were observed when A10 was administered in PBTE:D5W even after 100 days of treatment.

Effects of A10 on Body Weight

The effect of daily administration of A10 (20 mg/kg/day) on body weight was examined over a 100 day period. A10 had an initial effect on weight gain compared to controls. However, after several weeks, the animals gained weight at a rate similar to untreated or vehicle-treated animals. Over the treatment period, no mortality was observed. In addition there were no effects on blood differentials and no observable effects on major organ histopathology, including heart, liver, lung, kidneys, spleen, long bone, stomach, mesenteric lymph node, small and large intestine and pancreas.

Determination of LD₅₀

The lethal dose of A10 for 50% of animals (LD₅₀) was determined for both athymic mice (BALB/c, nu/nu, female) and BALB/c mice (male and female) using a number of dosing regimens. As shown in Table XXV, the LD₅₀ of A10 ranged from 83 - 145 mg/kg.

The effects of Dilantin® (phenytoin sodium for injection), an anti-convulsant agent, and Decadron® (dexamethasone sodium phosphate for injection), an anti-inflammatory agent, on the LD₅₀ of A10 were also determined (Table XIV). The LD₅₀ for A10 following pretreatment of animals with Decadron® or Dilantin® was 94 and 144 mg/kg, respectively.

Table XXV

Determination of A10 LD₅₀ in mice

10	Dose/Regimen	Strain, sex	LD ₅₀ (mg/kg)
	single dose	athymic, f	145
	every 4 days x 4	athymic, f	75
	every 7 days x 4	athymic, f	100
	single dose	BALB/c, f	83
15	single dose	BALB/c, m	107
	single dose with Decadron® pretreatment	BALB/c, f	94
	single dose with Dilantin® pretreatment	BALB/c, f	144

20 Table XXV. Decadron® was administered at 1.5 mg/kg/day for 7 days prior to administration of a single dose of A10. Dilantin® was administered at 20 mg/kg/day for 7 days prior to administration of a single dose of A10. The LD₅₀ was calculated from a plot of % mortality versus dose (log M) using a four parameter logistic equation. 25 f=female, m=male, n=5 animals per group.

Example 14: In vivo inhibition of tumor by a mutated PDGF-R receptor

30 This example illustrates the use of nucleic encoding a truncated PDGF-b receptor to inhibit in vivo tumor growth. C6 rat glioma cells were infected with retroviruses carrying a mutant gene for the human PDGF-b receptor. Seven G418-selected clones were screened for

expression of the truncated receptor by Western blotting with an antibody that recognizes the extracellular domain of the human receptor but does not cross-react with the wild type rat receptor. Two clones, HiMut.1 and HiMut.2, express high levels of a protein with the predicted molecular weight for the receptor lacking most of the intracellular region. Several clones expressed low levels of the truncated receptor; LoMut.1 was chosen for further experiments. HiMut.1 expressed PDGF-R 8.3 fold higher than LoMut.1. HiMut.2 expressed PDGF-R 9.4 fold higher than LoMut.1. The isolation and characterization of the clones containing the mutant receptors were carried out as described below.

Cell culture. All culture media, fetal bovine serum (FBS) and chemicals were purchased from Gibco BRL. C6 rat glioma cells were grown in Ham's/F-10 medium supplemented with 5% fetal bovine serum and 2 mM glutamine. COS cells were cultured in 10% fetal bovine serum and 2 mM glutamine in Dulbecco's Modified Eagle's medium (DMEM).

Expression of mutant PDGF-b receptor. A stop codon was introduced by site-directed mutagenesis into the gene for the human PDGF-b receptor directly upstream from the first tyrosine kinase domain. The mutant gene was cloned into a vector under the control of the murine sarcoma virus long terminal repeat (Muller, A.J., et al., Mol. Cell. Biol. 11:1785-1792, 1991). Four mg each of this vector and a vector containing the genes required for retroviral virus packaging (Muller, supra) were cotransfected into COS cells (2×10^5 cells/60 mm plate) by calcium phosphate precipitation (Chen, C. A., and H. Okayama, BioTech. 6:632-638, 1988). The cells were washed with PBS and refed the following day and conditioned media collected on days 4-6 after transfection. C6 cells (10^5 cells/60 mm plate) were infected with dilutions of the conditioned media containing 6 mg/ml Polybrene (Sigma). Two days later, the cells were put into selection with 800 mg/ml G418 (Gibco) and colonies picked when distinguish-

SUBSTITUTE SHEET (RULE 26)

able. The vector control cells were prepared by the same method but with a vector lacking a gene under the LTR.

Co-immunoprecipitation of wild type and truncated receptors. Vector control cells and cells expressing high levels of the mutant PDGF-b receptor (HiMut.1) were each seeded with 3×10^5 cells/well on 6-well plates. The following day, the media was changed for 0.5 ml 3% FBS in -cys-met DMEM (ICN) containing 100 mCi/ml Tran³⁵S-label (ICN). The cells were incubated at 37°C for 16 hrs. They were washed twice with binding buffer (0.1% BSA, 10 mg/ml CaCl₂·2H₂O, 10 mg/ml MgSO₄·7H₂O, 10 mg/ml aprotinin and 0.2 mM PMSF in PBS), and 0.5 ml binding buffer or 0.5 ml 20 ng/ml PDGF-BB (Collaborative Research Inc.) in binding buffer was added to each well. The cells were incubated at 4°C for 4 hrs, washed twice with PBS and lysed with 0.5 ml 1% Triton X-100 in HNTG (20 mM HEPES (pH 7.5), 150 mM NaCl, Triton X-100, 10% glycerol, 10 mg/ml each of aprotinin, leupeptin and pepstatin, and 0.2 mM PMSF). PDGF-BB was included in the lysis buffer of cells that had been treated with PDGF. The lysates were spun at 100,000xg for 30 min at 4°C. The supernatants were transferred to new tubes and precleared with Protein A-agarose (Vector Laboratories). SDS was added to a final concentration of 0.1% to 2 PDGF-treated samples for each cell line. Duplicate samples were immunoprecipitated with either an antibody that recognizes the C-terminus of the wild type rat receptor (UBI anti-PDGF-b receptor) or the human mutant receptor (Genzyme anti-PDGF-b receptor). Rabbit anti-mouse IgG was used as a secondary antibody for the samples incubated with the Genzyme anti-receptor. The complexes were precipitated with Protein A-agarose and washed 5 times with 0.1% Triton X-100 in HNTG. The proteins were separated by SDS-polyacrylamide gel electrophoresis on 7.5% gels under reducing conditions. The gels were fixed, treated with Amplify (Amersham) and exposed to X-ray film for 3 days.

Western blotting. Each cell line was plated in multiple wells at 5×10^5 cells/well on 6-well plates. The following day they were fed with 1% FBS in MCDB 105 (UCSF Cell Culture Facility) and incubated for 24 hrs in a 0% CO₂ environment. PDGF-AA or -BB (Collaborative Research Inc.) was added to one well of each clone to the desired final concentration. After incubating for 7 min at room temperature, the cells were washed with PBS and lysed with 50 mM Tris-HCl (pH 7.4), 1% nonidet P-40, 10% glycerol, 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mg/ml each aprotinin and leupeptin, 1 mM PMSF and 1 mM sodium orthovanadate. Equal volumes of each lysate were run on multiple 7.5% SDS polyacrylamide gels and transferred to nitrocellulose (Schleicher & Schuell). The membranes were blocked with 5% instant nonfat milk in Tris-buffered saline/0.05% Tween-20 (TBST-T). Duplicate membranes were incubated with either polyclonal anti-phosphotyrosine 1:3000 or anti-PDGF-b receptor (UBI) 1:1000 in blocking buffer. The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit IgG (Sigma) 1:1000. To detect the truncated receptor, a monoclonal antibody against the extracellular domain of the human PDGF-b receptor (Genzyme) diluted 1:500 was utilized. The secondary antibody used was peroxidase-conjugated rabbit anti-mouse IgG (ICN) 1:1000. ECL (Amersham) was used for detection on all blots. Relative band areas were determined with a Molecular Devices Computing Densitometer. Basal levels of phosphorylation were subtracted from each point.

Adherent growth of cell lines. To determine growth densities, each cell line was seeded with 10^4 cells/well on 5 24-well plates with triplicate samples in 1% or 5% FBS in Ham's/F-10 medium. The media was changed every 3 days. Every 2 days, the cells on one plate were trypsinized and counted on a Coulter counter. To determine cloning efficiencies, 100 cells of each cell line were plated on three 10 cm plates in 1% or 5% FBS in Ham's/F-10 medium. The media was changed every 3 days for about 12

days. The colonies were fixed, stained with methylene blue and scored.

Anchorage-independent growth of cell lines (soft agar assay). A base layer was made in 35 mm plates with 0.8% SeaPlaque agarose (FMC BioProducts), 1% FBS 2 mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES and nonessential amino acids. Cells were suspended in 0.4% agarose containing the other ingredients listed above and the desired concentration of PDGF-BB (Collaborative Research Labs). The suspension was plated on the base layer with 3000 cells/plate. They were incubated for 2 weeks in a humidified chamber with 5% CO₂. Colonies were scored visually or with an automated Omincon 3800™ tumor colony counter.

Growth of cell lines in nude mice. Cells were expanded in roller bottles, trypsinized and resuspended in PBS. They were counted and the volume adjusted to 3×10^7 cells/ml. For each cell line, 4 to 8 athymic nude mice (Simonsen Labs) were injected subcutaneously with 100 μ l (3×10^6 cells). Tumor volumes were measured with calipers twice a week for 18 to 21 days.

Immunohistochemical staining of tumor sections. Tumors were resected from the mice and frozen in OCT (Miles Lab). Five mm thick sections were cut and fixed with acetone. The sections were blocked with 10% normal goat serum prior to incubation with 20 mg/ml biotinylated-anti-human PDGF-b receptor (Genzyme antibody, biotinylated by Molecular Probes). Peroxidase-conjugated streptavidin (Caltag) 1:100 and diaminobenzidine (Sigma) with H₂O₂ were used for detection. For a negative control, a biotinylated monoclonal antibody to an unrelated protein was used at the same protein concentration as the anti-PDGF-b receptor. The counter stain was Harris hematoxylin (Anatech).

Using the retroviral expression system described above, a truncated PDGF-b receptor was introduced into rat C6 glioma cells. In G418-resistant clones expressing the mutant receptor, PDGF-BB-induced tyrosine phosphorylation

of the wild type receptor was significantly reduced. Furthermore, these cells grew to lower density and formed smaller colonies in culture and in soft agar than the parental C6 cells.

- 5 Cells expressing the truncated receptor were significantly impaired in their ability to grow in nude mice. After 21 days, the volumes of the tumors from HiMut.1 and HiMut.2 were only 12-16% of the size of the tumors from the parental cells. Tumors derived from the
- 10 C6 parental cells and vector control cells were essentially identical indicating that G418 selection of the vector control cells did not affect their ability to grow in nude mice. Tumors derived from HiMut.1 gave very dark immunological staining in at least 10% of the cells.
- 15 HiMut.2-derived tumors were stained in 45-85% of the cells.

The presence of the truncated PDGF-b receptor was also confirmed by Western blotting of lysed tumor sections. Thus, the truncated PDGF-b receptor was

20 expressed *in vivo* for up to 21 days and it had to be present in at least 10% of the cells to be inhibitory. These studies demonstrate the usefulness of dominant negative mutants of PDGF-R to inhibit growth of tumors characterized by inappropriate PDGF-R activity *in vivo*.

25 Example 15: Cellular Culture and *In vitro* Affects of Other Compounds

This example illustrates the effect of featured compounds, other than A10 and B11, on tumor growth in cell culture or *in vivo*. PDGF-R activity, C6 SRB, and *in vivo*

30 efficacy were measured using the procedures described in the appendices above. The results are shown in Table XXVI and XXVII. These results are preliminary data. One skilled in the art can improve the efficacy of the different compounds using factors known in the art such as

35 different dosing regimens.

Table XXVI

Com- pound	U1242 KINASE IC ₅₀ (μM)	C6 SRB IC ₅₀ (μM)	LD ₁₀ (mg/kg)	C6 in vivo EFFICACY (% at mg/kg)	p Value	Comments
P10	3.0 (W)	12				
J10	1 (W) >50	12	171	73% at 40		100% mor- tality at d18
G13	1.5	>50	not tested	12% at 15		0% mor- tality
G14	0.8 (W)	>50	not tested	36% at 15	0.285	0% mor- tality at d14
G21	6.0 (W) >50	>12 >12	>200 no deaths	no effect at 40		0% mor- tality
G22	0.9 (W) 14	>6 >6	25	no effect at 20		0% mor- tality only one dose tested in MTD due to solu- bility problems
P16	0.8 >50	17	>400 no deaths	no effect at 60		0% mor- tality
F10	45 (W)	>12.5				
G24	0.6 5	1 2.2	>200 no deaths	no effect at 20 no effect at 40 no effect at 60		0% mor- tality 12.5% mortality at d15 100% mor- tality at d10
G25	1.0	50				
P13	1.2	>100				
P17	0.8/3.0 >50	12	>100 no deaths			only one dose tested in MTD due to solu- bility problems
H10	25 (W) >50	13	75	52% at 30	0.006	14.3% mortality at d17
H12	>250 (W) 25 (W)	19				

SUBSTITUTE SHEET (RULE 26)

	H13	>50 >50	20 10.5	>400 no deaths	0% at 40 41% at 100	0.12	0% mor- tality 0% mor- tality
	E15	5.0 (W) 10 (W) >50	4.4	>400 no deaths	66% at 15 58% at 50 0% at 100	0.019 0.1	0% mor- tality 12.5% mortality at d15 100% mor- tality at d8
	P19		>50				
	P21		>25				
5	J11	3.1	14				
	P21	93	>25				

W = done in Western assay

Tables XXVII

	Compound	U1242 KINASE IC ₅₀ (μ M)	C6 SRB IC ₅₀ (μ M)	LD ₁₀ (mg/kg)	Comments
10	A13		>>25	>200 no deaths	~30% inhibition at 25 μ M
	P22		>>25		~10% inhibition at 25 μ M
	P23		18		
	P24		14		
	G28	16.4 (scndry)	4.5		
15	G29	23.2	>13 killed all cells at >12.5 μ M		
	G30	32.5	2		

W = done in Western assay

Example 16: Combination Therapy

Studies were conducted to look at the effect on tumor growth when PDGF-R inhibitors are used in combination with known cytotoxic drugs currently used to treat cancer. In
5 separate experiments CALU-6 cells and MCF-7/Her2 cells were implanted subcutaneously in nude mice. In one experiment the mice were then treated with A10 alone, cisplatin alone or a combination of cisplatin and A10. A10 was given intraperitoneally twice weekly at 5/mg/kg.
10 Cisplatin was given in a single intraperitoneal dose of 5/mg/kg on day two.

In the mice implanted with MCF-7/Her2 cells, the combination of A10 and cisplatin was better at inhibiting tumor growth than cisplatin alone or no treatment, but did
15 not enhance tumor suppression compared to A10 alone. However, in the mice implanted with CALU-6 cells, the combination of A10 and cisplatin resulted in a significant suppression of tumor growth compared to A10 alone, cisplatin alone or no treatment.

20 In a second experiment with CALU-6 cells, mice were treated with A10, cisplatin or VP-16 alone (10/mg/kg on days 4, 7 and 10) or the combination of cisplatin and VP-16 or A10, cisplatin and VP-16. The combination of A10, cisplatin and VP-16 was better at suppressing tumor growth
25 than either drug alone or the combination of cisplatin and VP-16.

Example 17: Chemical Synthesis

Some of the compounds of this invention may be prepared by employing procedures known in the literature
30 starting from known compounds or readily made intermediates. Quinoxalines compounds were prepared by either 1) reacting 1,2 aromatic diamine with a-ketoaldehyde or a-diketone, or 2) an exchange reaction of a-bis thiosemi-carbazones and a 1,2-diamine in the presence of an acid
35 catalyst. In the following preparations the aromatic diamine was obtained commercially or prepared as described

in the example. In examples where the reaction solvent is not specified, the reaction was carried out in ethanol-acetic acid. Some quinoxalines synthesized using this solvent were isolated as acid addition complexes with one
5 molecule acetic acid, based on elemental analysis. Reactions in ethanol alone, followed by solvent evaporation and recrystallization, gave a cleaner product and higher yield.

Group 1 Compounds

10 A10

A10 can be prepared as in European Patent Application 0 013 376 A2. Alternatively A10 can be prepared as follows:

15 Step 1: Preparation of acetoacetic acid-(4-trifluoromethyl)aniline.

A mixture of 4-trifluoromethylaniline (16.1 g, 0.1 mol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (purity 95%; 14.97 g, 0.1 mol), and xylene (20 ml) was heated to reflux for 30 minutes in a bath preheated to 150°C. The result-
20 ing dark solution was cooled to room temperature to crystallize the product. The crystals were filtered and collected. More material was obtained from mother liquors (the solution remaining after the initial crystallization and filtration). The yield of crude anilide was 17.75 g
25 (72%), the anilide had a melting point of 153-154°C.

Step 2: Preparation of 2-Ethoxymethyleneacetoacetyl-(4-trifluoromethyl)aniline.

Acetoacetyl-(4-trifluoromethyl)aniline (14.11 g., 57.6 mmol), triethoxymethane (9.43 g, 63.4 mmol), and
30 acetic anhydride (16.30 ml, 173 mmol) were mixed together and heated to reflux for 90 minutes. The resulting dark solution was evaporated to dryness. The residue was resuspended in benzene/isooctane and the product was crystallized. More material was obtained from mother

liquors. Yield of pure product was 11.93 g (72%), mp. 120-122°C.

Step 3: Preparation of A10

2-Ethoxymethyleneacetoacetyl-(4-trifluoromethyl)
5 aniline (3.01 g, 10.4 mmol) in ethanol (6 ml) was slowly added to an ice cooled solution of hydroxylamine hydrochloride (0.77 g, 11.0 mmol) in 2 M NaOH (5.5 ml). The mixture was heated to reflux for 1 hour, cooled to room temperature and evaporated to dryness. The residue was
10 resuspended, and distributed between ethyl acetate and water. The organic layer was separated, extracted with water, dried by sodium sulfate and the solvent was evaporated. The residue was resuspended in toluene and crystallized to yield a solid residue (2.45 g, 87%) of A10
15 having a melting point of 166-167°C.

A11

Preparation of 5-Methyl-isoxasole-4-carboxylic acid-(3-trifluoromethyl)-anilide was carried out in three steps:

20 a) Preparation of Acetoacetic acid - (3-trifluoromethyl)-anilide.

In a 25 ml round bottom flask equipped with Claisen distillation head and magnetic stirrer 4 g (18.6 mM) of α,α,α -Trifluoro-p-toluidine, 3.71 g (24.8 mM, 1 equiv.)
25 95% 2,2,6-trimethyl-4H-1,3-dioxin-4-one, 112 ml diethanolamine and 12.4 ml xylene was combined. The temperature of the mixture was raised to 110°C, and the mixture was stirred at this temperature for 6 hours while acetone was distilled off from the system. The progression of the
30 reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄ eluent: Petroleum ether (90-110°C fraction):acetone 2:1) visualization with 5% PMA in EtOH).

After 6 hours the xylene was distilled off at 20 Hgmm and the residue was purified with medium pressure (2 atm)

100

liquid chromatography using Silica gel 60 as fixed phase and petroleum ether (90-110°C fraction):acetone 2:1 as eluent.

The product fractions at $R_f = 0.3$ were collected -
5 using the TLC system used for the monitoring of the reaction - and after stripping the solvent, 3.82 g of Acetoacetic acid - (3-trifluoromethyl)-anilide was isolated. Melting point: 91-92°C.

$^1\text{H-NMR}$ (ppm, acetone- d_6)

10	ArH	7.36-7.87	4H	(m)
	NH	9.41	1H	(s)
	CH ₂	3.62	2H	(s)
	CH ₃	2.64	3H	(s)

15 b) Preparation of 2-propenamide, 2-acetyl-3-ethoxy-N-[(trifluoromethyl)phenyl].

In a dried (120°C, 30 min) 50 ml round bottom flask equipped with magnetic stirrer, thermometer, rubber septum and Argon balloon on a T stopcock, 1.0 g (4.1 mM) Acetoacetic acid-(3-trifluoromethyl)-anilide, 0.85 g (5.7
20 mM) orthoformic acid triethylesther 1.37 g acetic anhydride and 450 mg dry zinc chloride was combined. The mixture was stirred in argon atmosphere at 60°C for 30 minutes. The progress of the reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄, eluent: Petroleum
25 ether (90-110°C fraction):acetone 5:1. If the reaction was not complete after 30 minutes, a further 0.85 g (5.7 mM) of orthoformic acid triethylesther was added.

The reaction mixture gradually turned brown. After the completion of the reaction, the reaction mixture was
30 stripped in vacuo, the residue was dissolved in ethyl acetate, which was washed with water, the organic phase was dried with magnesium sulfate then filtered and the ethyl acetate was distilled off in vacuo. The 1.16 g crude product was purified with medium pressure (2 atm)
35 liquid chromatography using Silica gel 60 as fixed phase

SUBSTITUTE SHEET (RULE 26)

and petroleum ether (90-110°C fraction):acetone 5:1 as eluent.

The product fractions at $R_f = 0.231$ were collected - using the TLC system used for the monitoring of the
5 reaction - and after stripping the solvent, 0.46 g of 2-propenamide, 2-acetyl-3-ethoxy-N-[(trifluoromethyl)phenyl] was isolated. Melting point: 100.5°C.

$^1\text{H-NMR}$ (ppm, acetone- d_6)

	ARH	7.29-8.00	4H	(m)
10	NH	11.25	1H	(s)
	CH=	8.46	1H	(s)
	EtCH ₂	4.37	2H	(s)
	EtCH ₃	1.45	3H	(s)
	AcMe	2.48	3H	(s)

15 c) Preparation of 5-Methyl-isoxasole-4-carboxylic acid-(3-trifluoromethyl)-anilide.

In a 25 ml round bottom flask equipped with magnetic stirrer and thermometer 0.11 g (1.58 mM) of hydroxylamine hydrochloride was dissolved in 0.5 ml of water and to this
20 solution 64 mg (1.6 mM) sodium hydroxide was added in 0.5 ml of water. To this solution 2.2 ml of methanol was added and at room temperature 0.44 g (1.5 mM) 2-propenamide, 2-acetyl-3-ethoxy-N-[(trifluoromethyl)phenyl] was added. The progress of the reaction was monitored by
25 TLC (plate Merck Kieselgel 60 F₂₅₄ eluent: Petroleum ether (90-110°C fraction):acetone 4:1, visualization with 5% PMA in EtOH. After completion of the reaction, the reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate. The organic phase was washed
30 with water, dried with magnesium sulfate, filtered and concentrated. The obtained 0.51 g crude product was purified with medium pressure (2 atm) liquid chromatography using Silica gel 60 as fixed phase and petroleum ether (90-110°C fraction):acetone 4:1 as eluent.

35 The product fractions at $R_f = 0.162$ were collected - using the TLC system used for the monitoring of the

102

reaction - and after the stripping of the solvent, 0.22 g of 5-Methyl-isoxasole-4-carboxylic acid-(3-trifluoromethyl)-anilide was isolated. Melting point: 115-120°C.
¹H-NMR (ppm, acetone-d₆)

5	ArH+NH	7.42-7.88	4H	(m)
	CH=	8.50	1H	(s)
	CH	8.50	1H	(s)

A12

A12 can be prepared as described by Patterson et al.,
10 *J. Med. Chem.* 35:507-510 (1992).

A13: N-trifluoromethylphenyl 3,5-dimethylisoxazole-4-carboxamide

A mixture of 320 mg of 3,5-dimethylisoxazole-4-carbonylchloride and 1 ml of 4-trifluoromethylaniline in
15 2 ml of dichloromethane was stirred at room temperature overnight. The mixture was then worked up with ethyl acetate and water. The crude was crystallized with ethanol and water to provide 330 mg of N-trifluoromethylphenyl 3,5-dimethylisoxazole-4-carboxamide.

20 Group 2 Compounds

B10

B10 was synthesized in two steps.

a) Synthesis of cyanoacetyl-(4-nitro)anilide.

1.38 g (10 mmol) 4-nitroaniline was dissolved in 30
25 ml of absolute pyridine, then cooled to -30°C, 0.43 ml (5 mmol) phosphorus trichloride was added dropwise with continuous stirring to avoid increasing the temperature above -20°C. After 0.5 hour 0.85 g cyanoacetic acid was added, and the solution was stirred for 0.5 hour at -20°C
30 then 12 hours at room temperature.

The solvent was evaporated in vacuum. The residue was covered with 1N HCl and extracted with ethylacetate. The ethylacetate solution was dried over Na₂SO₄, filtered

SUBSTITUTE SHEET (RULE 26)

103

and evaporated. The residue was triturated with ether filtered and dried in vacuo. 1.70 g (83%) product yield was obtained. The product had the following characteristics:

- 5 Melting point: 81-83°C
 R_F: 0.95 (hexane-EtOAc; 1:1)

b) Acetylation of cyanoacetyl-(4-nitro)anilide.

- 0.82 g (4 mmol) cyanoacetyl 4-nitroanilide was dissolved in 2 ml absolute pyridine, followed by the
10 addition of 20 mg 4-aminopyridine catalyst and 0.50 ml tetramethylguanidine. The reaction mixture was stirred while the nitroanilide dissolved. 5 ml of acetic anhydride was then dropped in at 0°C.

- After 2 days the pyridine was evaporated, ethyl-
15 acetate was added and the organic layer was extracted with 5 % NaHCO₃ solution, in 1N HCl, and water. The organic layer was dried over Na₂SO₄ and evaporated. The residue was crystallized from ether and 210 mg (21% yield) of product was obtained. The product had the following
20 characteristics:

R_f=0.35 (EtOAc)
Melting point: 260°C

B11

- B11 was synthesized using two different methods:
25 method A and method B.

Method A

- A mixture of 27 grams of A10 in 150 ml of ethanol was combined with 16.2 grams of 1,8-diazabicyclo[5.4.0]undec-7-ene. The reaction mixture was then stirred at room
30 temperature for 30 minutes and ethanol was evaporated off. The resulting solid was suspended in 500 ml of ethyl ether and combined with 200 ml of 0.6 N hydrochloric acid solution. All the solids was suction filtered, washed.

SUBSTITUTE SHEET (RULE 26)

with 200 ml ethanol and suction dried to provide 25 grams product.

Method B

2-Butenamide, 2-cyano-3-hydroxy-N-[(4-trifluoro-methyl)phenyl] ($C_{12}H_{19}F_3NO_3$) was prepared in two steps as follows:

a) Preparation of Cyanoacet-(4-trifluoromethyl)-anilide.

A mixture of 3 g (18.6 mM) a,a,a-Trifluoro-p-toluidine and 3.37 g (29.8 mM, 1.6 equivalent) cyanoacetic acid ethyl ester in a 50 ml flask, equipped with magnetic stirrer, thermometer and nitrogen vent, was stirred on a 180°C oil bath for 5 hours. The progress of the reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄, eluent: Petroleum ether (90-110°C fraction):acetone 1:1. The reaction mixture was purified with medium pressure (2 atm) liquid chromatography using Silica gel 60 as fixed phase and petroleum ether (90-110°C fraction):acetone 1:1 as eluent.

The product fractions were collected - using the TLC system used for the monitoring of the reaction - and after stripping the solvent, 2.11 g of Cyanoacet-(4-trifluoromethyl)-anilide was isolated. Melting point: 192-194°C.

¹ H-NMR (ppm, Acetone-d₆)

ArH	7.68-7.85	4H	(dd)
NH	9.84	H	(s)
CH ₂	3.90	2H	(s)

b) Preparation of 2-Butenamide, 2-cyano-3-hydroxy-N-[(4-trifluoromethyl)phenyl].

In a 50 ml round bottom flask equipped with magnetic stirrer, thermometer, a rubber septum and a T stopcock (with vacuum and Argon blanket balloon joints), 1.78 g (0.89 g, 37.1 mM) 50% NaH oily dispersion was suspended in 4 ml dry (from P₂O₅) acetonitrile. The suspension was cooled to 10°C and while stirring at this temperature 2.72

105

g (11.9 mM) Cyanoacet-(4-trifluoromethyl)-anilide was added dissolved in 25 ml dry (from LiAlH₄) tetrahydrofuran in 10 minutes. The reaction mixture turned yellow, and was cooled down after the addition to -10°C, and then 1.05 g (13.11 mM, 1.1 equiv.) Acetylchloride was added in 20 minutes. During the addition, the temperature of the reaction mixture can not be higher than -5°C. The progress of the reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄, eluent: Petroleum ether (90-110°C fraction):acetone 1:1.

When the reaction was complete, the reaction mixture was stirred at 0°C for 30 minutes, at 35°C for 30 minutes and at 65°C for another 30 minutes, then the reaction mixture was stripped in vacuo. The residue was dissolved in 30 ml distilled water, charcoaled at 80°C and filtered. The resulting pale yellow filtrate was acidified with a 10% hydrochloric acid solution, the precipitated crystals were filtered, washed with water and dried. The crude crystals (2.51 g) were purified with medium pressure (2 atm) liquid chromatography using Silica gel 60 as fixed phase and petroleum ether (90-110°C fraction):acetone 1:1 as eluent.

The product fractions at R_f = 0.138 were collected - using the TLC system used for the monitoring of the reaction - and after stripping the solvent, 1.99 g of 2-Butenamide, 2-cyano-3-hydroxy-N-[(4-trifluoromethyl) phenyl] was isolated.

TLC petroleum ether (90-110°C)/acetone 1/1=0.138.

¹ H-NMR (ppm, DMSO-d₆)

30	ArH	7.65-7.78	4H	(dd)
	NH	10.85	1H	(s)
	CH ₃	2.26	3H	(s)
	OH	6.39	1H	(s)

SUBSTITUTE SHEET (RULE 26)

B12

Preparation of 2-Propenamide, 2-cyano-3-hydroxy-3-(4-fluorophenyl)-N-[(4-trifluoromethyl) phenyl] ($C_{17}H_{10}F_4N_2O_2$ MW:350.3) was carried out as follows:

5 a) Preparation of Cyanoacet-(4-trifluoromethyl)-anilide:

A mixture of 3g (18.6 mM) a,a,a-Trifluoro-p-toluidine and 3.37 g (29.8 mM, 1.6 equivalent) cyanoacetic acid ethyl ester in a 50 ml flask, equipped with a magnetic stirrer, thermometer and nitrogen vent, was stirred on a
10 180°C oil bath for 5 hours. The progress of the reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄, eluent: Petroleum ether (90-110°C fraction):acetone 1:1. The reaction mixture was purified with medium pressure (2 atm) liquid chromatography using Silica gel 60 as fixed
15 phase and petroleum ether (90-110°C fraction):acetone 1:1 as eluent.

The product fractions were collected and after the stripping of the solvent, 2.11 g of cyanoacet-(4-trifluoromethyl)-anilide was isolated. The product had
20 the following characteristics:

Melting point: 192-194°C.

¹H-NMR (ppm, acetone-d₆)

ArH	7.68-7.85, 4H	(dd)
NH	9.84	1H (s)
25 CH ₂	3.90	2H (s)

b) Preparation of 2-Propanamide, 2-cyano-3-hydroxy-3-(4-fluorophenyl)-N-[(4-trifluoromethyl) phenyl]:

In a 50 ml round bottomed flask equipped with magnetic stirrer, thermometer, a rubber septum and a T
30 stopcock (with vacuum and Argon blanket balloon joints) 0.55 g (0.275 g, 11.4 mM) 50% NaH oily dispersion was suspended in 1 ml dry (from P₂O₅) acetonitrile. The suspension was cooled to 10°C and under stirring at this temperature 1 g (4.4 mM) cyanoacet-(4-trifluoromethyl)-
35 anilide, dissolved in 10 ml dry (from LiAlH₄) tetra-

SUBSTITUTE SHEET (RULE 26)

hydrofuran, was added in 10 minutes. The reaction mixture was then cooled down to -10°C and at this temperature 0.77 g (4.8 mM, 1.1 equiv.) 4-fluorobenzylchloride was added in 20 minutes. During the addition the temperature of the reaction mixture was not allowed to go higher than -5°C. The progress of the reaction was monitored by TLC (plate Merck Kieselgel 60 F₂₅₄, eluent: Petroleum ether (90-110°C fraction):acetone 1:1.

The reaction mixture was then stirred at 0°C for 30 minutes, at 35°C for 30 minutes and at 65°C for another 30 minutes, then the reaction mixture was stripped in vacuo. The residue was dissolved in 30 ml distilled water, charcoaled at 80°C and filtered. The resulting pale yellow filtrate was acidified with 10% hydrochloric acid solution, the precipitated crystals were filtered, washed with water and dried. Crude crystals (2.47 g) were purified with medium pressure (2 atm) liquid chromatography using Silica gel 60 as fixed phase and petroleum ether (90-110°C fraction):acetone 1:1 as eluent.

The product fractions at R_f=0.216 were collected and after the stripping of the solvent, 1.05 g of 2-Propenamide, 2-cyano-3-hydroxy-3-(4-fluorophenyl)-N-[(4-trifluoromethyl) phenyl] was isolated. The product had the following characteristics:

Melting point: 195°C (dec).

¹H-NMR (ppm, acetone-d₆)

ArH	7.36-8.13	8H	(m)
NH	9.5	1H	(s)
OH	16.5	1H	(s)

30 B13

Preparation of 2-Propenamide, 2-cyano-3-hydroxy-3-cyclohexyl-N-[(4-trifluoromethyl)phenyl] (C₁₇H₁₇F₃N₂O₂ MW: 338.3) was carried out as described for B12 substituting 0.71 g (4.8 mM, 1.1 equiv.) cyclohexylacetyl-chloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:

TLC: $R_f=0.265$ (petroleum ether (90-110°C):acetone, 1:1)

Melting point: 212°C (dec.)

B14

- 5 Preparation of 2-cyano-3-hydroxy-3-(2,2,3,3-tetramethylcyclopropyl)-propanol-4-(trifluoromethyl)anilide was carried out as described for B12 above using 2,2,3,4-tetramethylcyclopropylcarboxyl chloride for 4-fluorobenzoylchloride.

10 B15

- Preparation of 2-Propenamide, 2-cyano-3-hydroxy-3-(pentafluorophenyl)-N-[(4-trifluoromethyl)phenyl] was carried out as described for B12 substituting 1.5 g (6.51 mM, 1.1 equiv.) pentafluorobenzoylchloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:

TLC: $R_f=0.360$ (petroleum ether (90-110°C):acetone, 1:1)

Melting point: 157-158°C.

B16

- 20 Preparation of 2-Propenamide, 2-cyano-3-hydroxy-3-((3-phenoxy)phenyl)-N-[(4-trifluoromethyl)phenyl] ($C_{23}H_{15}F_3N_2O_3$ MW: 424.4) was carried out as described for B12 substituting 1.65 g (4.8 mM, 1.1 equiv) 3-phenoxybenzoyl chloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:

TLC: $R_f=0.300$ (petroleum ether (90-110°C):acetone, 1:1)

Melting point: 197-198°C.

B17

- 30 Preparation of 2-Butenamide, 2-cyano-3-hydroxy-4-phenyl-N-[(4-trifluoromethyl)phenyl] was carried out as described for B12 substituting 0.68 g (4.8 mM, 1.1 equiv.) phenyl-acetyl chloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:

109

TLC: $R_f=0.165$ (petroleum ether (90-110°C):acetone, 1:1)
Melting point: 156-158°C.

B18

- Preparation of 2-Hexeneamide, 2-cyano-3-hydroxy-5-methyl-N-[(4-trifluoromethyl)phenyl] ($C_{15}H_{15}F_3N_2O_2$ MW: 312.3) was carried out as described for B12 substituting 0.58 g (4.8 mM, 1.1 equiv.) isovalerylchloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:
- 10 TLC: $R_f=0.323$ (petroleum ether (90-110°C):acetone, 1:1)
Melting point: 161-163°C.

B19

- Preparation of 2-Butenamide, 2-cyano-3-hydroxy-4,4-diphenyl-N-[(4-trifluoromethyl)phenyl] ($C_{24}H_{17}F_3N_2O_2$ MW: 422.4) was carried out as described for B12 substituting 1.12 g (4.8 mM, 1.1 equiv.) diphenylacetyl-chloride for 4-fluorobenzoylchloride. The resulting product had the following characteristics:
- 15 TLC: $R_f=0.354$ (petroleum ether (90-110°C):acetone, 1:1)
20 Melting point: 195-202°C.

Group 3 CompoundsC10

- 340 mg (1.5 mM) 1-phenyl-3-amino-4-cyano-5-cyanomethyl-2-pyrazole, 210 mg (1.5 mM) 3,4-dihydroxy benzaldehyde and 4 drops of piperidine in 30 ml ethanol were refluxed for 6 hours. Cooling and filtering gave 145 mg yellow solid. Evaporation of the solvent and trituration with CH_2Cl_2 -acetone gave another 145 mg yellow solid (56% yield). The product had a melting point of 147°C.
- 25 NMR acetone d_6 δ -7.87 (1H,s, Vinyl), 7.68 (1H,d, $J=2.2$ Hz, H_2) 7.66-7.45 (5H,m, Ph), 7.28 (1H,dd, $J=8.3.2.2$ Hz, H_6). 6.92 (1H,d, $J=8.3$ Hz, H_5).
- 30

SUBSTITUTE SHEET (RULE 26)

C11

C11 was synthesized using a two step procedure.

a. Synthesis of 3-amino-4-cyano-5-cyanomethyl-2 pyroazole:

2.2 g malononitrile dimer and 0.9 ml N_2H_4 in 20 ml of
5 water were heated for 15 minutes at 100°C. Cooling and
filtering gave 1.5 g (61% yield) of a white solid having
a melting point of 187°C. (NMR acetone d_6 δ 3.88 (s).)
(Cf. Carboni et al., *J. Am. Chem. Soc.* 80:2838 (1958),
reporting m.p. 197°C.)

10 b. Condensation with dihydroxybenzaldehyde:

To 0.28 g (2 mM) 3,4-dihydroxybenzaldehyde and 1.33
g (2.2 mM) of 3-amino-4-cyano-5-cyanomethyl-2 pyroazole in
20 ml ethanol were added three drops piperidine and the
reaction was refluxed 3 hours. Cooling, filtering and
15 washing with ethanol gave 1.3 g (56% yield) of a yellow
solid having a melting point of 300°C.

C13

0.7 g, 3 mM, 3,5 di-t-butyl-4-hydroxyaldehyde 0.46 g,
3.1 mM, 3-amino 4 cyano 5-cyanomethyl pyrazole (prepared
20 according to Carboni et al., *J. Chem. Soc.*, 80:2838, 1958)
and 40 mg β -alanine were refluxed 15 hours. Cooling and
filtering gave 0.5 g, 46% yield, yellow solid, mp. 255°C.
NMR $CDCl_3$ δ 7.92(1H,S,vinyl), 7.80(2H,S), 5.76(1H,S,OH),
3.75(2H,br,S, NH_2), 1.48(18H,S). MS-364 (M^+ 1,28),
25 363 (M^+ ,100%), 348 ($M-CH_3$,58), 292 ($M-56-CH_3$,31), 147(41),
m/e.

Group 4 CompoundsD11

435 mg (3 mM) 3-formyl indole, 300 mg (4.5 mM) 2-
30 thiocarboxamido acetonitrile and 20 mg β -alanine in 30 ml
ethanol were refluxed for six hours. Cooling and filter-
ing gave 0.47 g (81% yield of a yellow solid having a
melting point of 238°C).

111

D12

This was synthesized as for D11 except 1,1,4-tricyano-2-amino-1-propene was used instead of the acetonitrile derivative. The final product had a melting point of 293°C.

D13

This was synthesized as for D11 except 2-carboxamido-acetonitrile was used instead of the acetonitrile derivative. The final product had a melting point of 242°C.

10 D14

0.29 g (2 mM) 3-formyl indole, 0.29 g (2 mM), 3-amino-4-cyano-5-cyanomethyl-2-pyrazole and 20 mg β -alanine in 30 ml of ethanol were refluxed 4 hours. Cooling and filtering gave 0.34 g (62% yield) of yellow solid having a melting point of 281°C.

NMR acetone d_6 δ 8.52 (1H, s, vinyl), 8.42 (1H, s, H_2), 7.79 (1H, m), 7.57 (1H, m), 7.27 (2H, m), 6.17 (1H, br. s, NH).

MS-274 (M⁺, 100%), 219(14), 91(35), m/e.

D15

0.3 g (1.3 mM) 3-amino-4-cyano-5-cyanomethyl-2-pyrazole, 0.2 g (1.36 mM) of 1-(3-dimethylaminopropyl)-3-formyl indole and 20 mg β -alanine in 20 ml ethanol were refluxed 4 hours. Evaporation, trituration with benzene and filtering gave 0.4 g of yellow solid (94% yield) containing 10% 3-amino-4-cyano-5-cyanomethyl-2-pyrazole. 0.4 g was chromatographed on silica gel (70-220 mesh) eluting with 85:15 methylene chloride:methanol to give 0.12 g of a bright yellow solid having a melting point of 250°C.

30 NMR acetone d_6 δ 8.45 (1H, s, vinyl), 8.37 (1H, s, H_2), 7.78 (1H, m), 7.60 (1H, m), 7.28 (2H, m), 4.47 (2H, t, J=6.8 Hz), 2.29 (2H, t, J=6.8 Hz), 2.24 (6H, s, N-(CH₃)₂). MS-360 (M+1, 8%), 359 (M⁺, 31), 289 (100), 261 (15), 144 (6), m/e.

SUBSTITUTE SHEET (RULE 26)

D16

0.4 g (1.7 mM) 3-amino-4-cyano-5-cyanomethyl-2-pyrazole, 0.3 g (1.73 mM) 1-oxo-1-(3,4-dihydroxyphenyl)-2-cyanothane and 20 mg β -alanine in 20 ml ethanol were
5 refluxed 5 hours. Cooling and filtering gave 0.1 g of a brown solid. Preparative chromatography gave 20 mg (3% yield) of an orange solid having a melting point of 115°C. NMR acetone d_6 δ 8.72(1H, S, Vinyl), 8.52(1H, S, H₂), 7.90(1H, m), 7.73(1H, m), 7.40(4H, m), 7.0(1H, d, J=8.2 Hz, H₅).
10 4.57(2H, t, J=7.2 Hz), 2.46(2H, t, J=7.2 Hz), 2.34(6H, s, N(CH₃)₂), 2.17(2H, quintet, J=7.2 Hz).

D17

0.4 g (2 mM) 3-formyl indole, 0.36 g 1-oxo-1-(3,4-dihydroxyphenyl)-2-cyanothane and 3 drops of piperidine,
15 in 25 ml ethanol, were refluxed 6 hours. Workup and trituration with benzene gave 0.36 g of a yellow solid having a melting point of 225°C. NMR acetone d_6 8.77(1H, S), 7.90(1H, m), 7.70(1H, m), 7.40(4H, m), 7.0(2H, t, J=6.7 Hz), 4.92(2H, t, J=6.8 Hz),
20 3.26(2H, t, J=6.8 Hz).

D18

0.29 g, 2 mM, 3-formyl indole, 0.29, 2 mM, 3-amino-4-cyano-5-cyanomethyl-2-pyrazole, and 20 mg β -alanine in 30 ml ethanol were refluxed 4 hours. Cooling and filtering
25 gave 0.34 g, 62% yield, yellow solid, mp. 281°C. NMR acetone d_6 δ 8.52 (1H, S, Vinyl), 8.42 (1H, S, H₂), 7.79 (1H, m), 7.75 (1H, m), 7.27 (2H, m), 6.17 (1H, Br. S, NH), MS-274 (M⁺, 100%), 219(14), 91(35), m/e.

D20

30 80 mg. 0.55 mM, 3-formyl indole, 130 mg, 0.6 mM, 3-amino-4-cyano-5-cyanomethyl-1-phenylpyrazole and 2 drops of piperidine in 10 ml ethanol were refluxed 8 hours. Cooking and filtering gave 120 mg, 62% yield, yellow-green solid, mp. 258°C.

NMR acetone d_6 δ 8.56 (1H, S), 8.52 (1H, S), 7.84 (1H, m), 7.60-7.25 (8H, m).

Group 5

Group 5 compounds were prepared in three steps.

5 a) Preparation of N-aryl-oxamic acid esters (=Ethyl-oxalyl anilides):

0.025 mol (3.4 ml) diethyl-oxalate and 0.1 mol of the appropriate aniline were mixed together and refluxed at 190°C for 15 minutes. The resulting solution was cooled and left overnight to crystallize the product. The crystals were filtered, washed with ethanol and extracted with hot ethanol. The insoluble material was filtered off and the solution put in the refrigerator. The resulting crystals were filtered and dried.

15 Table XXVIII

No.	Subs.	MP °C	Formula:	MW	Yield [%]
1a	4-N(CH ₃) ₂	116-118	C ₁₂ H ₁₆ N ₂ O ₃	236.27	75
1b	3-OH	184-185	C ₁₀ H ₁₁ NO ₄	209.20	86
1c	2-OCH ₃	81-82	C ₁₁ H ₁₃ NO ₄	223.23	60
1d	2-OC ₂ H ₅	74-76	C ₁₂ H ₁₅ NO ₄	237.26	64
1e	3-NO ₂	93-96	C ₁₀ H ₁₀ N ₂ O ₅	238.20	53

b) Preparation of N-aryl-oxamic acid hydrazides (N-aryl-oxamoyl hydrazides)

0.05 mol of the appropriate N-aryl-oxamic acid ester (1a...1e) was dissolved in 200 ml of ethanol and slowly added to a well-stirred solution of 7.5 ml (~0.15 mol) hydrazine hydrate in 50 ml ethanol. The mixture was left at room temperature for 48 hours. The resulting heterogeneous solution was refluxed for 15 minutes and filtered the hot solution. After cooling to room temperature the

precipitated substance was filtered washed with ethanol and dried.

Table XXIX

No.	Subs.	MP °C	Formula:	MW	Yield [%]
2a	4-N(CH ₃) ₂	228-232	C ₁₀ H ₁₄ N ₄ O ₂	222.25	83
2b	3-OH	200-202	C ₈ H ₉ N ₃ O ₃	195.18	72
2c	2-OCH ₃	165-167	C ₉ H ₁₁ N ₃ O ₃	209.21	67
2d	2-OC ₂ H ₅	152-154	C ₁₀ H ₁₃ N ₃ O ₃	223.23	58
2e	3-NO ₂	231-234	C ₈ H ₈ N ₄ O ₄	224.18	49

10 c) Preparation of N-aryl-oxamoyl hydrazones:

E10

0.001 mol (0.222 g) of N-(4-dimethylamino)-phenyl-oxamoyl hydrazide (2a) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.138 g) of 3,4-dihydroxy benzaldehyde for 20-25 minutes in the presence of a catalytic amount of sodium acetate. The mixture then cooled and left overnight at room temperature. The separated crystals were filtered off and washed with acetic acid and water.

20 Yield of pure product was 0.23 g (68%) m.p. 253°C.

(C₁₇H₁₈N₄O₄, MW:342.36)

Elemental Analysis [%]: Found C, 59.51; H, 5.28; N, 16.25
Calculated C, 59.64; H, 5.30; N, 16.37.

E11

25 0.001 mol (0.195 g) of N-3-hydroxy-phenyloxamoyl hydrazide (2b) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.138 g) of 3,4-dihydroxy benzaldehyde for 20-25 minutes in the presence of a catalytic amount of sodium acetate. The mixture was then
30 cooled and left overnight at room temperature. The separated crystals were filtered off and washed with acetic acid and water.

115

Yield of pure product was 0.142 g (45%) m.p. > 260°C.
($C_{15}H_{13}N_3O_5$, MW:315.29).

Elemental Analysis [%]: Found C, 57.06; H, 4.10; N, 13.20. Calculated C, 57.14; H, 4.16, N, 13.33

5 E12

0.001 mol (0.195 g) of N-3-hydroxyphenyl-oxamoyl hydrazide (2b) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.122 g) of 2-hydroxy-benzaldehyde for 20-25 minutes in the presence of a
10 catalytic amount of sodium acetate. The mixture was then cooled and left overnight at room temperature. The separated crystals were filtered off and washed with acetic acid and water.

Yield of pure product was 0.224 g (75%) m.p. 264-
15 266°C. ($C_{15}H_{13}N_3O_4$, MW:299.29)

Elemental Analysis [%]: Found C, 60.11; H, 4.40; N, 13.76. Calculated C, 60.20; H, 4.38; N, 14.04

E13

0.001 mol (0.21 g) of N-2-methoxyphenyl-oxamoyl
20 hydrazide (2c) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.138 g) of 3,4-dihydroxy-benzaldehyde for 20-25 minutes in the presence of a catalytic amount of sodium acetate. The mixture was then cooled and left overnight at room temperature. The
25 separated crystals were filtered off and washed with acetic acid and water.

Yield of pure product was 0.21 g (64%) m.p. 232-
238°C. ($C_{16}H_{15}N_3O_5$, MW:329.31). Elemental Analysis [%]:
Found C, 60.01; H, 4.51; N, 12.59. Calculated C, 58.36;
30 H, 4.59; N, 12.72.

E14

0.001 mol (0.22 g) of N-2-ethoxyphenyl-oxamoyl hydrazide (2d) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.138 g) of 3,4-dihydroxy-

SUBSTITUTE SHEET (RULE 26)

benzaldehyde for 20-25 minutes in the presence of a catalytic amount of sodium acetate. The mixture was then cooled and left overnight at room temperature. The separated crystals were filtered off and washed with
5 acetic acid and water.

Yield of pure product was 0.15 g (44%) m.p. 208-214°C. ($C_{17}H_{17}N_3O_5$, MW:343.34). Elemental Analysis [%]: Found C, 59.78; H, 4.81; N, 12.10. Calculated C, 59.47; H, 4.99; N, 12.24

10 E15

0.001 mol (0.22 g) of N-3-nitrophenyl-oxamoyl hydrazide (2e) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.138 g) of 3,4-dihydroxy-benzaldehyde for 20-25 minutes in the presence of a
15 catalytic amount of sodium acetate. The mixture was then cooled and left overnight at room temperature. The separated crystals were filtered off and washed with acetic acid and water.

Yield of pure product was 0.19 g (56%) m.p. >260°C.
20 ($C_{15}H_{12}N_4O_6$, MW:344.286). Elemental Analysis [%]: Found C, 52.08; H, 3.47; N, 16.10. Calculated C, 52.32; H, 3.51; N, 16.27.

E16

0.001 mol (0.22 g) of N-3-nitrophenyl-oxamoyl
25 hydrazide (2e) was dissolved in 5 ml acetic acid and heated at 100°C with 0.001 mol (0.122 g) of 4-hydroxy-benzaldehyde for 20-25 minutes in the presence of a catalytic amount of sodium acetate. The mixture was then cooled and left overnight at room temperature. The
30 separated crystals were filtered off and washed with acetic acid and water.

Yield of pure product was 0.19 g (61%) m.p. >260°C. ($C_{15}H_{12}N_4O_5$, MW:328.29). Elemental Analysis [%]: Found C, 54.80; H, 3.59; N, 16.86. Calculated C, 54.88; H, 3.68;
35 N, 17.07.

Group 6 compoundsF10

F10 can be prepared using a two step approach.

5 a) Preparation of 2-methyl-3-hydroxyethyl quinazolin-4-one:

1.37 g (0.01 mol) anthranilic acid was refluxed with 8 ml acetic anhydride for 3 hours. The formed acetic acid was distilled off continuously at atmospheric pressure. After the acetic acid formation was finished the mixture
10 was evaporated in vacuo to dryness. The resulting oil was mixed with 2 ml of ethanolamine and heated at 160°C for 3 hours. After the reaction was completed the substance was cooled, mixed with alcohol and left at room temperature overnight. The precipitated crystals were collected by
15 filtration. m.p. 159-60°C; 1.40 g (65%).

Step b

1.08 g (0.005 mol) 2-methyl-3 hydroxyethyl-quinazolin-4-one and 0.69 g 3,4-dihydroxy-benzaldehyde were fused at 160°C and heated for additional 30 minutes.
20 The resulting substance was dissolved in isopropanol, decolorized by charcoal and left at room temperature overnight. The precipitated crystals were filtered and dried. Yield of pure product was 0.79 g (49%) m.p. 221-223°C. (C₁₈H₁₆N₂O₄, MW:324.34) Elemental Analysis [%]:
25 Found C, 66.48 H, 4.86; N, 8.62. Calculated C, 66.66; H, 4.97; N, 8.64.

F11 and F12

1.01 g (5 mmol) of 3,4-dihydro-1,4-oxazine-[3,4-b]quinazolin-6-one were fused with 6 mmol of the correspond-
30 ing benzaldehyde derivative on an oil bath at a temperature of 100-200°C. After removal of the water of reaction, the resulting mixture was dissolved in ethanol and clarified with charcoal. The solvent was evaporated and the product recrystallized.

For preparation of F11, 3,4-dihydroxybenzaldehyde was used to obtain the product (85% yield) having a melting point of 290-292°C.

For preparation of F12 3-hydroxybenzaldehyde was used
5 to obtain the product (63% yield) having a melting point of 208-214°C.

Group 7 Compounds

Benzoylhydroxyiminoethylacetate

To 10 g benzoyl ethylacetate in 20 ml acetic acid,
10 cooled with ice, was added 3.7 g NaNO₂. After 10 minutes 5 ml water was added. After 3 hours 100 ml water was added and the solid filtered to give 7.7 g, 84% yield, mp. 110°C.

NMR CDCl₃ δ 7.90 (2H,m), 7.6-7.5 (3H,m), 4.30 (2H,q,J=7.4 Hz),
15 1.24 (3H,t,J=7.4 Hz).

2-Ethoxycarbonyl-6,7-dimethyl-3-phenyl-quinoxaline

5 g, 22.6 mM benzoylhydroxyiminoethylacetate and 3.1, 22.8 mM, 4,5 dimethyl 1,2-phenylene diamine in 20 ml ethanol and 5 ml HCl were refluxed 6 hours. Workup H₂O,
20 NaHCO₃, CH₂Cl₂, chromatography and trituration with hexane gave 2 g, 29% yield, white solid, mp. 100°C.

NMR CDCl₃ δ 7.96 (1H,S), 7.93 (1H,S), 7.7 (2H,m), 7.5 (3H,m) 4.30 (2H,q,J=7.0 Hz), 2.53 (6H,S), 1.17 (3H,t,J=7.0 Hz).

6,7-Dimethylquinoxalin-2-one

25 2g, 15 mM, 4,5-dimethyl 1,2-diamino benzene and 1.5g, 16 mM, glyoxalic acid hydrate in 30 ml ethanol were refluxed 2 hours. Cooling and filtering gave 1.2g, 46% yield, white solid mp-263°C, Sl. soluble acetone.

NMR DMSO d₆ δ 60:40 mixture

30 major - 8.07 (1H,S), 7.55 (1H,S), 7.06 (1H,S), 2.30 (6H,S).

minor - 8.02 (1H,S), 7.42 (1H,S), 7.28 (1H,S), 2.28 (6H,S).

Remark - reaction of 4.1 g gave 3g, 57%.

2-Chloro-6,7 Dimethyl Quinoxaline

1.1g, 6.2 mM, 6,7-dimethylquinoxalin-2-one, 1 ml POCl₃ and 1 ml dimethyl aniline in 20 ml toluene were refluxed 2 hours. Workup (NH₃, CH₂Cl₂) and chromatography gave
5 0.4g, 33% yield, white solid, mp-86°C. NMR CDCl₃ δ 8.68(1H,S,H₂), 7.85(1H,S), 7.76(1H,S), 2.50(6H,S).

G10

0.4 g (4 mM) phenylene diamine and 0.6 g (4 mM) phenyl glyoxal monohydrate in 20 ml of ethanol, and 10 ml
10 acetic acid was refluxed 3 hours. Workup using 50 ml H₂O and 80 ml CH₂Cl₂ followed by trituration with hexane gave 0.38 g (46% yield) of a white solid having a melting point of 65°C.

NMR CDCl₃ δ 9.44 (1H,S), 8.1(4H,m),
15 7.8(2H,m), 7.6(3H,m).

MS-206(M+,100%), 179(M-HCN, 25), 152(37), 103(M -Ph-CN, 42), m/e.

G12

To 3 ml DMF and 16 ml PCCl₃ was added 2.7 g (10 mM)
20 N-(3,4-dimethoxyphenyl)phenylacetamide. The reaction was heated at 90°C for 4 hours, decanted on ice, filtered and washed with water to give 2.9 g (96% yield) of a white solid having a melting point of 234°C.

NMR CDCl₃: δ 8.26 (1H, s h₄), 8.0 (1H, s, H₆), 7.15 (5H,
25 s Ph), 7.15 (1H, s, h₅), 4.13, 4.05 (6H, 2s, OCH₃).

MS: 301, 299 (M+, 33%, 100%), 286, 284 (M-CH₃, 2%, 6%), 258, 256, (6%, 18%), 220 (9%), 215, 213 (4%, 13%), m/e.

G11

The compound was synthesized by the procedure used
30 for G12, except that the reactant N-(3,4,5-trimethoxy phenyl)phenylacetamide was substituted. The final product had a melting point of 103°C.

120

G13

2.4 g (16 mM) phenyl glyoxal hydrate and 2.2 g (16 mM) 3,4-dimethyl-1,2-phenylene diamine in 20 ml ethanol were refluxed for 1.5 hour. Cooling and filtering gave
5 3.25 g (88% yield) of a white solid having a melting point of 124°C.

NMR CDCl_3 δ 9.23(1H,S, H_2), 8.19(1H,d, $J=1.6\text{H}_2$), 8.15
(1H,d, $J=1.7\text{H}_2$), 7.90(2H,d, $J=9.0\text{H}_2$),
7.57(3H,m) 2.52(6H,S, CH_3).

10 MS-234 (M^+ , 100%), 219 ($\text{M}-\text{CH}_3$, 11), 207 ($\text{M}-\text{HCH}$, 12), 165 ($\text{M}-2\text{HCN}-\text{CH}_3$, 2), 131 ($\text{M}-\text{ph}-\text{CN}$, 3), m/e.

G14

7 g of veratrole (51 mM) was added to 19 ml of ice-cooled 70% HNO_3 . After 0.5 hour in the cold, 10 ml H_2SO_4
15 was slowly added in 0.5 hour. The resulting dark suspension was stirred for 3 hours at room temperature and ice and water were added to the suspension to precipitate the product. Filtering, washing with water and drying gave
20 10.2 g (96% yield) of a yellow solid having a melting point of 120°C (NMR CDCl_3 δ 7.35(2H,S), 4.06(6H,S, OCH_3)).
(Cf: *J. Org. Chem.* 12: 522 (1947), reported m.p. 130°C, and *J. Med. Chem.* 36:331 (1993) reported m.p. 122°C. The compound is sold by Lancaster Co., (reported m.p. 101°C).

Two grams of 1,2-dinitro-4,5-dimethoxybenzene was
25 hydrogenated over 0.3g PtO_2 for 1 hour, then filtered and evaporated to give 1.5 g of a black solid (Cf. *J. Med. Chem.* 36:331 (93), reported red brown solid, m.p. 151°C). The black solid was mixed with 1.3 g phenyl glyoxal, 15 ml absolute ethanol and 15 ml of concentrated HCl and
30 refluxed 5 hours. Workup, as for G10, gave a dark solid which was recrystallized from ethanol to give 0.72 g (31% yield) of a white solid having a melting point of 134°C.
NMR CDCl_3 δ 9.13(1H,S, H_2), 8.16(1H,d, $J=1d.6\text{H}_2$), 7.60-7.40(5H,m), 4.09(6H,S, OCH_3).
35 MS-266 (M^+ , 100%), 251 ($\text{M}-\text{CH}_3$, 12), 223 ($\text{M}-\text{CH}_3-\text{CO}$, 13), 196 ($\text{M}-\text{CH}_3-\text{CO}-\text{HCN}$, 5), m/e.

SUBSTITUTE SHEET (RULE 26)

G15

Thiophene-2-glyoxal-bis-thiosemicarbazone (3.4 mM) and 0.6 g (4 mM) o-phenylenediamine in 15 ml acetic acid were refluxed 6 hours. The solvent was removed by
5 distillation in vacuo, and the residue was dissolved in CH_2Cl_2 and washed with H_2O . The organic layer was evaporated in vacuo and the residue was triturated with benzene-hexane to give a white solid (23% yield) mp 104°C .
NMR (CDCl_3): δ 9.25(1H, s, H_2), 8.07, 7.72(4H, m, H_{5-8}),
10 7.85, 7.56, 7.21(3H, m, thiophene).
MS: 212(M^+ , 100%), 185(M-HCN, 25%), 141(6%), 106(8%), m/e.

G16

2,3-diaminopyridine and phenyl glyoxal were reacted as for G13 to give a white solid (77% yield) having a
15 melting point of 135°C .
NMR CDCl_3 δ 9.47(1H, s, H_2), 9.21 8.50, 7.71 (8 line ABC m, $\text{H}_7, \text{H}_5, \text{H}_6$), 8.35(2H, m, Ph), 7.60(3H, m).
MS-207(M^+ , 100%), 180(H-HCN, 8), 179(11), 104(23), 77(14), m/e.
 CDCl_3 δ 7.67(1H, dd), 6.89(dd), 6.62(dd), 4.25, 3.30
20 (br.s.).

G17

G17 was synthesized in two steps as follows:

a. Synthesis of 2-methoxy-4,5-dinitro phenol.

3.3 g 1,2-dimethoxy-4,5-dinitrobenzene in 20 ml of
25 48% HBr was refluxed for 16 hours. Water was added and the reaction was extracted with CH_2Cl_2 to give 1.1 g of an orange solid. Chromatography on silica gel, eluting with 2% CH_3OH in CH_2Cl_2 gave 0.42 g (13% yield) of a yellow solid which turned red with KOH.
30 NMR (CDCl_3): δ 7.44(1H, s), 7.42(1H, s), 6.30(1H, s), 4.07(3H, s).

Extraction of the aqueous phase with ethyl acetate gave 2 g of a red oil. Chromatography on silica gel, eluting with 5% CH_3OH in CH_2Cl_2 gave a yellow solid, 0.1 g

122

(3.5% yield) having a melting point of 160°C with a KOH violet color, corresponding to 1,2 dihydroxy-4,5-dinitrobenzene.

NMR (acetone- d_6) δ 7.51(2H,s).

5 b. Reduction and condensation with phenylglyoxal.

0.2 g 2-methoxy-4,5-dinitrophenol was hydrogenated on Pd/C in 20 ml ethanol for one hour. The Pd was filtered, 0.3 g phenyl glyoxal was added, and the reaction was refluxed for three hours. Evaporation and chromatography
10 on silica gel, eluting with 1% CH_3OH in CH_2Cl_2 gave a 0.1 g of an orange oil.

NMR ($CDCl_3$): δ 8.10, 7.6(7H,m), 3.54(3H,S).

G18

0.56 g (4 mM) 4,5-dimethyl 1,2-diaminobenzene and 0.6
15 g (4 mM) benzoyl formic acid in 15 ml ethanol were refluxed 5 hours. Cooling and filtering gave 0.8 g (80% yield) of a yellow solid having a melting point of 275°C.
NMR ($CDCl_3$): δ 8.38(2H, m), 7.51(3H, m), 7.70(1H, s),
7.06(1H, s) 2.40(3H, s), 2.37(3H, s). Irradiation at 8.38
20 ppm gave a Singlet at 7.51 ppm.

G19

3,4-diaminotoluene and phenyl glyoxal were reacted as for G13 to give a light brown solid (31% yield) having a melting point of 114°C.

25 NMR $CDCl_3$ δ 9.29, 9.26(2S,2:1, H_2), 8.2, 8.17(2br.S), 8.07-7.90(3H,m), 7.60(3H,m), 2.62(3H,S).

G20

0.15 g of G14 in 5 ml 48% HBr was refluxed 23 hours. Cooling and filtering gave 95 mg (53% yield) of a green-
30 yellow solid corresponding to the HBr salt of the quinazoline derivative, mp 280°C. HBr was determined by elemental analysis.

SUBSTITUTE SHEET (RULE 26)

123

NMR (DMSO- d_6): δ 9.25(1H, s, H_2), 8.24(1H, d, $J=1.9$ Hz), 8.20(1H, d, $J=1.9$ Hz), 7.50(3H, m), 7.35(2H, m).

The mother liquid was neutralized with $NaHCO_3$. Extraction with EtAc gave 20 mg (15% yield) of an orange solid, mp 305°C corresponding to the free base.

NMR (acetone d_6): δ 9.19(1H s, H_2), 8.29(1H, d, $J=1.5$ Hz), 8.25(1H, d, $J=1.5$ Hz), 7.6(3H, m), 7.40(2H, m).

MS: 238(M^+ , 54%), 211($M-HCN$, 10%), 154(7%), 108(1,2-benzoquinone, 100%), m/e.

10 G21

4-Benzoyl 1,2-phenylene diamine and phenyl glyoxal were reacted as for G13 to give a white solid (69% yield) having a melting point of 133°C.

NMR: $CDCl_3$ δ 9.40(1H, s, H_2), 8.49(1H, s, H_5), 8.27(4H, br, s, $H_{7,8}H_{2,6}$), 7.90(2H, d, $J=7.6$ Hz), 7.60(6H, m).

G22

0.47 g (3 mM) 2,3-diaminoaphtalene and 0.47 g phenyl glyoxal hydrate in 20 ml ethanol were refluxed for 1.5 hour. Cooling and filtering gave 0.5 g (65% yield) of a light brown solid having a melting point of 163°C.

NMR: $CDCl_3$ δ 9.38(1H, s, H_2), 8.71, 8.67(2H, 2d, $H_{5,10}$), 8.25, 8.10(4H, AA'BB' m., $H_{6,9}$), 7.58(5H, m, Ph), MS- 256(H^+ , 100%), 229($H-CN$, 12%), 126(71), m/e.

G23

0.6 g, 4 mM, phenyl glyoxal and 0.6 g, 4 mM, 4-nitro phenylene diamine in 15 ml ethanol were refluxed 1.5 hours. Cooling and filtering gave 0.9 g, 90% yield, white solid, mp-203°C.

NMR $CDCl_3$ δ 9.49 (1H, s, H_2), 9.02(1H, d, $J=2.5$ Hz, H_8), 8.54(1H, dd, $J=9.2, 2.5$ Hz, H_7), 8.27(3H, m, Ph + H_7), 7.60 (3H, m, Ph).

G24

1.4 g, 10.3 mM, 4,5-dimethyl 1,2-phenylene diamine and 1.9 g, 10.2 mM, α -chloro 3,4-dihydroxy acetophone in 25 ml ethanol were refluxed 2 hours. Cooling and filtering
5 gave 0.76 g, 18 % yield, deep yellow solid, mp. 278°C as the HCl salt.

G25

2.4 g 2-ethoxycarbonyl-6,7-dimethyl-3-phenyl-
quinoxaline and 5 g KOH in 20 ml ethanol and 20 ml H₂O were
10 stirred 20 hours at room temperature. Acidification with HCl, filtering and washing with water gave 2.1 g, 96% yield, light-yellow solid, mp. 153°C.
NMR acetone d₆ δ 7.92(1H,S), 7.90(1H,S), 7.85(2H,m), 7.50(3H,m), 2.56(6H,S).

15 G27: 2-(4-nitrophenyl) 6,7 dimethylquinoxaline
1. 4-nitrophenyl glyoxal

6.60 (40 mmol) 4-nitroacetophenone was dissolved in 30ml of dioxane and 5 g, (45 mmol) selenium dioxide was dissolved in 2.2 ml water and mixed. The mixture was
20 refluxed for 16 hours with continuous stirring. The reaction mixture was passed through an alumina column to remove selenium. The solvent was evaporated in vacuum. The crude product was used in the next step without further purification.

25 R_f 0.80 (EtOAc)

Y:7.00 (85%)

IR(cm⁻¹): 1730 (CO), 1520, 1330 (NO₂)

2. 2-(4-nitrophenyl) 6,7 dimethylquinoxaline

0.50. g (3 mmol) 4-nitrophenyl glyoxal was dissolved
30 in 20 ml ethanol. 0.34 g (2.5 mmol) 1,2 dimethyl 4,5 diaminobenzene was dissolved in ethanol. The reaction mixture was stirred and refluxed for 1 hour. Product crystallized after cooling, and filtrated washing with ethanol then ether.

125

G28

G28 can be produced using the protocol described for G29 *infra*, except that 3-bromoaniline is used instead of m-iodoaniline.

5 G29

150 mg, 0.8 mM, 2-chloro-6,7 dimethyl quinoxaline and 0.8g, 3.6 mM, m-iodoaniline were heated at 100°C for 3.5 hours. Chromatography gave 100 mg, 35% yield, yellow solid, mp-185°C.

10 NMR CDCl₃ δ 8.33 (1H,S), 8.22 (1H,m), 7.7 (2H,m), 7.40 (1H,m), 7.10 (2H,m), 2.45 (3H,S), 2.43 (3H,S).

G30

210 mg, 1.1 mM, 2-chloro-6,7 dimethyl quinoxaline and 0.8g, 3.6 mM, p-iodoaniline were heated at 100°C for 4 hours. Chromatography gave 245 mg, 60% yield, light green solid, mp-228°C.

15 NMR, CDCl₃ δ 8.32 (1H,S), 7.67 (1H,S), 7.64 (H,S), 7.68, 7.56 (4H,ABq, Jab=9.0 Hz).

Group 820 H10

0.01 mol (1.07 g) of benzylamine and 0.01 mol (1.38 g) of 3,4-dihydroxybenzaldehyde were mixed together in 15 ml of ethanol and refluxed on a waterbath for 15 minutes then 0.01 mol (3.44 g) of 2-(1'-tosyloxyethyl)-quinazolin-4-one and one drop of pyridine were added and the mixture was refluxed for six hours. The resulting solution was evaporated and extracted with a 5% water solution of sodium bicarbonate. The remaining crystals were filtered off, washed with water and recrystallized from isopropanole.

30 Yield: 3.07 g (77%) M.p.: 209-211°C Formula: C₂₄H₂₁N₃O₃
Elemental analysis [%]

Calculated: C: 72.17 H: 5.30 N: 10.52

Found: C: 72.12 H: 5.26 N: 10.46

SUBSTITUTE SHEET (RULE 26)

H11

0.01 mol (1.07 g) of benzylamine and 0.01 mol (1.22 g) of salicylaldehyde were mixed together in 15 ml of ethanol and refluxed on a waterbath for 15 minutes then
5 0.01 mol (3.44 g) of 2-(1'-tosyloxyethyl)-quinazolin-4-one and one drop of pyridine were added and the mixture was refluxed for six hours. The resulting solution was evaporated and extracted with a 5% water solution of sodium bicarbonate. The remaining crystals were filtered
10 off, washed with water and recrystallized from isopropanole.

Yield: 2.99 g (78%) M.p.:189-192°C Formula: $C_{24}H_{21}N_3O_2$

Elemental analysis [%]

Calculated: C: 75.18 H: 5.52 N: 10.96

15 Found: C: 75.09 H: 5.49 N: 10.90

H12

0.01 mol (1.07 g) of benzylamine and 0.01 mol (1.22 g) of 3-hydroxybenzaldehyde were mixed together in 15 ml of ethanol and refluxed on a waterbath for 15 minutes then
20 0.01 mol (3.44 g) of 2-(1'-tosyloxyethyl)-quinazolin-4-one and one drop of pyridine were added and the mixture was refluxed for six hours. The resulting solution was evaporated and extracted with a 5% water solution of sodium bicarbonate. The remaining crystals were filtered off,
25 washed with water and recrystallized from isopropanole.

Yield: 2.72 g (71%) M.p.:184-185°C Formula: $C_{24}H_{21}N_3O_2$

Elemental analysis [%]

Calculated: C: 75.18 H: 5.52 N: 10.96

Found: C: 75.02 H: 5.45 N: 11.08

30 H13

0.01 mol (1.07 g) of benzylamine and 0.01 mol (1.22 g) of 4-hydroxybenzaldehyde were mixed together in 15 ml of ethanol and refluxed on a waterbath for 15 minutes then
0.01 mol (3.44 g) of 2-(1'-tosyloxyethyl)-quinazolin-4-one
35 and one drop of pyridine were added and the mixture was

127

refluxed for six hours. The resulting solution was evaporated and extracted with a 5% water solution of sodium bicarbonate. The remaining crystals were filtered off, washed with water and recrystallized from isopropanole.

5 Yield: 3.40 g (89%) M.p.: 217-219°C Formula: $C_{24}H_{21}N_3O_2$
Elemental analysis [%]

Calculated: C: 75.18 H: 5.52 N: 10.96

Found: C: 75.26 H: 5.47 N: 10.88

H14

10 0.01 mol (1.07 g) of benzylamine and 0.01 mol (1.54 g) of 3,4,5-trihydroxybenzaldehyde were mixed together in 15 ml of ethanol and refluxed on a waterbath for 15 minutes then 0.01 mol (3.44 g) of 2-(1'-tosyloxyethyl)-quinazolin-4-one and one drop of pyridine were added and
15 the mixture was refluxed for six hours. The resulting solution was evaporated and extracted with a 5% water solution of sodium bicarbonate. The remaining crystals were filtered off, washed with water and recrystallized from isopropanole.

20 Yield: 3.36 g (81%) M.p.: 223-225°C Formula: $C_{24}H_{21}N_3O_4$
Elemental analysis [%]

Calculated: C: 69.39 H: 5.10 N: 10.11

Found: C: 69.51 H: 5.07 N: 10.08

Group 9

25 I10

0.3 g (2 mM) 5-formyl indole and 0.4 g (2 mM), of 2-cyano-H-(1-(+) phenylethyl)acetamide in 5 ml ethanol and 2 drops piperidine were refluxed 3 hours. Water and HCl were added and the reaction extracted with ethyl acetate
30 to give viscous oil. Chromatography on silica gel gave 0.42 g (66% yield) of pale-yellow solid having a melting point of 76°C.

MS-315 (M+, 24%), 196 (M-NCH(CH₃)C₆H₅, 22), 195 (25), 188 (21), 173 (24), 168 (13), 149 (57), 145 (100), 134 (92),

35 116 (53), m/e.

SUBSTITUTE SHEET (RULE 26)

Group 10J10

230 mg, 1.06 mM, 5-bromo 3,4-dihydroxy benzaldehyde, 76 mg, 0.53 mM, diactonitrile sulphone and 10 mg β -alanine in 10 ml ethanol were refluxed 5 hours. Cooling and filtering gave 220 mg, 76% yield, orange solid, mp>300°C. NMR acetone d_6 δ 8.18(2H,S, vinyl), 7.90(2H, d, J=1.6Hz), 7.78(2H, d, J=1.6 Hz).

10 J11: 2-(3-bromo-4,5-dihydroxyphenyl)-1-cyano-1-cyanomethylsulfonyl ethene

A mixture of 500 mg of 5-bromo-3,4-dihydroxybenzaldehyde and 700 mg of sulfonyl diacetonitrile in 6 ml of ethanol was refluxed with few drops of piperidine for 4 hours. Ethanol was removed in rotavap and the mixture worked up with ethyl acetate, diluted acid and brine. A portion of the crude was then purified by HPLC on a C-18 column to provide about 50 mg of 2-(3-bromo-4,5-dihydroxyphenyl)-1-cyano-1-cyanomethylsulfonyl ethene.

Group 11

20 6,7-Dimethoxy quinazolin-4-one

7 g 4,5-dimethoxy 2-amino benzoic acid and 8 ml formamide were heated 2 hours at 170°C. Cold water was added and the solid filtered to give 0.9 g, 12% yield, light-brown solid, mp. 308°C.

25 NMR - DMSO d_6 δ 8.0(1H,S) 7.43(1H,S), 7.12(1H,S) 3.89(3H,S), 3.85 (3H,S).

4-Chloro-6,7, Dimethoxy Quinalazine

0.8 g, 6,7-dimethoxy quinazolin-4-one, 1 ml POCl₃ and 1 ml dimethyl aniline in 20 ml toluene were refluxed 3.5 hours. Workup and trituration with hexane gave 0.5 g light grey solid, 0.5 g, 57% yield, mp. 188°C.

30 NMR CDCl₃ δ 8.88 (1H,S), 7.41(1H,S), 7.36(1H,S), 4.09 (3H,S), 4.08(3H,S).

P10

0.3 g, 1.4 mM, 3,4-dihydroxy 5-bromo benzaldehyde,
0.15 g, 0.7 mM, N-3-cyanomethylcarbonylamino-N-
propylcyanoacetamide, and 25 mg β -alanine in 20 ml ethanol
5 were refluxed 3 hours. Cooling and filtering gave 0.24 g,
57% yield, yellow solid, mp 283°C.

P12: thiophene-2-carboxylic acid (3,5-bis-(trifluoro-
methyl) anilide

0.45 ml (2.9 mmol) of 3,5-bis-(trifluoromethyl)
10 aniline was dissolved in 5 ml of abs pyridine, then cooled
to 10°C. 0.12 ml (1.5 mmol) phosphorous trichloride was
added with continuous stirring dropwise. After 0.5 hour
0.51 g (4 mmol) thiophene-2-carboxylic acid was added, and
stirred for 12 hours at room temperature. Solvent was
15 evaporated in vacuum, 1N HCl was added to the residue and
extracted with ethylacetate. The ethylacetate solution
was extracted with bicarbonate solution, dried on sodium
sulfate, filtrated and evaporated. Product was trituated
with ether, filtrated and dried in vacuum.

20 m.p.: 145-147°C

Rf: 0.80 (Hexane-Et)Ac=1:1)

y:0.62g (80%)

IR(cm^{-1}): 3280 (N-H); 1640 (CONH); 1560 (Car); 1130 (C-F)

P13

25 3 g, 20.1 mM, 3-methyl isoquinoline in 20 ml acetic
acid and 5ml 30% H_2O_2 was heated at 70°C for 14 hours.
Water was added to the cooled solution and bicarbonate to
neutrality. Extraction with CH_2Cl_2 and trituration with
hexane gave 1.9 g, 57% yield, white solid, mp 128°C.
30 (J.O.C., 21:1337(1956), mp-138°C).

NMR CDCl_3 δ 8.86(1H,S), 7.70-7.50(5H,m), 2.64 (3H,S).

P14

a. 0.04 g, 1.8 mM, 4-chloro-6,7, dimethoxy
35 quinalozine and 0.19 g, 2 mM, aniline in 15ml ethanol were

130

refluxed for 1 hour. Cooling and filtering gave 0.445 g, 78% yield, light yellow solid, mp-268°C, as the HCl salt P14a.

- b. free base - 0.35g P14a was treated with H₂O-Na₂CO₃ and extracted with CH₂Cl₂ to give 0.13 g, 42% yield, white solid, mp-241°C. NMR CDCl₃ δ 8.66 (1H,S,H₂), 7.67(1H,S), 7.63(1H,S), 7.4-7.14(5H,m), 3.96(3H,S), 3.93(3H,S).

P15: 1-(2-chlorophenylmethylene)-3-(3-methoxy-n-propyl)-2,4-thiazolidinedione

- 10 A solution of 400 mg of 3-(3-methoxy-n-propyl)-2,4-thiazolidinedione and 260 mg of 2-chlorobenzaldehyde in 4 ml of ethanol with one drop of piperidine was refluxed for 4 hours. The mixture was then worked up with ethyl acetate and water. The crude product was purified on a
15 silica gel column (5% methanol in dichloromethane) to provide 200 mg of 1-(2-chlorophenylmethylene)-3-(3-methoxy-n-propyl)-2,4-thiazolidinedione. (P15 can also be obtained from Aldrich Chemical.).

P16

- 20 0.69 g, 2.5 mM, 5-iodo vaniline, N-3-phenyl-N-propyl cyanoacetamide (prepared as described by Gazit et al., J. Med Chem 34:1896, 1991) and 50 mg β-alanine in 30 ml ethanol were refluxed 5 hours. Evaporation gave an oil which was triturated with benzene-hexane and filtered to
25 give a bright yellow solid, 0.82g, 71% yield, mp. 83°C. NMR CDCl₃ δ 8.12(1H,S), 7.75(1H,d,J=2.0 Hz), 7.68(1H,d,J=2.0 Hz), 7.30-7.10(5H,m), 3.96(3H,S,O,CH₃), 3.45(2H,q,J=6.0 Hz), 2.70(2H,t,J=6.0 Hz), 1.95(2H,quin,J=6.0 Hz).
- 30 MS - 462(M⁺,53), 357(M-CH₂)₃Ph,18), 335(M-I,100), 327(M-NH(CH₂)₃ ph, 31), m/e

P17

- a. 0.4g, 1.8mM, 4-chloro-6,7, dimethoxy quinalozine and 0.24 g, 2 mM, indoline in 10 ml ethanol were refluxed

SUBSTITUTE SHEET (RULE 26)

sodium sulfate, filtered and concentrated. The crude was then crystallized with ethanol and water to provide 1.5 grams of N-trifluoromethylbenzyl 3-methylisoxazole-4-carboxamide.

5 P24: 1-trifluoromethylbenzylaminocarbonyl-1-cyano-2-hydroxy propene

A solution of 500 mg of N-trifluoromethylbenzyl 3-methylisoxazole-4-carboxamide in 5 ml of ethanol was added to 300 mg of 1,8-diazabicyclo[5.4.0]undec-7-ene. The
10 mixture was then stirred at room temperature for 1 hour and acidified with 2 ml of 2N hydrochloride solution. The solid was collected by filtration to provide 350 mg of 1-trifluoromethylbenzylaminocarbonyl-1-cyano-2-hydroxy propene

15 P25

0.42 g, 3 mM, 3,4-dihydroxy benzaldehyde, 0.6 g, 3.1 mM, N-4-fluorobenzylcyanoacetamide and 2.0 mg β -alanine were refluxed 5 hours. Concentration and filtration gave 0.89 g, 95% yield, yellow solid, mp-212°C, NMR acetone d_6
20 δ 8.10 (1H, s, Vinyl), 7.68 (1H, d, J=2.3 Hz, H_2), 7.40 (3H, m, H_6, H_2, H_6), 7.09 (2H, t, J=8.8 Hz, $H_{3,5}$), 6.98 (1H, d, J=8.3 Hz, H_5), 4.56 (2H, br, s).
MS-312 (M^+ , 46%), 311 (30), 295 (H-OH, 35), 161 (17), 124 ($NHCH_2C_6H_4F$, 100%),
25 109 ($CH_2C_6H_4F$, 73) -m/e.

Other embodiments are within the following claims.

Claims

1. A method of treating a patient suffering from a cell proliferative disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to
5 said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of:
- a) a Group 1 compound having the chemical structure shown in Figure 2a, wherein R_1 , R_2 , R'_2 , R''_2 , and R'''_2 are
10 independently selected from the group consisting of hydrogen, halogen, trihalomethyl, and NO_2 ; and R_3 is selected from the group consisting of hydrogen, carboxy, or carbalkoxy,
- b) a Group 2 compound having the chemical structure shown in Figure 2b, wherein R_4 and R_5 are independently
15 halogen, hydrogen, trihalomethyl, or NO_2 ; and R_6 is either aryl, alkyl, alkenyl, or alkynyl,
- c) a Group 3 compound having the chemical structure shown in Figure 2c, wherein R_7 , R'_7 , and R_8 are
20 independently selected from group consisting of; and R_9 is aryl or hydrogen,
- d) a Group 4 compound having the chemical structure shown in Figure 2d, wherein R_{10} is either =S, =O, SH, OH, or NH_2 ; and R_{11} is SH, OH, NH_2 , $=\text{C}(\text{CN})_2$ or aryl; or R_{10} and
25 R_{11} taken together are aryl; and R_{12} is hydrogen, aryl, alkyl, alkenyl, or alkynyl,
- e) a Group 5 compound having the chemical structure shown in Figure 2e, wherein R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , and R_{18} are independently hydrogen, halogen, alkoxy, OH, amino, alkylamino, or SH,
30
- f) a Group 6 compound having the chemical structure shown in Figure 2f, wherein R_{19} is aryl, alkyl, alkenyl or alkynyl;
 R_{20} is an alkyl; or R_{19} and R_{20} are together an aryl,
- 35 g) a Group 7 compound having the chemical structure shown in Figure 2g, wherein b is an optional pi bond, Y and Z are independently carbon or nitrogen;

sodium sulfate, filtered and concentrated. The crude was then crystallized with ethanol and water to provide 1.5 grams of *N*-trifluoromethylbenzyl 3-methylisoxazole-4-carboxamide.

5 P24: 1-trifluoromethylbenzylaminocarbonyl-1-cyano-2-hydroxy propene

A solution of 500 mg of *N*-trifluoromethylbenzyl 3-methylisoxazole-4-carboxamide in 5 ml of ethanol was added to 300 mg of 1,8-diazabicyclo[5.4.0]undec-7-ene. The
10 mixture was then stirred at room temperature for 1 hour and acidified with 2 ml of 2N hydrochloride solution. The solid was collected by filtration to provide 350 mg of 1-trifluoromethylbenzylaminocarbonyl-1-cyano-2-hydroxy propene

15 P25

0.42 g, 3 mM, 3,4-dihydroxy benzaldehyde, 0.6 g, 3.1 mM, *N*-4-fluorobenzylcyanoacetamide and 2.0 mg β -alanine were refluxed 5 hours. Concentration and filtration gave 0.89 g, 95% yield, yellow solid, mp-212°C, NMR acetone d_6
20 δ 8.10 (1H, s, Vinyl), 7.68 (1H, d, $J=2.3$ Hz, H_2), 7.40 (3H, m, H_6, H_2, H_6), 7.09 (2H, t, $J=8.8$ Hz, $H_{3,5}$), 6.98 (1H, d, $J=8.3$ Hz, H_5), 4.56 (2H, br, s).
MS-312 (M^+ , 46%), 311 (30), 295 (H-OH, 35), 161 (17), 124 ($NHCH_2C_6H_4F$, 100%),
25 109 ($CH_2C_6H_4F$, 73) -m/e.

Other embodiments are within the following claims.

Claims

1. A method of treating a patient suffering from a cell proliferative disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to
5 said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of:
- a) a Group 1 compound having the chemical structure shown in Figure 2a, wherein R_1 , R_2 , R'_2 , R''_2 , and R'''_2 are
10 independently selected from the group consisting of hydrogen, halogen, trihalomethyl, and NO_2 ; and R_3 is selected from the group consisting of hydrogen, carboxy, or carbalkoxy,
- b) a Group 2 compound having the chemical structure
15 shown in Figure 2b, wherein R_4 and R_5 are independently halogen, hydrogen, trihalomethyl, or NO_2 ; and R_6 is either aryl, alkyl, alkenyl, or alkynyl,
- c) a Group 3 compound having the chemical structure shown in Figure 2c, wherein R_7 , R'_7 , and R_8 are
20 independently selected from group consisting of; and R_9 is aryl or hydrogen,
- d) a Group 4 compound having the chemical structure shown in Figure 2d, wherein R_{10} is either =S, =O, SH, OH, or NH_2 ; and R_{11} is SH, OH, NH_2 , =C(CN)₂ or aryl; or R_{10} and
25 R_{11} taken together are aryl; and R_{12} is hydrogen, aryl, alkyl, alkenyl, or alkynyl,
- e) a Group 5 compound having the chemical structure shown in Figure 2e, wherein R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , and R_{18} are independently hydrogen, halogen, alkoxy, OH, amino, alkylamino, or SH,
30 alkylamino, or SH,
- f) a Group 6 compound having the chemical structure shown in Figure 2f, wherein R_{19} is aryl, alkyl, alkenyl or alkynyl;
 R_{20} is an alkyl; or R_{19} and R_{20} are together an aryl,
- 35 g) a Group 7 compound having the chemical structure shown in Figure 2g, wherein b is an optional pi bond, Y and Z are independently carbon or nitrogen;

R_{21} and R_{22} , are independently hydrogen, halogen, OH, SH, NH_2 , NO_2 , alkyl, alkenyl, alkynyl, alkoxy, benzoyl, COOH, or carbalkoxy, or R_{21} and R_{22} together form an aromatic ring to give an aryl;

5 R_{23} is hydrogen, halogen, =O, OH, SH, NH_2 , alkoxy, COOH, aryl; R_{24} is H or aryl; and

R_{25} is hydrogen, halogen, =S, or =O;

provided that if b is no bond, the adjacent nitrogen optionally has a substituent selected from the consisting
10 of hydrogen, alkyl, alkyleneamino, alkyleneaminoalkyl, and alkyleneacyano,

h) a Group 8 compound having the chemical structure shown in Figure 2h, wherein R_{26} and R_{28} is independently alkyl, aryl, alkenyl, or alkynyl; and

15 R_{27} is alkyl, and

i) a Group 9 compound having the structure shown in Figure 2i, wherein R_{29} is either hydrogen or halogen;

R_{30} is either alkyl, alkenyl, or alkynyl;

R_{31} is aryl; and

20 R_{32} is either =O or =S,

j) a Group 10 compound having the structure shown in Figure 2j, wherein R_{33} is alkyl or aryl; and

R_{34} , R_{35} , and R_{36} is each independently selected from the group consisting of: halogen, OH, hydrogen, alkoxy,
25 SH, NH_2 , or $C(CH_3)_3$

k) a compound belonging to group 11 having a structure shown Figure 1k;

j) the active drug of said compound, or a pharmaceutically acceptable salt of said compound,

30 wherein said compound significantly inhibits one or more PDGF-R activities *in vivo* or *in vitro*.

2. The method of claim 1, wherein said compound is selected from the group consisting of: A10, A11, A12, A13, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, C10,
35 C11, C13, D11, D12, D13, D14, D15, D16, D17, D18, D20, E10, E11, E12, E13, E14, E15, E16, F10, F11, F12, G10,

136

G11, G12, G13, G14, G15, G16, G17, G18, G19, G20, G21, G22, G23, G24, G25, G27, G28, G29, G30, H12, I10, J11, P10, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, the active drug of said compound, or
5 a pharmaceutically acceptable salt of said compound.

3. The method of claim 1, wherein said compound selectively inhibits PDGF-R activity.

4. The method of claim 3, wherein said compound also selectively inhibits one or more members of related
10 tyrosine kinases of the group consisting of KDR, Flt-1 and Flk-1.

5. The method of claim 1, wherein said patient is a human and said cell proliferative disorder is a cancer selected from the group consisting of intra-axial brain
15 cancer, ovarian cancer, colon cancer, prostate cancer, lung cancer, Kaposi's sarcoma, and melanoma.

6. The method of claim 5, wherein said cancer is either glioma, ovarian cancer, prostate, or Kaposi's sarcoma.

20 7. The method of claim 1, wherein said patient is a human and said disorder is either a blood vessel proliferation disorder or a fibrotic disorder.

8. The method of claim 7, wherein said fibrotic disorder is a hepatic fibrotic disorder or a mesangial
25 cell proliferative disorder.

9. The method of 8, wherein said blood vessel proliferative disorder is atherosclerosis.

SUBSTITUTE SHEET (RULE 26)

137

10. The method of claim 5, further comprising the step of determining whether said cancer has an inappropriate PDGF-R activity.

11. The method of claim 1, wherein said compound further comprises the physiological acceptable carrier is PBTE:D5W.

12. A method of treating a patient suffering from a cell proliferative disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of A10, A12, or B11.

13. The method of claim 12, wherein said patient is a human and said cell proliferative disorder is a cancer selected from the group consisting of intra-axial brain cancer, ovarian cancer, colon cancer, prostate cancer, lung cancer, Kaposi's sarcoma, and melanoma.

14. The method of claim 13, wherein said cancer is either glioma, ovarian cancer, prostate or Kaposi's sarcoma.

15. The method of claim 12, wherein said compound is A10 or B11.

16. The method of claim 15, wherein said cancer is glioma.

17. The method of claim 15, wherein said cancer is ovarian cancer.

18. The method of claim 15, wherein said cancer is prostate.

SUBSTITUTE SHEET (RULE 26)

19. The method of claim 12, wherein said patient is a human and said disorder is either a blood vessel proliferation disorder or a fibrotic disorder.

20. The method of claim 19, wherein said fibrotic
5 disorder is a hepatic fibrotic disorder or a mesangial cell proliferative disorder.

21. The method of 20, wherein said blood vessel proliferative disorder is atherosclerosis.

22. The method of claim 12, further comprising the
10 step of determining whether said cancer has an inappropriate PDGF-R activity.

23. A method of treating a patient suffering from a cancer characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a
15 therapeutically effective amount of a composition comprising an agent able to significantly inhibit PDGF-R activity and a cytotoxic agent.

24. The method of claim 23 wherein said cytotoxic agent is selected from the group consisting of VP-16 and
20 cisplatin.

25. The method of claim 24 wherein said cytotoxic agent is cisplatin and said cancer is lung cancer.

26. A method of evaluating susceptibility of a cancer to growth inhibition by a compound comprising the
25 steps of:

(a) culturing cells of said cancer in medium containing PDGF;

(b) culturing cells of said cancer in medium containing PDGF and said compound;

(c) measuring and comparing growth of said cells in (a) and (b).

27. The method of claim 26, further comprising the step of culturing non-cancer cells in medium containing
5 said compound and measuring cell growth.

28. A method of assaying for a compound able to inhibit PDGF-R activity and the activity of a PDGF-R related tyrosine kinase comprising the steps of:

(a) measuring the ability of said compound to
10 inhibit PDGF-R activity; and


(b) measuring the ability of said compound to inhibit Flk-1 activity.

29. The method of claim 28, wherein said compound significantly inhibits PDGF-R and Flk-1 activity.


15 30. A compound selected from the group consisting of: B10, B12, C10, C11, E10, E11, E12, E13, E14, E15, E16, F10, F11, F12, G21, G22, H11, H12, H13, and H14.

31. A composition comprising either A10, A12, or
20 B11, and a PBTE:DSW carrier.


1/14




A10



A11



A12




A13


FIG. 1A

GROUP 1


2/14




B10




B11




B12




B13




B14




B15




B16



B17




B18




B19

FIG. 1B
GROUP 2


3/14



C10




C11



C13







FIG. 1C
GROUP 3

**FIG. 1D**

GROUP 4

SUBSTITUTE SHEET (RULE 26)

5/14



E16






FIG. 1E
GROUP 5


6/14



F10



F11



F12

FIG. 1F
GROUP 6




FIG. 1G
GROUP 7

8/14








FIG. 1H
GROUP 8






FIG. 1I
GROUP 9

9/14




J10













J11



FIG. 1J

GROUP 10




11/14


**FIG. 2A****FIG. 2B****FIG. 2C****FIG. 2D****FIG. 2E****FIG. 2F****FIG. 2G****FIG. 2H****FIG. 2I****FIG. 2J**

**Fig. 3A****Fig. 3B**

13/14

**Fig. 4**

14/14

**Fig. 5**

PCTWORLD INTELLECTUAL
PROPERTY ORGANIZATION
Internationale

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/42, 31/275, 31/415, 31/40, 31/535, 31/505, 31/47, 31/495, 31/44, 31/165, 33/24, 31/70, C07D 231/38, 239/88, 241/42, 487/04 C07C255/23, 255/41, 251/86		A3	(11) International Publication Number: WO 95/19169 (43) International Publication Date: 20 July 1995 (20.07.95)
(21) International Application Number: PCT/US95/00363 (22) International Filing Date: 6 January 1995 (06.01.95) (30) Priority Data: 08/179,570 7 January 1994 (07.01.94) US (71) Applicants: SUGEN, INC. [US/US]; 515 Galveston Drive, Redwood City, CA 94063-4720 (US). BIOSIGNAL LTD. [HU/HU]; Varosmajor u. 9, H-1122 Budapest (HU). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; 46 Jabotinsky Street, P.O. Box 4279, 91042 Jerusalem (IL). MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstrasse 2, D-80539 Mönich (DE). REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: HIRTH, Klaus, Peter; 633 Grand View Avenue, San Francisco, CA 94114 (US). SCHWARTZ, Donna, Prueas; 812 Foothill Drive, San Mateo, CA 94402 (US). MANN, Elaine; 23 Redondo Court, Alameda, CA 94501 (US). SHAWVER, Laura, Kay; 216 Cotter Street, San Francisco, CA 94112 (US). KERI, Gyorgy; Modori u. 4, H-1021 Budapest (HU). SZEKELY, Istvan; Krajcar u. 6, H-2120 Dunakeszi (HU). BAJOR, Tamas; Almos u. 75, H-1221 Budapest (HU). HAIMICHAEL, Janis; Regenyess u. 5, H-1221 Budapest (HU). ORFI, Laszlo; Bathyanz u. 92, H-1161 Budapest (HU). LEVITZKI, Alex; 36 Palmach Street, Jerusalem (IL). GAZIT, Aviv; 14 Nof Harim, Jerusalem (IL). ULLRICH, Axel; Adalbertstrasse		108, D-8000 München 40 (DE). LAMMERS, Reiner; Karls- bergstrasse 3, D-81475 München (DE). KABBINAVAR, Fairouz, F.; 5809 Melissa Lane, Woodland Hills, CA 91367 (US). SLAMON, Dennis, J.; 23122 Calvert, Woodland Hills, CA 91367 (US). TANG, Cho, Peng; 827 Camino Ricardo, Moraga, CA 94556 (US). (74) Agents: HEBER, Sheldon, O. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 15 February 1996 (15.02.96)	
(54) Title: TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR			
(57) Abstract <p>The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity of other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see Figure 1A), and its ability to inhibit growth of tumor cells <i>in vivo</i> is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 95/00363

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/42 A61K31/275 A61K31/415 A61K31/40 A61K31/535
A61K31/505 A61K31/47 A61K31/495 A61K31/44 A61K31/165
A61K33/24 A61K31/70 C07D231/38 C07D239/88 C07D241/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 20642 (RHONE-POULENC RORER INTERNATIONAL INC.) 26 November 1992 cited in the application	1-10, 26-29
Y	see the whole document	1-10, 12-30
X	FEBS LETT (NETHERLANDS), NOV 15 1993, VOL. 334, NO. 2, PAGE(S) 161-4, Mattar T et al 'Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.'	1,2,4-6, 12-18
Y	see the whole document	1-10, 12-30
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

18 December 1995

Date of mailing of the international search report

16.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stierman, B

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 95/00363

A. CLASSIFICATION OF SUBJECT MATTER
 TPC 6 C07D487/04 C07C255/23 C07C255/41 C07C251/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AGENTS ACTIONS (SWITZERLAND), JAN 1991, VOL. 32, NO. 1-2, PAGE(S) 10-21, Bartlett RR et al 'Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.'	1,2,4-6, 12-18
Y	see the whole document	1-10, 12-30

X	WO,A,91 17748 (HOECHST AG) 28 November 1991	1,2,5,6, 12-18, 23-25
Y	see the whole document	1-10, 12-30

	-/--	

Y Further documents are listed in the continuation of box C.

☒ Patient family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T"** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X"** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y"** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A"** document member of the same patent family

Date of the actual completion of the international search

18 December 1995

Date of mailing of the international search report

16.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Stierman, B

INTERNATIONAL SEARCH REPORT

 Internat. Application No
 PCT/US 95/00363

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,O 537 742 (MITSUBISHI KASEI CORP.) 21 April 1993 see the whole document ---	1-10, 12-30
T	EP,A,O 665 013 (HOECHST AG) 2 August 1995 see the whole document ---	1-10, 12-30
P,Y	ACTA PHARMACOLOGICA SINICA, vol.15, no.3, May 1994 pages 223 - 226 JU D.-W. ET AL. 'Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture' see the whole document ---	1-10, 12-30
Y	ACTA PHARMACEUTICA SINICA, vol.29, no.2, 1994 pages 90 - 94 DW JU 'Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages' see abstract ---	1-10, 12-30
Y	IMMUNOBIOLOGY, vol.186, no.1-2, 1992 page 43 T. MATTAR ET AL. 'Effects of leflunomides active metabolite, A771726, on signal transduction pathways necessary for proliferation' see abstract ---	1-10, 12-30
X	DE,A,25 24 929 (HOECHST AG) 16 December 1976	30
Y	see the whole document see example 13; table 3 ---	1-10, 12-30
P,X	WO,A,94 26260 (YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM) 24 November 1994	30
Y	see the whole document ---	1-10, 23-30
P,X	ANTI-CANCER DRUGS, vol.5, no.2, April 1994 pages 213 - 222 G. KAUR ET AL. 'Tyrphostin induced growth inhibition: correlation with effects on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia' see the whole document ---	30
Y	see the whole document ---	1-10, 23-30
-/--		

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 95/00363

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	WO,A,95 21613 (SUGEN INC. ET AL.) 17 August 1995 see the whole document ---	1-10, 23-30
A	WO,A,87 04436 (LUNDBLAD L.) 30 July 1987 see the whole document ---	1-10, 23-30
P,X	CANCER RES, vol.54, no.23, 1 December 1994 pages 6106 - 6114 M. KOVALENKO ET AL. 'Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation'	1-10, 26-29
Y	see the whole document ---	1-10, 23-30
A	WO,A,92 18481 (RHONE-POULENC RORER INT.) 29 October 1992 see the whole document -----	1-10, 12-30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 00363

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
PLEASE SEE ENCLOSURE!
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
PLEASE SEE ENCLOSURE!
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

FOR FURTHER INFORMATION PLEASE SEE CONTINUATION SHEET!

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

please see enclosure
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

LACK OF UNITY OF INVENTION

1. Use of a compound of group 1 for the manufacture of a medicament for treating cell proliferative disorders; a composition comprising such a compound.
(Claims 1-29, 31 partially)
2. Use of a compound of group 2 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds; a composition comprising such a compound.
(Claims 1-31 partially, as far as not comprised in subject 1)
3. Use of a compound of group 3 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds.
(Claims 1-11, 23-30 partially, as far as not comprised in subjects 1-2)
4. Use of a compound of group 4 for the manufacture of a medicament for treating cell proliferative disorders.
(Claims 1-11, 23-29 partially, as far as not comprised in subjects 1-3)
5. Use of a compound of group 5 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds.
(Claims 1-11, 23-30 partially, as far as not comprised in subjects 1-4)
6. Use of a compound of group 6 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds.
(Claims 1-11, 23-30 partially, as far as not comprised in subjects 1-5)
7. Use of a compound of group 7 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds.
(Claims 1-11, 23-30 partially, as far as not comprised in subjects 1-6)
8. Use of a compound of group 8 for the manufacture of a medicament for treating cell proliferative disorders; specific compounds.
(Claims 1-11, 23-30 partially, as far as not comprised in subjects 1-7)
9. Use of a compound of group 9 for the manufacture of a medicament for treating cell proliferative disorders.
(Claims 1-11, 23-29 partially, as far as not comprised in subjects 1-8)
10. Use of a compound of group 10 for the manufacture of a medicament for treating cell proliferative disorders.
(Claims 1-11, 23-29 partially, as far as not comprised in subjects 1-9)

As the figures were not available at the time of the search, it is possible that further apart subject might come up when treating the application having the figures available (for example group 11, for which there is no formula given in the description).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

The problem to be solved by the present application is to provide a treatment against cell proliferative disorders, e.g. cancer or atherosclerosis.

The solution proposed in the present application is to use an inhibitor of PDGF-R (Platelet Derived Growth Factor-Receptor) activity to treat the above mentioned disorders.

The common technical feature and therefore the linking inventive concept a priori appears to be the use of an inhibitor of PDGF-R activity for the treatment of cell proliferative disorders.

From WO-A-9220642, pp. 1-2, it is known that compounds, which inhibit PDGF-receptor activity, are useful for treating disorders characterized by abnormal cell proliferation, e.g. cancer or atherosclerosis. Moreover, on p. 45 of the above cited document, compounds falling under the formulas of the present application are described for this use.

It is apparent from the cited state of the art that the proposed solution to the problem defined above is not novel. Therefore the application lacks unity of invention a posteriori and must be divided according to the different groups of compounds claimed, which differ substantially in their chemical structure and represent mere alternative solutions to the problem underlying the application.

In the present application no further technical feature(s) can be distinguished that could be regarded as a "special technical feature" involved in the technical relationship among the different inventions. Consequently, the present application lacks unity of invention, and the different solutions not belonging to a common inventive concept are identified as different subjects listed in the communication.

Each of the inventions listed is a distinct invention, characterized by its own special technical feature (the structural features of the compounds of the respective general formulae), defining the contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Searching these different subjects would have caused major additional searching efforts.
Only the first subject was searched.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

MEANINGFUL SEARCH NOT POSSIBLE OR INCOMPLETE SEARCHObscurities:

1. The way of drafting claims as it is done in claims 1 and 2 is not allowed. It must be clear directly from the claims, which compounds are meant.
2. The figures were missing at the time of the search.
3. The reference to figures is not always congruent (e.g. on p.15 of the description reference is made to Fig. 1a, while in claim 1, for the same group of compounds there is a reference to Fig. 2a).
The search performed for group 1 compounds has been done according to the formula and table on page 15 of the application. The Markush formula being too broad to be searchable completely the search has been restricted to the compounds explicitly mentioned in table I and to the general inventive concept.
4. Group j) is mentioned twice in claim 1, with different definitions.
5. It is not clear, which compound is meant by the carrier "PBTE:DSW". Claims containing this compound have not been searched.
6. Expressions like "a cell proliferative disorder" do not make sufficiently clear, which diseases are meant. The search has been restricted to the diseases explicitly mentioned in the claims and to the general inventive concept.

Incomplete search

Claims searchable incompletely: 1-10, 12-30

Claims not searched: 11, 31

Remark: Although claims 1-25 are directed to a method of treatment of the human/animal body, the search has been carried out/could be carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/00363

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9220642	26-11-92	AU-B- 658646	27-04-95
		AU-A- 1993492	30-12-92
		EP-A- 0584222	02-03-94
		JP-T- 6507643	01-09-94
		US-A- 5409930	25-04-95
WO-A-9117748	28-11-91	AU-B- 662465	31-08-95
		AU-B- 5799294	07-07-94
		AU-B- 649421	26-05-94
		CN-A- 1056684	04-12-91
		EP-A- 0527736	24-02-93
		FI-A- 951697	10-04-95
		HU-A- 64314	28-12-93
		NZ-A- 238165	26-08-94
EP-A-0537742	21-04-93	JP-A- 5301838	16-11-93
EP-A-0665013	02-08-95	AU-B- 1015095	20-07-95
		CA-A- 2140106	14-07-95
		JP-A- 7277976	24-10-95
DE-A-2524929	16-12-76	AT-B- 343641	12-06-78
		BE-A- 842688	08-12-76
		CA-A- 1082202	22-07-80
		CH-A- 627444	15-01-82
		FR-A, B 2313031	31-12-76
		GB-A- 1555555	14-11-79
		JP-C- 1309436	26-03-86
		JP-A- 52007929	21-01-77
		JP-B- 60032620	29-07-85
		LU-A- 75075	07-03-77
		NL-A- 7605845	07-12-76
		US-A- 4061767	06-12-77
WO-A-9426260	24-11-94	AU-B- 6910994	12-12-94
WO-A-9521613	17-08-95	AU-B- 1842395	29-08-95
WO-A-8704436	30-07-87	AP-A- 27	02-12-88
		AU-B- 606047	31-01-91

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/00363

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8704436		AU-B- 6899587	14-08-87
		CA-A- 1303613	16-06-92
		DE-A- 3778190	21-05-92
		EP-A, B 0238459	23-09-87
		JP-B- 7107066	15-11-95
		JP-T- 63502588	29-09-88
		OA-A- 8744	31-03-89
		SU-A- 1776259	15-11-92
		US-A- 4990510	05-02-91

WO-A-9218481	29-10-92	US-A- 5302606	12-04-94
		AU-A- 1321592	17-11-92
		EP-A- 0580598	02-02-94
		JP-T- 6506447	21-07-94
		US-A- 5418245	23-05-95
